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 Solid-state nuclear magnetic resonance (SSNMR) spectroscopy has been 
demonstrated to be a powerful technique for investigating solid dosage formulations.  
SSNMR has the ability to determine physical form, molecular structure, and 
dynamics of a pure or formulated active pharmaceutical ingredient (API). 
 To overcome two of the major shortcomings of SSNMR, acquisition time and 
sensitivity, a two-sample solids probe was designed, developed, and tested.  The 
prototype was designed according to traditional probe technology.  The probe allowed 
for two samples to be acquired simultaneously while being shuttled through the 
magnet bore with a stepper motor.  The probe exhibited signal to noise ratio (SNR) 
values comparable to current probes.  Pharmaceutical relevance was demonstrated by 
acquiring a spectrum of ibuprofen and a spectrum of aspirin simultaneously. 
 19F SSNMR was used to examine low-level amorphous impurities in 
crystalline physical mixtures.  A search for a pharmaceutically relevant fluorine-
containing compound was performed.  The model compound was chosen for 
amorphous form stability, cost, and 19F SSNMR spectral resolution between the 
crystalline and amorphous solid forms.  The search included over 20 compounds.  
Triamcinolone, a corticosteroid, was selected for quantitation studies using 19F 
SSNMR.   
 Pure forms of amorphous and crystalline triamcinolone were generated to 
prepare physical mixtures of varying percentages.  The physical mixtures were 
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studied by SSNMR through two quantitation techniques: spectral acquisition of five 
times the relaxation time and the difference-NMR technique.  The difference-NMR 
technique exploited the vast 19F relaxation time differences between the amorphous 
and crystalline forms.  With the difference-NMR technique, low levels (<1%) of 
amorphous triamcinolone were detected.   
 The effects of paramagnetic oxygen were studied on different pharmaceutical 
samples.  In the presence of oxygen, the 19F relaxation times were significantly lower 
than in the absence of oxygen.  A similar effect was shown on the 1H relaxation times 
of dextran.  Conversely the effect was not demonstrated on a crystalline form of 
dexamethasone.  The relaxation times of cryoground aspirin were compared to bulk 
as-received material when exposed to oxygenated and deoxygenated conditions.  The 
bulk material had a negligible change in relaxation time.  The cryoground material 
exhibited a large change in relaxation time.  Both forms were the same crystalline 
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 A solid formulation is the preferred delivery method for pharmaceuticals for 
several reasons.  First, drugs tend to be more chemically stable in the solid state than 
in solution.  Second, solid dosage forms are much more convenient for patients, 
which improves patient compliance.  Third, solid dosage forms are easier to store, 
transport, and manufacture. 
 Solid drug formulations such as tablets are mixtures of the active 
pharmaceutical ingredient (API) and excipients, coatings, and other components.  
Solid formulations are complex because of the need to process the drug into a 
uniform dosage form that has a predictable dissolution rate.  Because the physical 
form of the drug in the solid state plays such an important role in the dissolution of 
the drug, it is important to know which physical forms are present in solid drug 
formulations during different stages of manufacturing and upon storage.   
 Aqueous solubility of the API is an important concern during formulation, 
because it limits the overall bioavailability of the drug.  Different solid forms may 
have different solubilities.  In many cases, the solubility of the individual crystalline 
forms is not sufficient to proceed with formulation.  Sometimes amorphous solids are 
selected over their crystalline counterparts as the desired form because of their 
increased solubility.1   Although the dissolution rate may be faster, the amorphous 
form is metastable to the crystalline form.  The balance between having increased 
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stability (chemical and physical) but a lower dissolution rate is a common dilemma in 
solid-state drug development.  
 Identification of which solid forms of an API are present in a formulation is 
critical to determining if a solid dosage form will perform properly.  The focus of 
much of this dissertation is on the characterization of solid API in crystalline and 
amorphous forms using primarily solid-state NMR spectroscopy.  A basic description 
of crystalline and amorphous states is described in the following sections.   
 
1.2 Crystalline State 
 
 A crystalline solid is a material in which the atoms and/or molecules are 
arranged in a highly ordered and repeating fashion.2   The basic repeating unit of a 
crystalline solid is the unit cell.  The unit cell is the building block for a larger 
particle, and the conformation and packing of molecules within the unit cell is 
optimized to minimize void space or free volume while maximizing the favorable 
intermolecular interactions, including both ionic and non-covalent forces.  These 
interactions can lead to different solid-state forms, morphologies, and crystal habits.  
A crystalline material can exhibit polymorphism and/or pseudopolymorphism 
(solvates and hydrates), and can exist as a salt and co-crystal.  Each crystalline form 
may have unique physicochemical properties.  A solid form that is selected for 
development must be physically and chemically stable but with sufficient solubility 
and bioavailability.  If the incorrect crystalline form is chosen during development, 
 4 
there is a risk of conversion between forms.  If conversion could occur during 
formulation, manufacturing, or storage, then the drug may need to be reformulated.3   
Due to the importance of stability and solubility on the success of a drug product, a 
thorough selection process should occur to select the best solid form for the most 
robust and successful formulation.  The differences in crystalline and amorphous 
solid forms will be discussed further below. 
 
1.2.1 Polymorphism 
 The ability of a compound to adopt two or more crystalline states that differ in 
the conformation and/or arrangement of molecules in the crystal lattice is termed 
polymorphism.2   The presence of multiple polymorphic forms is very common for 
small organic molecules, especially pharmaceuticals.  Depending on which source is 
cited, polymorphism occurs in 32-57% of small organic molecules, and if solvates are 
included, the range rises to 56-87%.4-6 Despite the wide approximated estimations, it 
is evident that polymorphism is extremely prevalent.  Each polymorphic form has a 
different free energy and can be relatively more or less stable when compared to 
another polymorph at a given temperature.  Differences in packing structure and 
thermodynamics between polymorphic forms give rise to differences in 
physicochemical properties such as melting point, density, hygroscopicity, solubility, 
and overall chemical and physical stability of the solid.  If the physical form of an 
API changes during processing or manufacturing, the physicochemical properties 
might be different, and the intended dose may not be delivered due to an altered 
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dissolution profile.  These properties are all important to consider when developing a 
safe and efficacious solid drug product.2,7-9 Therefore, it is necessary to screen a drug 
candidate for polymorphs, and, in most cases, select the most thermodynamically 
stable form for development.  The thermodynamically stable form will not 
spontaneously crystallize into a less stable polymorph, so formulating and developing 
the most stable polymorphic form helps limit physical conversions of the drug 
substance.   
 Polymorphs can be either monotropically or enantiotropically related.  When 
one crystal form is always thermodynamically less stable than another form, the two 
polymorphic forms have a monotropic relationship.  Figure 1.1 illustrates the 
thermodynamics of a montropic relationship between two polymorphic forms, A and 
B.  At any temperature below the melting temperature of either form, the Gibb’s free 
energy of polymorphic form A (GA) is always lower than the free energy of form B 
(GB).  A theoretical inversion of free energy does exist between the two forms; 
however, the inversion occurs above the melting temperatures of both forms and will 
not be observed.  Figure 1.2 shows the energy-temperature diagram for 
enantiotropically-related polymorphic forms A and C. The difference between the 
two energetic relationships is the presence of a transition temperature, Tt.10   At the Tt, 
the Gibbs free energy relationship between forms A and C inverts.  Below Tt, form A 




Figure 1.1. Theoretical energy versus temperature diagram of a monotropic system.  
GA and GB are the free energies of two monotropically related polymorphs (Forms A 
and B), and GL is the free energy of the liquid.  HA, HB, and HL are the respective 
enthalpies for each form.  The melting temperatures of Forms A and B are denoted by 
Tm,A and Tm,B, respectively.  Adapted from reference 11.
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Figure 1.2. Theoretical energy versus temperature diagram of an enantiotropic 
system. GA and GC are the free energies of two enantiotropically related polymorphs 
(Forms A and C), and GL is the free energy of the liquid.  HA, HC, and HL are the 
respective enthalpies for each form.  The melting temperatures of Forms A and C are 
denoted by Tm,A and Tm,C, respectively.  The thermodynamic inversion of two 
enantiotropically related polymorphs occurs at a transition temperature, Tt.  Adapted 
from reference 11.
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 occur prior to the melting point of either form, Tm,A and Tm,C.
 Monotropic and enantiotropic polymorphic systems can be determined by 
plotting the log of solubility versus temperature for two polymorphic forms.  If the 
system is monotropic, the solubility profiles will not intersect below the melting 
temperature of either form.  If the system is enantiotropic, the lines will cross, and the 
energetic relationship will invert at the Tt.   
 Additionally, the energetic relationship between polymorphs can be 
determined by the “heat of transition” and “heat of fusion” rules constructed by 
Burger and Ramberger.11,12   The heat of transition rule states that two forms are 
related enantiotropically if an endothermic transition is observed between two forms 
at some temperature. On the other hand, if an exothermic transition is observed 
between two forms at some temperature it may be assumed that the two forms are 
monotropically related.  The heat of fusion rule states that if the lower melting 
polymorphic form has the higher heat of fusion, then the two forms are related 
enantiotropically.13
 
1.2.2 Solvates, salts, and co-crystals 
 In addition to polymorphs, a compound can also crystallize as a solvate, salt, 
or a co-crystal.2 The crystal form is termed a solvate when a solvent molecule is 
incorporated into the crystal lattice.  If the solvent of interest is water, then the solvate 
is designated a hydrate.  Solvates are also referred to as pseudopolymorphs and 
solvatomorphs in the literature.13-15   The ratio of solvent to the molecule of interest 
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can occur in stoichiometric or non-stoichiometric ratios.  When the solvent is 
incorporated into the crystal lattice in an orderly manner, typically in integer or half-
integer ratios, it is referred to as stoichiometric.  When the solvent is incorporated in a 
less defined manner, the solvate is non-stoichiometric.  An example of a non-
stoichiometric is a channel hydrate, where water molecules can move with relative 
ease through channels in the crystal lattice.  Like polymorphs, solvates have different 
free energies, which will result in different physico-chemical properties in relation to 
the desolvated forms.   
 If a compound has a low aqueous solubility, stability issues, permeability, or 
other undesirable properties, a salt form can be prepared.16   Salts of a compound can 
be formed when the compound has acidic or basic ionizable functional groups. A salt 
form is generated by crystallization of the drug substance with a complementary 
counterion forming a strong ionic interaction.  Salts often have more favorable 
physicochemical properties than the free-base or free-acid form, which makes them 
good options for solid dosage formulations.  Common acidic negative, anions for 
basic drugs are hydrochloride, sulfate, and acetate, whilst the common alkaline 
positive, cations for acidic drugs are sodium, magnesium, and potassium.17 
Approximately 50% of drugs used in medicinal therapy are administered as salts, 
which justifies preformulation salt screening.17 
 The last crystalline form to discuss is the co-crystal, which is formed when 
two compounds that are solids at room temperatures crystallize stoichiometrically in 
the same crystal lattice.18   The changes in structure and composition of a co-crystal 
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could affect the bioavailability and intellectual property of the drug.18   Formation of 
a co-crystal occurs when two different molecules have complementary functional 
groups that interact, typically through hydrogen bonds, more favorably than either 
molecule by itself.  Co-crystals are most commonly formed from solution, yet 
grinding, milling, and growth from a melt are also possible methods of crystal 
formation.18    
 In the solid state, form selection is extremely important and should be 
performed early in development to identify potential issues with bioavailability and 
stability early.  With the exception of co-crystals, high-throughput screening is 
typically performed for each crystalline form.  In some cases, the crystalline form of 
the API cannot be formulated because the form has extremely poor solubility and 
bioavailability.  For these compounds, the amorphous state of the API could be used 
as an alternative to enhance the solubility.   
 
1.3 Amorphous State 
  
1.3.1 Definition of the amorphous state 
 The word “amorphous” originated from the Greek word “αµορφος,” which 
means “shapeless.”19   Amorphous materials are highly disordered systems that lack 
the long-range order that is characteristic of crystalline solids.  However it should be 
noted that amorphous solids might maintain some short-range order on the molecular 
level.20   The amorphous form is thermodynamically metastable compared to the 
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crystalline form.  As compared to the crystalline forms, the amorphous form will 
likely have different physicochemical properties such as increased solubility and 
hygroscopicity, which generally lead to enhanced bioavailability and decreased 
stability.1   
 The amorphous state can be used as the desired solid form in a drug product to 
enhance the solubility of the API. However, the amorphous state is examined more 
often as a physical impurity that was produced during development or manufacturing. 
Undesired amorphous material can be generated in low levels from heat, pressure, or 
other high-energy manufacturing processes.  The physical degradation of the solid 
form can lead to changes in solubility and bioavailability of the API.  Additionally, 
the lack of stability of the amorphous material could raise a drug’s susceptibility to 
chemical degradation.  The physical and/or chemical degradation of the amorphous 
form can affect the therapeutic integrity of the solid dosage form.  Thus it is important 
to monitor amorphous content at low levels in a formulation. 
 
1.3.2 Characterization of the amorphous state 
 Basic identification of the amorphous state of a compound is most commonly 
determined by the lack of microscopic birefringence, and/or a broad (or no) powder 
pattern by powder X-ray diffraction.   Additionally, the peaks in a solid-state NMR 
spectrum of an amorphous solid can be 10 times broader than the peaks of its 
crystalline counterpart.21   The increased breadth of the NMR peaks is attributed to 
the lack of long-rage order in the amorphous state.       
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 To further characterize the amorphous state, it is helpful to understand the 
thermodynamic relationship between the crystalline and amorphous forms as well as 
the liquid state. Shown in Figure 1.3 is a graphical depiction of the change in enthalpy 
with temperature of the three states (crystalline, amorphous, and liquid).20   At lower 
temperatures, the enthalpy of a crystalline solid experiences small changes in 
enthalpy with respect to temperature.  When the crystalline solid reaches the melting 
temperature, Tm, there is a pronounced jump in enthalpy (ΔHm) that corresponds to a 
solid-liquid phase transition.  If the liquid state is cooled rapidly below the Tm, there 
may not be sufficient time to allow the material to crystallize.  When this occurs, the 
material is defined as an amorphous solid or supercooled liquid, maintaining the 
structural characteristics of a liquid with increased viscosity.  If the enthalpy of the 
supercooled liquid continued to decrease at the same rate at lower temperatures, the 
supercooled liquid would eventually have a lower enthalpy than the crystalline solid.  
The theoretical intersection is a critical temperature referred to as the Kauzmann 
temperature (TK).  Below this temperature, the supercooled liquid theoretically would 
have a lower enthalpy then the crystalline solid.  Therefore, a transition, or change in 
slope, could be considered a thermodynamic requirement for the system.20   
 Prior to reaching the enthalpy of the crystalline state, the slope of the 
enthalpy-temperature relationship of the supercooled liquid changes significantly.  
This change occurs at the glass transition temperature (Tg).  Above the Tg, the 
amorphous material is highly mobile and termed the rubbery state, and at 
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Figure 1.3.  Graphical relationship of variation of enthalpy with temperature for 
amorphous and crystalline solids.
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temperatures below the Tg, the material is termed the glassy state.  The change in 
mobility is a contributing factor to why the Tg is the primary defining characteristic of 
an amorphous solid.  Despite being the primary characteristic of an amorphous solid, 
the Tg can be difficult to detect and can change with thermal history and water 
content.  Ahlneck et al. noted that water plasticized the glass transition of amorphous 
solids, lowered the glass transition temperature, which increased the rate of 
crystallization.22  
 The amorphous state can be characterized through a wide variety of 
instrumental techniques.  The techniques can be classified in four main categories: 
thermal methods, dissolution techniques, crystallographic techniques, and 
spectroscopy.  Thermal (e.g. DSC, TGA, hot stage microscopy) and dissolution 
techniques provide bulk information of the material such as the glass transition 
temperature, birefringence (or lack thereof), and dissolution rate.  Crystallographic 
and spectroscopic techniques can yield information on the molecular level for a 
material.   Using powder X-ray diffraction (PXRD), the amorphous state will be 
observed as a diffuse “halo.”  The peaks of the amorphous state in a solid-state NMR 
spectrum are much broader than its crystalline counterpart.  Because NMR 
spectroscopy detects changes in the local environment, the chemical shifts of NMR 
peaks in a solid-state spectrum can be different between amorphous and crystalline 
forms.   
 
1.3.3 Preparation of amorphous solids 
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 The amorphous state of small-molecule organic solids is commonly generated 
by four techniques: quench cooling a melt, milling, spray drying, and lyophilization.23   
 Quench cooling a melt involves rapidly cooling a melted drug typically by 
immersion in liquid nitrogen.  Ideally, the molecular disorder in the liquid state is 
frozen before the molecules can rearrange into a crystal lattice.  This technique is 
often the first method used to prepare the amorphous form.  However, many small-
molecule organic compounds degrade upon melting.    
 Another process for generating an amorphous form is milling or grinding the 
compound.  The material is subjected to a high amount of mechanical stress, which 
reduces the particle size until the order of the crystal lattice is destroyed.  At times, 
milling can induce thermal degradation from the heat generated during the process.  
To reduce the likelihood of thermal degradation, grinding can be performed in a 
liquid nitrogen bath.  This process is referred to as cryomilling or cryogrinding.  
 Another process for generating the amorphous state is by controlled removal 
of the solvent from a solution of the compound.  Lyophilization and spray drying are 
two techniques that employ this process.  During lyophilization, the material is 
dissolved in a solvent (typically water) that exhibits a triple point.  The solution is 
frozen and exposed to a vacuum.  The frozen solution goes through two drying 
processes: primary and secondary.  During primary drying, the water sublimes from 
the lyophilization matrix.  In the secondary phase, the residual, bound water is 
removed.  When frozen, the material is locked in the random disorder of the liquid 
state.  As the water sublimes, the material may maintain the structural disorder of the 
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liquid state.  In contrast, during spray drying, the solution of drug and solvent is 
sprayed through a heated nozzle at a temperature higher than the boiling point of the 
solvent.  The solvent evaporates rapidly, leaving behind small particles of highly 
disordered solid.  Lyophilization is generally limited to samples with a fairly high 
aqueous solubility, whereas spray drying can be performed with organic solvents 
under the proper conditions.   
 The amorphous state can also be generated by dehydrating crystalline hydrates 
and solid dispersions.  Solid dispersions are used to enhance the bioavailability of a 
drug product by creating a matrix of the amorphous form of the drug and a carrier, 
usually an excipient.  This is commonly used for drugs that are too insoluble to 
provide an efficacious dose.  
 
1.4 Overview of Thesis Research 
 
1.4.1 Motivations 
 Understanding the solid-state properties of a drug substance is paramount to 
the success of a solid drug product.  The amorphous state is a very important topic 
because of the regulatory concerns regarding low-level presence in a formulation.  
Current instrumentation and techniques are very limited in the ability to study low 
levels of drugs in formulation.  Solid-state NMR spectroscopy has the potential to 
differentiate between the API and the excipients.  However, the low sensitivity of the 
13C nucleus means that SSNMR can be time and cost prohibitive, which limits the 
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feasibility for some applications, particularly quantitation of low-levels of amorphous 
material.  The research presented in this thesis is aimed at ways to increase the 
sensitivity of solid-state NMR spectroscopy for studying solid-state pharmaceuticals 
through two approaches:  1) the design, construction and testing of a multiple-sample 
NMR probe and  2) the detection and quantitation of low levels of an amorphous drug 
in a crystalline physical mixture using 19F SSNMR spectroscopy. 
 
1.4.2 Importance of solid-state NMR spectroscopy 
 Although there is no single characterization technique that can garner all the 
necessary information on a solid drug or drug product, solid-state NMR spectroscopy 
(SSNMR) is emerging as a valuable technique for determining the state of the API in 
a formulated product.  The technique is non-invasive, non-destructive, inherently 
quantitative, and has the ability to discriminate between different crystalline and 
amorphous forms as well as excipients.  In Chapter 2, the theory and applications of 
SSNMR will be presented.  Several articles that highlight the application of SSNMR 
will be reviewed.  Additionally, the 19F nucleus will be closely examined as a high-
sensitivity alternative to 13C, when applicable.  A brief review of literature pertaining 
to 19F SSNMR of pharmaceuticals will be presented. 
 
1.4.3 Increasing sensitivity and throughput with a multiple-sample NMR probe 
 SSNMR is a powerful analytical technique, but there are a few drawbacks. 
The inherent lack of sensitivity of the 13C nucleus and long NMR relaxation times 
 18 
require extensive signal averaging and long (hours to days) data acquisition times.  
These long acquisition times hinder the routine use of SSNMR in the analysis of 
drugs at the preformulation and formulation stages of drug development.  
 In Chapter 3, the first research project is presented, which increases the 
throughput and sensitivity of SSNMR.  The design, construction, and proof of 
concept are demonstrated on a two-module multiple sample probe for SSNMR.  
SSNMR spectra are presented that show simultaneous data acquisition on identical 
samples of hexamethyl benzene.  Additionally, spectra on two different 
pharmaceutically relevant samples with significantly different NMR relaxation times 
were collected simultaneously (aspirin and ibuprofen).  The probe can be used to 
increase throughput by a factor of two or increase sensitivity by acquiring data on the 
same sample packed in two rotors.    
 
1.4.4 Production of stable amorphous small molecules 
 In Chapters 4 and 5 the alternative of using 19F SSNMR to quantitate 
crystalline and amorphous forms is shown.  Very few techniques can measure low-
level limits of amorphous material in a crystalline physical mixture, and no current 
techniques can be used to measure low-levels (>1%) of amorphous material in a 
formulation.  13C SSNMR is partially limited because of the inherent insensitivity.  
19F SSNMR spectroscopy was employed to detect and quantitate low levels of 
amorphous material in a crystalline physical mixture.  A process was designed to 
select the ideal model compound for the 19F SSNMR studies.  In Chapter 4, the 
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sample screening process is outlined for selecting a fluorinated drug for low-level 
amorphous quantitation. Approximately twenty drugs were examined as potential 
candidates.  Many of the drugs were not approved for this proof-of-concept study due 
to issues such as physical or chemical stability, limited aqueous solubility for spray 
drying and lyophilization, chemical degradation at the melting point, inability to 
amorphize the compound, or there was limited chemical shift resolution from the 
crystalline peaks in the 19F SSNMR spectra.  Triamcinolone was selected as the 
model form for low-level amorphous quantitation using 19F SSNMR.  Once the model 
form was selected, the crystalline polymorphs were studied, and the amorphous 
generation technique was optimized. 
 
1.4.5 Using 19F SSNMR spectroscopy to quantitate low levels of amorphous drug 
 In Chapter 5, physical mixtures of the amorphous and crystalline forms of 
triamcinolone were prepared and examined with 19F SSNMR.  Two unsuccessful 
quantitation attempts are presented.  In the first attempt, stability concerns of the 
amorphous state required low-temperature conditions during data acquisition.  
Straightforward quantitation from a single spectrum did not provide sufficient 
expression of the amorphous form.  In the second quantitation attempt, the difference-
NMR technique was used.24   Two SSNMR spectra were collected with different 
pulse delays and spectrally subtracted to increase the suppression of the crystalline 
form.  During this attempt, form conversion was observed, and the NMR relaxation 
times of the amorphous and crystalline components were unstable.  Finally, physical 
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mixtures of stable amorphous and crystalline forms were prepared and analyzed with 
the difference-NMR technique.  The technique exhibited great power in suppressing 
the crystalline form, and detected the amorphous form in the 0.5% physical mixture. 
  
1.4.6 Effect of oxygen-induced relaxation phenomenon  
 When performing the difference-NMR technique, accurate determination of 
NMR relaxation times is extremely important.  During the second quantitation 
attempt in Chapter 5, the relaxation time of amorphous triamcinolone increased 3-4 
fold during an overnight experiment.  After removing the sample from the 
spectrometer, the relaxation time returned to the initially measured value, and 
followed a similar relaxation time profile overnight.  In Chapter 6, the relaxation 
change was studied and determined to arise from oxygen being purged from the 
sample rotor while spinning.  The effect of oxygen was demonstrated on amorphous 
and crystalline material as well as both 19F and 1H nuclei.  Aspirin was cryoground 
and cycled through oxygen-rich, nitrogen-rich, and oxygen rich environments.   The 
NMR relaxation times were measured under each condition and compared to a bulk 
sample treated identically.  The changes in relaxation time highlight the importance in 
accurate determination of NMR relaxation times, and the changes in relaxation time 
upon exposure to oxygen.  The effect of oxygen on NMR relaxation gives us a 
potential probe to measure the presence of oxygen in solid-state pharmaceutical 
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 In Chapter 1, the basics of the solid-state chemistry of pharmaceuticals were 
provided.  The focus of this chapter is the application of nuclear magnetic resonance 
(NMR) spectroscopy for the analysis of pharmaceuticals in the solid state.  Solid-state 
NMR (SSNMR) spectroscopy has developed into an extremely powerful analytical 
tool for pharmaceuticals in the solid state.  SSNMR is a non-destructive, non-invasive 
technique that can obtain unique information about the structure and dynamics of 
drugs in pharmaceutical formulations.  SSNMR can be used for a variety of 
applications from routine collection of NMR spectra of drug substance to multi-
dimensional analyses of drug product.  For pharmaceutical systems, 13C spectra are 
typically collected.  An understanding of some basics of NMR and the differences 
between collecting solution and solid-state data are necessary to fully understand the 
strengths and weaknesses of SSNMR and are reviewed below. 
 
2.2 Basics of NMR 
  
2.2.1 Spin and Resonance 
 All nuclei have a spin quantum number, typically referred to as “I”. Certain 
nuclei have NMR ‘active’ spins.  Nuclei that have a spin quantum number of zero (I = 
0) do not produce an NMR signal.  Nuclei with a non-zero spin quantum number in 
multiples of ½ (I = 1/2, 1, 3/2, 2, 5/2, etc.)  have angular momentum, P, and charge.  
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The motion of charge generates a small magnetic moment, µ.  Angular momentum 
and magnetic moment are related in Equation 2.1.   
 
! 
µ = "P                     (2.1) 
 
The term γ is the magnetogyric ratio and defined as the ratio of angular momentum to 
magnetic moment.  The magnetogyric ratio is a constant for a given nucleus.  Because 
the energy states are quantized, the magnetic moments exist in distinct numbers of 
spin states.  The number of spin states are determined by the spin quantum number, I.  
There are 2I+1 potential spin states. For example, a spin I = 1/2 nucleus such as 13C 
has two possible spin states.  The spin states can be thought of as being antiparallel to 
each other. When an I  ≠ 0 nucleus is exposed to a static, external magnetic field, the 
energy states become non-degenerate.  For example, the spins that are aligned with 
the static magnetic field have a lower energy.   One spin state is aligned with the 
external magnetic field and the other against.  
 A magnetic moment within an external field experiences torque, which causes 
the nucleus to precess around the axis of the field.  The precession is commonly 
referred to as Larmor precession, and the frequency of precession is related to the 
magnetogyric ratio of each nucleus.  The motion is defined by the angular velocity (ν) 
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The direction of precession, clockwise or counter-clockwise, is determined by the 
sign of γ, but the direction is always the same for a given nuclide.  In order for 
nuclear magnetic resonance to occur a nucleus must change its spin state by the 
absorption of quantized energy specific to the Larmor precession frequency.  The 
appropriate energy can be determined from Equation 2.3.   
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The Larmor frequency is proportional to the external magnetic field (B0).  NMR 
spectrometers are typically equipped with magnets between 2.35 and 21.15 T (tesla). 
Magnet field strengths are often referred to by their proton resonance frequency. 
Magnets with the field strengths described above would have a proton resonance 
range of 100-900 MHz in the radiofrequency portion of the electromagnetic spectrum. 
 As noted above, when a nucleus with spin I=1/2 is exposed to an external 
field, two spin states exist, +½ or α and -½ or β, that have different energy values.  
Because the α state is parallel to the magnetic field, it has a lower energy than does 
the β state.  At magnetic equilibrium there will be an excess of nuclei in the α state.  
The population distribution of spins between the two states is defined by the 







"E kbT                       (2.4) 
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h  is Plank’s constant 
divided by 2π), kb is the Boltzmann constant, and T is absolute temperature.  The 
difference in energy levels of spin states is extremely small.  The small energy 
difference is the reason NMR is very insensitive compared to other techniques.  
 
2.2.2 NMR relaxation  
 After the spins have been perturbed from their equilibrium values, they must 
return to their original state prior to the perturbation.  This process is called 
relaxation, and there are three basic types of relaxation in NMR spectroscopy: spin-
lattice (T1), spin-spin relaxation (T2), and spin-lattice relaxation in the rotating frame 
(T1ρ).  
 An understanding of the spin-lattice relaxation (T1), or longitudinal relaxation, 
is important when collecting a spectrum, quantitating components in a sample, or 
studying the dynamics of a system.  T1 relaxation occurs when the equilibrium spin 
states are repopulated after a 90° radiofrequency (RF) pulse.  The magnetization 
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M0 is the magnetization at thermal equilibrium and Mz is the magnetization along the 
+z axis at time t.  T1 is a first order time constant for the re-establishment of the 
original spin-state populations.  In order for spins to fully relax after a  pulse, a delay 
of  times the T1 value must be used (99.3% magnetization). In small-molecule 
pharmaceutical solids, spin-lattice relaxation times can vary from below one second 
to hundreds of seconds.  The times are long because relaxation must occur through 
stimulated relaxation at the Larmor frequency.  These frequencies can be generated 
by molecular motion such as the rotation of a methyl group or flipping of a phenyl 
ring.  Due to the nature of the relaxation mechanisms of Ti, it is sensitive to molecular 
motion on the time scale of the resonance frequency.  Spin-lattice relaxation times are 
measured with either a saturation recovery or inversion recovery pulse sequence.   
 After a 90° pulse, the individual magnetization vectors fan out in the x-y 
plane.  After the magnetization fans out (ignoring longitudinal relaxation), there is no 
net magnetization in the transverse plane.  Similar to T1, spin-spin (T2) or transverse 
relaxation occurs via exponential decay.  Magnetic field differences can arise from 
two different sources: instrumental imperfection (T2(ΔB0)) that can be partially 
corrected for by shimming and intra- and intermolecular interactions in the sample 
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magnetization is observed in the free induction decay.  T2* is proportional to NMR 
line widths.  T2* can be calculated from the line width at half height of a peak in the 
NMR spectrum.  T2 relaxation occurs by a spin-spin exchange process.  For example, 
a spin in the α-state will flip to the β-state and the reverse occurs simultaneously.  
Transverse relaxation occurs through a swapping of energy between spins.  Because 
T2 relaxation occurs prior to T1 relaxation, T2 relaxation will be finished prior to T1 
relaxation.  Therefore, spin-spin relaxation can only be equal to or shorter than the 
spin-lattice relaxation. 
 A third relaxation rate is the spin-lattice relaxation time in the rotating frame 
(T1ρ).  After a 90° pulse the RF pulse is normally turned off.  If the phase of the RF 
field is changed 90°, the field will be aligned with the magnetization in the transverse 
plane.  When the applied RF field is along the same axis as the magnetization vector, 
the sample is spin locked.  T1ρ is the time constant for the decay of magnetization 
along this axis.  T1ρ is sensitive to molecular motions that correspond to the strength 
of the spin locking field.  It is also sensitive to motions occurring at lower frequency 
(kHz) than those of which T1 (MHz) times are sensitive.   
 All three relaxation time constants are related to correlation time (τc).  
Correlation time is the average time it takes a molecule to rotate through one radian 
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In the two equations, the nuclear precession frequency is ω0 and ω1 is the frequency 
of the applied spin locking field.  The correlation time can be obtained by plotting log 
of the relaxation time (T1 or T1ρ) versus inverse temperature.  For both relaxation time 
constants, a V-shaped curve will be plotted.  At the minimum in each plot, the 
following conditions are true: (T1) ω0τc = 0.62 and (T1ρ) ω1τc = 0.52.  The V-curve is 
indicative of two distinct motional regimes.  On the left-hand side or fast-motional 
regime, relaxation times (T1, T2, and T1ρ) are approximately equal with all increasing 
with increasing temperature.  On the other side of the curve, the relaxation time 
constants are markedly different.  In the slow-motional regime, the relaxation time 
constants increase with decreasing temperature.  
 
2.2.3 Sensitivity 
 A thorough understanding of NMR sensitivity is important when acquiring 
NMR data.  Equation 2.9 shows the relationship between signal, S, magnetogyric 




, number of nuclei present in the sample, 
! 
N , a 
signal shape factor, 
! 
g v( ) , and temperature, T.  From Equation 2.9, it is clear why  
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quantitation studies using NMR can be straightforward.  The signal observed is 










                  (2.9) 
This relationship also illustrates the advantage of isotopic labeling to increase signal 
intensity.  Due to the exponent on the γ term, nuclei with higher magnetogyric ratios 
have more intense signals than a nucleus with identical abundance at with a smaller γ 
value.  Signal increases with higher magnetic field strengths, and at lower 
temperatures. 
 To compare the sensitivity of different nuclei both the magnetogyric ratio and 
the natural abundance must be considered. NMR receptivity is defined as 
! 
" 3C  where 
C is the natural abundance.  Often times a nucleus is compared to the receptivity of 
commonly observed 1H or 13C nuclei to more clearly illustrate the sensitivity 
differences.  The ratio is called the relative receptivity.       
 
2.3 Solid-State NMR Spectroscopy 
 
2.3.1 NMR spectroscopy for pharmaceutical analysis 
 In the past half century, nuclear magnetic resonance spectroscopy has been 
primarily used as a solution-based technique.  In solution NMR, lines are very sharp, 
because molecular tumbling that occurs in solution average most of the interactions 
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that lead to line broadening.  Narrow NMR lines and the highly abundant (99.99%) 
1H nucleus have made solution 1H NMR a walk-up machine for routine data 
collection that is an invaluable technique for all aspects of drug research. However, in 
the solid state, the molecules are in rigid and defined molecular orientations and 
conformations, which can lead to large dipolar couplings and chemical shift 
anisotropy.  In addition, the 1H nucleus is not easy to routinely observe.  Lastly, the 
lack of extensive molecular motion in the solid state leads to longer spin-lattice 
relaxation times from a few seconds to minutes.  This increases the time required to 
obtain a high-quality NMR spectrum from signal averaging.  These factors have kept 
solid-state NMR spectroscopy from being incorporated into pharmaceutical 
development by because it is difficult and time intensive to perform SSNMR 
experiments.  Three important advances have been made to acquire high-resolution 
NMR spectra of the solid state, which are high-power proton decoupling, magic-angle 
spinning, and cross polarization. 
 
2.3.2 High-power proton decoupling 
 Due to the lack of molecular tumbling and limited molecular motion in the 
solid state, the 1H/1H homonuclear dipolar couplings are very strong.  This causes 
extensive line broadening when trying to detect the 1H nucleus.  Therefore, the 
primary focus of SSNMR of pharmaceuticals has been on the 13C nucleus.  13C is also 
strongly coupled with the 1H nucleus.  The coupling can be eliminated by using a 
high-power 1H decoupling sequence, such as continuous wave, two-pulse phase 
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modulated (TPPM), or Spinal-64.  In general, high power 1H decoupling is required 
for any system where there is an abundance of 1H nuclei in the system.   
 Shown in Figure 2.1a is a 19F SSNMR spectrum of triamcinolone applied with 
a single 19F 90° pulse and high-power TPPM decoupling.  A spectrum collected under 
typical solution conditions (not shown) would be fairly noisy with very weak or no 
signal.  Using high-power proton decoupling produces the 19F powder pattern of 
triamcinolone.  When decoupling is employed, the peaks in the spectrum are broad 
and featureless providing limited information about the sample. 
 
2.3.3 Magic-angle spinning 
 High-power proton decoupling eliminates a significant amount of line 
broadening.  However, there is orientation dependence in the solid state that still 
exists due to the lack of molecular tumbling that occurs in solution. The narrow lines 
that are observed in solution NMR spectra are not present in the solid state even with  
high-power proton decoupling. Both dipole-dipole interactions and chemical shift 
anisotropy are orientation dependent.   The orientation dependence gives rise to 
chemical shift anisotropy (CSA), an effect not typically observed in solution 
spectroscopy.  CSA is a result of the different molecular orientations with respect to 
the magnetic field.  For example, a single crystal placed in an external magnetic field 
would exhibit different chemical shifts depending upon its orientation with respect to 
the static magnetic field.  Rapid molecular tumbling averages this effect to zero in 
solution, and only a single isotropic chemical shift is observed.  The rigidity of 
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Figure 2.1. 19F SSNMR spectra of triamcinolone a) single pulse experiment, static, 
TPPM proton decoupling, 100-s pulse delay, 512 scans, ~14 hour experiment time b) 
spinning at 15 kHz with no proton decoupling, 100-s delay, 256 scans, ~7 hour 
experiment time c) spinning at 10 kHz with TPPM proton decoupling, 100-s delay, 16 
scans, ~26 minute experiment time and d) spinning at 15 kHz with TPPM decoupling 
and 1H/19F cross polarization 3-s delay, 16 scans, 48 seconds
experiment time. Asterisks denote spinning sidebands.
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 molecules in the solid state compared to the external magnetic field give rise to a 
distribution of chemical shifts that is referred to as the powder pattern.  The effect is 
due to a chemical shielding tensor, σobs, which can be separated into an anisotropic 







+ 3cos2# $1( )" aniso               (2.10) 
 
 The anisotropic shielding tensor can be eliminated when the sample is spun at 
an angle, θ, such that (3cos2θ-1) = 0.  The angle at which the term equals zero is 
54.74°, and is termed the magic angle.  The angle corresponds to the body diagonal of 
a cube.  When spinning along that axis, commonly referred to as magic-angle 
spinning (MAS), the sample spends an equal amount of time on all three axes (x,y,z).  
The orientation dependence of the solid state is significantly reduced and the isotropic 
chemical shift is observed.  If the sample-spinning rate is less than the width of the 
powder pattern, spinning sideband artifacts will appear at harmonics of the spinning 
speed.  Dixon et al. developed a pulse sequence, which can be applied for total 
suppression of spinning sidebands (TOSS).  A spectrum collected with TOSS will 
contain only the isotropic chemical shifts.  
 The line narrowing capability of MAS is shown in Figure 2.1b.  A 19F 
SSNMR spectrum of triamcinolone was collected with a single-pulse experiment with 
no proton decoupling with a 15 kHz MAS rate.  The spectrum shows significant 
reduction in line broadening as compared to simply employing proton decoupling.  
 38 
However, the peak is still extremely broad.  Figure 2.1c shows the use of both proton 
decoupling and MAS in a single-pulse experiment.  There are now two well-resolved 
peaks in the 19F SSNMR spectrum of triamcinolone.   
  
2.3.4 Cross polarization 
 Most of the solid-state NMR spectra of pharmaceutics are acquired for 13C.  
However, the natural abundance of the 13C nucleus is only 1.1% as compared to the 
99.9% abundance of the 1H nucleus.  A technique that is often implemented to 
increase the sensitivity of a low-abundance nucleus, such as 13C, is cross-polarization 
(CP).  In the CP experiment, magnetization is transferred from an abundant spin (1H) 
to a low abundance spin (e.g. 13C and 15N,).   
 CP is accomplished by applying a 90° radio-frequency (rf) pulse at the proton 
resonance frequency aligning the proton magnetization on the x-y plane.  The phase 
of the pulse is immediately rotated by 90° and maintained for a short period of time, 
locking the spins in the x-y plane.  Simultaneously, a second rf pulse is applied at the 
resonant frequency of the dilute spin (i.e. 13C) for the duration of the contact time.  
With the appropriate rf field power levels and durations for each nucleus, the 
Hartmann-Hahn matching conditions are satisfied, and cross polarization is 











                (2.11) 
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 is the magnetogyric ratio of the dilute spin 




 is the magnetic field strength applied to the X nuclei.   
 There are two valuable benefits that arise from using cross polarization. First, 
when executed at the Hartman-Hahn conditions, cross polarization results in a gain in 
sensitivity that corresponds to the ratio of the magnetogyric ratios of the abundant and 
dilute spins.   For 1H to 13C cross polarization, the sensitivity per scan gain is 
approximately four-fold.  Secondly, the relaxation times are now governed by the 1H 
spin-lattice relaxation times rather than the 13C T1.  1H relaxation times are typically 
much faster than 13C times because of the increased atomic motion of the 1H nucleus 
and spin diffusion.  The faster relaxation times allow for more signal averaging in the 
same amount of time.   
 Figure 2.1d shows the 19F spectrum of triamcinolone acquired with all three 
techniques: proton decoupling, magic-angle spinning, and 1H/19F cross polarization.  
Cross polarization does not appear to have a large effect on the resolution of the 
spectrum.  This is due to the closeness in magnetogyric ratio between the 1H and 19F 
nucleus, so there is a minimal sensitivity enhancement expected (~1.05) compared to 
the four-fold enhancement for 1H/13C CP.  The advantage to using CP is the time 
difference in relaxation of the proton nucleus.  The pulse delay used for the single-
pulse experiment is 100 s and 3 s for the CP experiment.  A comparable 19F CP 
spectrum can be acquired in a fraction of the time that it would take for the single-
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pulse experiment.  It should be noted that the benefits are based on the difference 
between relaxation times, and the difference is not always this extreme.   
 The use of high-power proton decoupling, magic-angle spinning, and cross 
polarization allow the collection of high-resolution NMR spectra in the solid state. 
 
2.4 Characterization of Bulk Drugs Using SSNMR 
 
2.4.1 Background on physical forms 
 As described in Chapter 1, drugs can exist in a multitude of physical forms in 
the solid state.  Each state can have a variety of different physicochemical properties 
such as melting point, dissolution rate, hygroscopicity, solid-state reactivity, and 
processability.  The changes in physicochemical properties can vastly affect the 
therapeutic efficacy of a drug product.  Changes to the solid state can occur at any 
stage during processing, formulation, and/or storage of the drug product.  Therefore, 
the formulated product must be monitored throughout all stages to ensure that the 
physical and chemical integrity of the drug substance is maintained.    
 Solid-state form changes are due to changes in the arrangement of molecules 
in the unit cell.  The electronic environments of atoms will be different for each form 
of the drug.  These changes in electronic environment are fairly easy to detect with 
13C CPMAS (cross polarization with magic-angle spinning) spectroscopy.  
Polymorphs, solvates, hydrates, and amorphous forms all give a unique SSNMR 
spectrum.  The spectral difference allow for form identification and quantitation using 
 41 
SSNMR spectroscopy.  Chemical shift differences can vary up to 10 ppm between 
different solid forms in an NMR spectrum. 
  
2.4.2 Identification of physical form 
 An early example of crystal form identification using SSNMR spectroscopy 
was performed by Byrn et al.2   The crystal structures of five different solid forms (I 
(ethanol), II (2-propanol), III (DMF), IV (anhydrate), and V (hydrate)) of 
prednisolone tert-butylacetate were determined by single-crystal X-ray diffraction and 
SSNMR.  The steroid rings were determined to be in similar configurations, yet the 
tert-butyl side chain conformation was the primary difference in conformation.  The 
crystal packing was also shown to be very different between all forms, with the 
exception of Forms I and II.  The 13C CPMAS spectra of each of the forms showed 
significantly different chemical shifts, which were attributed to differences in the 
individual crystal packing of each form.  The chemical shifts of the carbon atoms in 
the ester side chain are similar for each of the five crystal forms.  The largest 
difference between forms was observed in the carbonyl carbon atoms and the 
unsaturated carbon atoms conjugated with them.  Some of the chemical shift 
differences were as large as 8 ppm.  The five forms were examined for reactivity with 
oxygen catalyzed by UV light.  Oxygen reactivity only occurred with the 
monohydrate Form V.  From the crystal structure it was hypothesized that oxygen 
traveled down a tunnel penetrating the crystal lattice.  In this example, SSNMR 
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provided a knowledge of how the crystal packed, which helped explain the 
differences in chemical stability between various solid forms of a drug compound.  
 
2.4.3 Quantitation of forms 
  Solid-state NMR spectroscopy is uniquely suited for the quantitation of solid 
forms and solid formulations.  The technique is non-invasive, non-destructive, and 
inherently quantitative, so there is no need for a calibration curve with pure standards.  
The area of NMR peaks is proportional to the nuclei producing the NMR signal.  In 
order to obtain quantitative data, several factors must be considered.  First, the 
spectrum must be acquired with NMR parameters such that full relaxation of all 
compounds of interest is allowed.  Saturation occurs when a sample is acquired with a 
pulse delay shorter than five times the longest spin-lattice relaxation time of the 
individual components.  A pulse delay of five times the T1 results in 99.33% of the 
magnetic equilibrium to recover.  For single-pulse experiments using a sufficiently 
long pulse delay for all components in the sample, the relative peak areas can be 
compared to determine the percentage of each component in the sample.   
 During experiments where cross-polarization is used, the relaxation time is 
governed by the 1H spin-lattice relaxation.  The 1H T1 time is often shorter than 13C or 
19F T1 times, and the T1 is uniform throughout the sample due to spin diffusion. 
Comparing relative peak areas, which is done in a single-pulse experiment, is not 
acceptable for CP experiments because the magnetization transfer in a CP experiment 
is not instantaneous, and the kinetics of the transfer must be accounted for during 
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quantitation.  A review by Harris discusses the different aspects that must be 
considered during quantitative analysis using SSNMR spectroscopy.3 
 Offerdahl et al. demonstrated the utility of 13C CPMAS SSNMR to quantitate 
crystalline and amorphous forms of anhydrous neotame.4   The first thing to 
determine is which peaks are attributed to each solid form.  Peaks in SSNMR can 
vary up to 10 ppm from their solution chemical shifts, and spectral interpretation can 
be difficult.  Additionally, adequate peak resolution of each form present for ideal 
quantitation is necessary.  Once the specific carbon was selected for quantitation of 
each form it was necessary to determine the relaxation time constants TCH, 1H T1, and 
1H T1ρ associated with CP dynamics for each form.  By measuring each of these time 
constants, one can determine the relative number of nuclei for each form.  As noted 
before, the 1H T1 time is the amount of time it takes for the sample to return to 
magnetic equilibrium.  The 1H TCH and T1ρ time constants associated with the rise and 
decay, respectively, of the 13C magnetization upon cross polarization.  Figure 2.2 
displays the CP dynamics by plotting the natural log of relative peak area as a 
function of CP contact time for pure Forms A and G of anhydrous neotame.  From the 
plot, it is clear that spectra acquired at different contact times would produce different 
relative intensities for the same carbon in each form.  Because of this, spectra 
acquired with CP have traditionally been thought to be non-quantitative. 
  Figure 2.3 shows a 13C CPMAS spectrum of a 50/50 mixture of Forms A and 
G acquired with a 2-ms contact time.  The same aromatic peak in each form was 
deconvoluted.  The deconvoluted peak areas have different values because of the CP 
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Figure 2.2.  13C CPMAS SSNMR contact time profiles for neotame Form A and 




Figure 2.3. 13C CPMAS NMR spectra of a 50/50 (w/w) physical mixture of 
anhydrous Forms A and G of neotame.  The inset depicts the integrated peak areas for 








dynamics in the system. In order to determine the quantitative peak area, a plot of log 
of relative peak area versus contact time (> 5 TCH) was extrapolated back to the y-
intercept for each form.  This simulates the absence of 1H T1ρ relaxation and 
simultaneous magnetization transfer from 1H to 13C nuclei.  From the y-intercepts, the 
absolute peak area for each form can be determined.     
 Table 2.1 displays the calculated weight percent by mass and the percentage 
determined from 13C CPMAS experiments (NMR%) for the series of physical 
mixtures.  The SSNMR data agrees well for all of the mixtures in the series.   
 Quantitation was also performed on physical mixtures of the amorphous form 
and crystal Form G.  Figure 2.4 shows the 13C CPMAS spectrum of a 50/50 physical 
mixture of Form G and amorphous neotame.  Deconvolution peaks and peak areas are 
highlighted for the aromatic carbon used for quantitation.  The same method of CP 
correction, which was applied for quantitation of crystals Forms A and G, was used to 
quantitate the physical mixtures of amorphous neotame and crystal Form G.  Table 
2.1 displays the quantitation data for the physical mixtures of amorphous and 
crystalline neotame.  At first glance, the quantitation data does not agree between the 
calculated weight percent by mass and the calculated weight percent by SSNMR.  
When weight percent by mass and weight percent by SSNMR were plotted against 
each other, the slope was not one and a non-zero y-intercept was present.  The y-
intercept determined there to be a 13.5% amorphous impurity in the Form G standard.  
The data in Table 2.2 were recalculated to take into account the amorphous impurity  
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Table 2.1.  Quantitation data for various physical mixtures of Form A and Form G of 
neotame.  Adapted from reference 4. 
 
 
%A Form Mass (g) Wt. % Intercept Rel. Area R2 NMR % Diff (abs) 
A 0.0478 12.62 7.2984 1478 0.9998 13.7 10% G 0.3309 87.38 9.1421 9340 0.9899 86.3 1.0 
A 0.0759 21.20 4.9549 141.9 0.9992 22.0 20% G 0.2822 78.80 6.2208 503.1 0.9906 78.0 0.8 
A 0.1034 29.71 4.8991 134.2 0.9928 29.4 30% G 0.2446 70.29 5.7772 322.9 0.9682 70.6 0.4 
A 0.1273 39.12 5.0380 154.2 0.9779 37.9 40% G 0.1981 60.88 5.5337 253.1 0.9956 62.1 1.3 
A 0.1961 49.73 4.8556 128.5 0.9994 50.3 50% G 0.1982 50.27 4.8449 127.1 0.9954 49.7 0.5 
A 0.1954 61.56 4.8684 130.1 0.9995 62.3 60% G 0.1220 38.44 4.3667 78.8 0.9996 37.7 0.7 
A 0.2413 70.29 4.8870 132.6 0.9981 71.4 70% G 0.1020 29.71 3.9714 53.1 0.9476 28.6 1.1 
A 0.2966 80.88 4.8781 131.4 0.9991 81.8 80% G 0.0701 19.12 3.3723 29.1 0.9995 18.2 1.0 





Figure 2.4.  13C CPMAS spectrum of a 50/50 (w/w) physical mixture of amorphous 
Neotame and crystal Form G.  The inset shows the aromatic region of the spectrum 
and the deconvolution peaks and areas for each form.  Adapted from reference 4. 
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Table 2.2.  Quantitation data for various physical mixtures of the amorphous form 
and Form G of neotame.  Adapted from reference 4. 
 
% Amorphous Form Mass (g) Wt. % Rel. Area NMR % Diff (abs) 
Amorphous 0.0966 20.07 119.3 32.1 20% 
G 0.3847 79.93 252.8 67.9 
12.0 
Amorphous 0.1381 26.93 137.2 36.2 30% 
G 0.3748 73.07 242.2 63.8 
9.2 
Amorphous 0.1845 41.08 124.5 47.7 40% 
G 0.2646 58.92 136.6 52.3 
6.6 
Amorphous 0.2701 51.08 121.4 56.3 50% 
G 0.2587 48.92 94.1 43.7 
5.3 
Amorphous 0.3220 67.10 121.5 69.8 70% 
G 0.1579 32.90 52.5 30.2 
2.7 
Amorphous 0.3788 47.48 131.5 91.5 90% 





in the crystal Form G.  The new quantitation data agreed very well for each physical 
mixture 
 13C CPMAS SSNMR spectroscopy is able to quantitate both mixtures of 
crystalline forms and physical mixture of crystalline and amorphous form.  However, 
Offerdahl et al. were not able to easily observe the 13% amorphous impurity in the 
crystalline standard.  Additional NMR experiments confirmed the presence of the 
amorphous impurity.  Because NMR peaks of the amorphous form can be up to 10 
times broader than the crystalline form, a sample containing 10% amorphous material 
could give a peak with ~1% of the crystalline peak intensity.  To increase the 
sensitivity of similar experiments, other relevant nuclei are considered 15N, 17O, and 
19F.   
   
2.5 Pharmaceutically Relevant NMR-Observable Nuclei 
 
 The employment of high-power decoupling, magic-angle spinning, and cross 
polarization have transformed SSNMR into a powerful technique for pharmaceutical 
analysis.  As previously noted, it is difficult to obtain high-resolution NMR spectra 
for the 1H nucleus due to the large homonuclear coupling that exists in the solid state.  
13C CPMAS NMR is the primary experiment used on pharmaceutically relevant 
samples.  The low abundance, 1.1%, of the 13C isotope leads to long experiment 
times.  In some cases other nuclei should be considered.  The two most obvious 
choices with pharmaceutical relevance are 15N and 17O.  The 17O nucleus has a low 
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natural abundance (0.037%) and relative receptivity (0.0611) as compared to the 13C 
nucleus.  It is also a quadrupolar nucleus with a spin of 5/2.   The 15N nucleus also has 
a low abundance (0.37%) and relative receptivity (0.0219) as compared to the 13C 
nucleus.   
 31P and 19F are two other nuclei to be considered from an NMR perspective.  
Both nuclei are 100% abundant and have respective relative receptivities of 377 and 
4730.  When appropriate, 31P is an attractive nucleus to observe. However, there are 
few pharmaceutical compounds that contain 31P. 
 Over the past several decades, 19F has been designed into drug molecules to 
increase certain drug properties such as inductive effects, enhanced binding 
interactions, and metabolic stability by lowering the susceptibility of cytochrome 
P450 enzymatic oxidation.5-7   Current estimates have fluorine atoms in ~20% of all 
pharmaceuticals.5   The combination of high relative receptivity and growing 
presence in pharmaceuticals make 19F an attractive nucleus to utilize for analysis of 
pharmaceutical solids.   
 
2.6 19F SSNMR spectroscopy 
  
2.6.1 Comparison to 13C SSNMR spectroscopy 
 When applicable, the 19F nucleus is a good complement to observing the 13C 
nucleus.  Depending on the sample, 13C SSNMR spectra typically take several hours 
to days to collect.   Due to the high relative receptivity of 19F, a SSNMR spectrum can 
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be collected in a fraction of the time with a fraction of the sample mass.  The 13C 
spectrum often has many peaks that can overlap with each other and make spectral 
interpretation difficult.  Additionally, the excipients will be observed in the spectrum 
that could complicate interpretation further.  19F SSNMR spectra typically have just a 
few peaks due to the fewer number of 19F atoms in the molecule.  There is no spectral 
interference from excipients, because no commonly used excipients contain fluorine.  
The chemical shift range is also much larger for 19F NMR.  Typically, 13C SSNMR is 
acquired with a spectral width of 30 kHz and 19F SSNMR is collected with a spectral 
width of 100 kHz.   
 There are several drawbacks to observing the 19F nucleus.  First, fluorine is 
not present in every pharmaceutical.  Second, the strong homonuclear coupling and 
large CSA in fluorine-containing samples may require fast MAS speeds (>10 kHz).  
To spin faster than 10 kHz rotors with smaller sample volumes must be used to reach 
these speeds.  The fast MAS speeds also cause significant sample heating8, which 
could induce physical transformations in a sample.  Next, the linewidths in 19F 
SSNMR spectra are broader than in 13C spectra.  Finally, there are generally fewer 19F 
peaks in the NMR spectrum.  When quantitating solid forms, it can be beneficial to 
have several different peaks to compare.  Different atoms can have varying degrees of 
resolution.  If corresponding peaks from multiple forms overlap in a 13C NMR 




2.6.2 Pharmaceutical applications 
 The homonuclear interaction of fluorine atoms can produce NMR linewidths 
in excess of 30 kHz in the solid state, if fluorine atoms are present at high levels.9   In 
order to overcome such large dipolar couplings it is necessary to spin at a higher rate 
than the dipolar interactions present in a sample, or approximately 10 kHz.  Prior to 
these probe developments, several multiple-pulse sequences were employed to reduce 
homonuclear dipolar interactions such as the WAHUHA-4, MREV-, and BR-24 
sequences.  All of them operate under the same principle: suppression of the dipolar 
interaction while the shielding anisotropy information is retained.  The multiple-pulse 
sequences were troublesome when there were multiple fluorine types in a sample.  
The uses of these sequences were limited to mobile polymers and inorganic fluorides 
spinning at slow speeds. Commercially available probes that spin samples at fast 
spinning speeds (>15 kHz) have been developed over the last 20 years.  These probes 
opened the door to more fast-spinning applications such as the study of fluorocarbon 
polymers.  Isbester et al. used 19F SSNMR spectroscopy and combined high MAS 
rates (>25 kHz) with elevated temperatures (>150 °C) to dramatically improve the 
resolution of the NMR spectra of Kel-F, a fluorocarbon polymer composed of 
vinylidene fluoride and chlorotrifluoroethylene.10   The research was extended to six 
other vinylidene fluoride based polymers where elevated temperatures (250 °C) and 
fast MAS rates (>25 kHz) produced solution-like spectra of the polymers.11   The 
increased resolution from these conditions allowed assignment of monomer peaks 
based on solution NMR data.  The monomer composition of each of the six polymers 
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was quantitated and agreed with monomer composition data from solution 
spectroscopy.    
 Fast spinning speeds help eliminate the 19F homonuclear dipolar coupling, but 
the samples analyzed have had few to no 1H nuclei in the molecular structure.  There 
is little heteronuclear line broadening that exists.  However this is far from the case 
for pharmaceutical samples. Prior to 1996, solids containing abundant protons 
received very little attention with 19F SSNMR spectroscopy.12 For other common 
pharmaceutically relevant NMR nuclei (13C, 15N), high-power proton decoupling can 
be applied with relative ease, and the dipolar interactions with 1H nuclei can be 
suppressed.  However, due to the proximity of the 19F and 1H resonant frequencies 
(284 vs 300 MHz at 7 T), high-power proton decoupling represents a significant 
challenge for 19F NMR of proton-containing solids.  High-specification filters that can 
efficiently discriminate between two nearby frequencies became available in the past 
15 years.12   Carss et al. demonstrated the use of high-power proton decoupling, fast 
MAS, and cross polarization on three fluorinated steroids.12   The researchers were 
able to detect polymorphism in one of the steroid samples.  The improvement in 
resolution from the employment of these techniques also allowed the researchers to 
study several other phenomena: dipolar dephasing, rotational resonance, and spin 
diffusion.    
 The production of probes equipped to spin at fast speeds coupled with high-
specification filters, the increased development of fluorine-containing 
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pharmaceuticals and the advent of SSNMR spectroscopy, have made 19F SSNMR a 
promising tool for analysis of solid-state drug substances and drug products.   
  
2.6.3 Pharmaceutical applications of  19F SSNMR spectroscopy 
 19F SSNMR has been applied to a variety of pharmaceutical systems.  
Wenslow used 19F SSNMR spectroscopy with fast MAS (15 kHz) to characterize 
low-dose (2%) tablets of multiple solid forms, including two anhydrous (forms I and 
II), one sesquihydrate, and one amorphous form, of a Muscarinic M3 receptor 
antagonist.13   19F SSNMR was successful in distinguishing between each of the four 
pure solid forms.  The 19F NMR spectrum of a low-dose placebo of 2% form I was 
compared to a tablet dosed with 2% form I.   The spectra of the tablet showed that the 
desired form I had converted to another crystalline form or the amorphous form.  
High-temperature (110 °C) 19F MAS conditions were used in an attempt to produce 
higher resolution spectra.  The spectra of the sesquihydrate and amorphous forms 
were collected immediately upon reaching the elevated temperature.  Line narrowing 
was observed for both forms, which was attributed to increased molecular motion due 
to solvent escape.  Multiple solid forms were identified and analyzed with 19F 
SSNMR spectroscopy.  Additionally, it was shown that changes in the solid form of 
the API could be monitored in low-dose formulations.13 
 Farrer et al. used 1H/19F CPMAS SSNMR to quantitate crystalline material 
within a liquid vehicle.14   Crystalline sodium (2R)-7-{3-[2-chloro-4-(2,2,2-
trifluoroethoxy)phenoxy]propoxy}-2-methyl-3,4-dihydro-2H-chromane-2-
 56 
carboxylate (I) was detected at low levels (0.2mg/g) within a solid mixture and a 
slurry with a liquid vehicle.   The area of the NMR peaks in the 1H/19F CPMAS 
spectra of the solid mixture and the slurry were both linearly dependent upon the 
mass of I in the rotor as determined by HPLC with a least square fit below 2%.  The 
limit of detection was 2% crystallization within a 100mg/g formulation of I.  
Increased signal-averaging could improve the signal-to-noise ratio and lower the limit  
of detection.   
 Aso et al. demonstrated that 19F SSNMR spectroscopy could be used to assess 
the molecular mobility of amorphous flufenamic acid in a melt quenched solid 
dispersion15   Amorphous solid dispersions were prepared by melt-quenching 
flufenamic acid (FLF) in various ratios with poly(vinylpyrrolidone) (PVP) or 
hydroxypropylmethylcellulose (HPMC).  The spin-lattice relaxation times (T1 and 
T1ρ) were measured for each dispersion across a range of temperatures (-20 to 150 
°C).  A minimum in the relaxation times was exhibited across the temperature range.  
The minimum relaxation time and the observed relaxation value were used to 
calculate the correlation time (τc) or rotational molecular mobility of the sample.  The 
τc value for the 20% PVP dispersion was 2-3 times longer than the 20% HPMC 
dispersion.  This indicated that the molecular mobility of FLF in the 20% PVP solid 
dispersion was significantly lower than the 20% HPMC dispersion.  When the solid 
dispersions were stored at 60 °C, the crystallization of the amorphous FLF was 
monitored by analyzing the solid echo signals of the fluorine atoms in FLF, and the 




 The incorporation of magic-angle spinning, high-power proton decoupling, 
and cross polarization have transformed 13C SSNMR spectroscopy into a powerful 
tool for analysis of solid-state pharmaceuticals.  It has been demonstrated to be 
particularly useful in distinguishing different crystalline and amorphous solid forms, 
quantitation of different forms, and observing the API in a formulation.  However, the 
low natural abundance of the 13C nucleus and long relaxation times in the solid state 
can lead to prohibitively long analysis times, especially in low-dose formulations and 
low-level detection of the amorphous state.  19F NMR is a relatively new technique to 
be used for the analysis of solid-state pharmaceuticals.  19F SSNMR can distinguish 
between different physical forms, quantitate crystalline material in a formulation, and 
be used to monitor differences in molecular mobility of amorphous solid dispersion 
that correlate with the relative physical stability of the drug in dispersion.  
 The objective of the research presented in this thesis was designed to reduce 
the analysis time of SSNMR by increasing the sensitivity of this technique using two 
approaches.  First, the design, development, and testing of a multiple-sample solids 
probe for solid-state NMR spectroscopy was accomplished and is presented in 
Chapter 3.  A prototype probe was constructed that shuffled two samples through the 
bore of the superconducting magnet for simultaneous data collection.  Data for 
identical samples could be acquired in both modules to increase sensitivity, or data 
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for different samples could be acquired simultaneously in each module to increase 
throughput.   
      In Chapters 4 and 5, a second method for increasing sensitivity is 
presented.  This approach takes advantage of the relative NMR receptivity of the 19F 
nucleus as compared to the 13C nucleus.  It is then possible to quantitate low-level 
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Solid-state NMR spectroscopy (SSNMR) is a very powerful technique for the 
analysis of pharmaceuticals and pharmaceutical formulations, because of the vast 
quantity of information obtained about the structure and dynamics of compounds in a 
formulation.1-3  SSNMR has the capability to determine the state of a drug either in 
the bulk state or within a formulated product without having to extract the drug from 
the formulation.  It is selective, in that the drug usually has a different chemical shift 
than that of the excipients, making it easy to identify the drug in the formulation.  
SSNMR is quantitative, and can be used to determine the relative amounts of 
different crystalline forms and amorphous content.  Drug–excipient interactions can 
also be studied.  Determination of mobilities can help identify why a drug may have 
failed (or will fail) stability tests.  Controlled-release devices are complex systems 
which could be much better formulated if the state of the drug could be determined 
directly, which is possible using SSNMR.   
New drug compounds are often poorly crystalline or even amorphous, have 
long relaxation times, and are present at low levels in a formulation.  This creates a 
significant problem for analyzing these compounds with SSNMR.  Analysis times can 
range from a few minutes to a few days, depending upon the state of the sample (i.e. 
bulk drug or formulated product; crystalline or amorphous), relative sensitivity (i.e. 
choice and number of different nuclei in molecule), and relaxation parameters.  For 
example, quantitation of a mixture of two forms of a compound can take a few hours 
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(for a sample with short relaxation times) to a few days.  Analyzing a series of 
formulated products may take a month or more of spectrometer time.  This leads to 
low throughput, high cost per sample analysis, and has relegated SSNMR in many 
cases to be a prohibitively expensive problem-solving technique compared to other 
analytical techniques such as powder X-ray diffraction (PXRD), infrared and Raman 
spectroscopy, and differential scanning calorimetry (DSC).  
 Increasing the signal to noise ratio (SNR) by signal averaging (in samples 
containing nuclei with low magnetogyric ratios, low natural abundance, and low 
sample concentration) is a problem if the sample has spin-lattice relaxation times (T1) 
of minutes, hours, or even days, because the number of transients acquired is limited 
to one to several dozen.  Table 3.1 shows the relaxation times for many 
pharmaceutical solids reported in the literature.4-10   For example using aspirin as a 
representative pharmaceutical solid, it has a 1H T1 relaxation time of approximately 
30 s at 300 MHz.  In a 13C cross polarization magic-angle spinning (CPMAS) 
experiment the delay between acquisitions must be > 90 s to avoid saturation.  Note 
that some of the compounds listed in Table 3.1 may have been chosen for study by 
researchers because they have relatively short relaxation times and could produce 
high-quality spectra in a short period of time. 
 The SNR in an NMR experiment is proportional to the signal divided by the 
noise.11   The two most common approaches to improve SNR are to increase signal or 
decrease noise (or both).  This assumes that the sample and coil are at the same 
temperature, and does not take into consideration fixed parameters such as line width,  
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Table 3.1.  Pulse delays for various pharmaceutical compounds. 
Compound 1H Frequency 
Pulse Delay 
(s) used 
Pulse Delay at 
9.4 T (s) Ref, 
R.O.Y.* 300 40-70 70-125 4 
Cimetidine 360 15 18 5 
LY297802 400 5-10 5-10 6 
Ephedrine 200 1.5 6 7 
Aspirin 300 90 160 † 
Salicylic Acid 300 1000 1780 † 
Prednisolone t-Butylacetate 200 3 12 8 
Acetaminophen 200 2 8 9 
Carbamazepine 200 3 12 10 
Enalapril Maleate 200 2 8 9 
Ibuprofen 200 2 8 9 




magnetogyric ratios, spin quantum numbers, etc.  A further discussion of optimizing 
sensitivity can be found in Freeman.11   One potential solution to increasing signal is 
higher magnetic field strengths, but that also has several disadvantages for solid 
pharmaceuticals.  First, resolution often will not increase dramatically at higher fields 
if the sample line width is limited by bulk magnetic susceptibility or a range of 
conformations (as in amorphous materials).  Second, higher fields require faster 
spinning speeds to obtain the same separation in parts per million (ppm) between 
isotropic peaks and spinning sidebands.  This implies smaller sample volumes or 
masses and therefore less signal per scan.  Third, for crystalline solids, especially 
those without methyl groups, the relaxation rate is often inversely proportional to the 
square of the magnetic field strength.12,13   Going from 7.05 T to 18.8 T could 
potentially increase relaxation delays by about a factor of seven, significantly 
mitigating any sensitivity gains obtained by going to higher field strengths.   
 Another method to increase signal intensity is to increase the sample volume.  
However, there are several significant limitations to the development of a large MAS 
probe capable of CP and high-power 1H decoupling.  These include producing a high-
power 1H RF field capable of minimal decoupling for a moderately rigid proton 
environment, the ability to spin a large sample at the magic angle with minimal 
sidebands, and producing a homogeneous magnetic field over the entire sample.  In 
fact, the directions of research in MAS has been to decrease sample size.  Finally, 
lowering the temperature of the coil and other electronics can reduce noise, and is the 
approach taken in the cryoprobe.14,15  The sensitivity gains arise from lower noise 
 67 
figures for both the coil and the preamplifier, and a higher Q (quality factor).14   Some 
sacrifice is made in filling factor, which limits the gains in sensitivity.  In the solid 
state, especially for MAS systems, cooling the coil without cooling the sample would 
be extraordinarily difficult, although there are current research efforts in this area.16  
Even cooling the entire MAS system is technically challenging. 
 Oldfield recognized more than a decade ago that throughput was a significant 
issue with high-field NMR spectrometers.17   He designed a probe that contained 
three different samples simultaneously located in the homogeneous region of the 
magnetic field.  Although in his design all of the samples were static, he proposed 
that at least one could incorporate sample spinning.  The resolution of this system was 
quoted as ~1 ppm.  This concept has been extended to solution NMR spectroscopy.18-
25  Raftery and coworkers have shown that up to four different samples could be 
located simultaneously in the homogeneous region of the magnetic field.18  However, 
the increase in the number of samples simultaneously present in this region of the 
magnetic field comes at a cost of smaller sample volumes.  This design does not 
easily allow for incorporation of MAS for multiple samples at typical (0.5 cm3) solid 
sample sizes. 
 In a typical 1-dimensional NMR experiment, an RF pulse is applied and a 
single scan or transient is acquired and collected on the order of the spin-spin 
relaxation (T2) time.  In signal averaging, a pulse delay, on the order of the spin-
lattice relaxation (T1) time, is necessary before a subsequent pulse can be applied.  
This means that the preparation and acquisition time, rather the time the spectrometer 
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is actively collecting data is typically tens of milliseconds (typical T2 times).  Before 
the sample can be pulsed again, the spins must relax for several seconds to several 
hours (representative T1 times) as the bulk magnetization returns to its equilibrium 
value.  During this time the sample must remain in a large static magnetic field while 
the spectrometer hardware is idle.  During relaxation the external magnetic field is not 
required to be homogeneous.  The spin-lattice relaxation time, T1, is usually several 
orders of magnitude longer than T2 in the solid state.12   Because of this, the 
spectrometer is idle for a very large percentage of the time a sample occupies the 
magnet. Our approach to increasing sensitivity and throughput uses the fact that in 
SSNMR, the spin-spin relaxation time, T2, is usually several orders of magnitude 
shorter than T1.  We exploit this fact by shuttling multiple MAS systems through the 
magnet bore, pulsing another sample while the original sample is undergoing T1 
relaxation. 
 
3.2 Probe Concept and Design Considerations 
 
3.2.1 Probe concept 
 The basic probe design consists of multiple MAS systems that are located in 
the bore of the superconducting magnet dewar.  One possible design of this probe is 
shown in Figure 3.1.  The MAS modules can be moved into the homogeneous region 
of the magnet for signal acquisition.  When the signal is not being acquired, the 
spinning systems may be moved into a non-homogeneous magnetic field.  The MAS 
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modules are moved in the bore of the magnet using an electric, hydraulic, or other 
mechanism that can change the location of the MAS modules in the magnet bore.  In 
Figure 3.1, the concept of using a stepping motor assembly to move the probe in the 
magnetic field is shown.  Ideally, each spinning system would feature its own air 
supply lines, radio-frequency (RF) connections, and magic-angle adjustment 
mechanism, although some or all of these features may be combined. In the design 
shown in Figure 1, there is a remote RF tuning and switching box that serves two 
purposes.  First, each MAS module/circuit can be selected independently for signal 
acquisition.  Second, it allows each circuit to be tuned independently outside the bore 
of the magnet dewar.  Each module may have variable-temperature capability, 
independent spinning speed control, and independent shimming parameters.  
There are several advantages of this probe design.  First, it has the capability 
of increasing throughput by a factor of 2–10, depending upon the number of spinning 
modules/samples that could be analyzed.  This number could be significantly higher, 
if the analysis time for one sample was several days.  During that time, the samples in 
the other spinning modules could be changed several times without disturbing the 
sample with the long analysis time. Moreover, this system has the capability of being 
automated, because the probe would be designed so that all of the MAS modules 
could be accessed from below the magnet. The throughput advantage could be 
increased to 10–50 compared to a probe with no autosampler, if the samples were 
changed five times during an overnight run or over a weekend.  If the choice were  
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Figure 3.1.  Schematic of experimental design. (A) superconducting magnet dewar; 
(B) MAS modules in magnet bore; (C) homogeneous region of magnet; (D) coaxial 
cables supplying each module; (E) RF switching and external tuning device; (F) 
connection to X and H high-power RF amplifiers; (G) air supply lines; (H) micro-











made to run the same sample nine times, then the SNR would be tripled.  It would 
take nine times as long to triple the SNR by signal averaging using just one spinning 
module.  Moreover, there should be little or no loss in field homogeneity, sensitivity, 
MAS speed, or 1H decoupling field strength compared to conventional NMR probes, 
nor is there a need to develop specialized spinning modules, pulse sequences, or RF 
technology.  While this approach can be used at any magnetic field strength, it would 
work better at higher field strengths, where T1 relaxation times are several times 
longer than at lower field strengths.13   Higher fields also imply faster spinning 
systems and therefore smaller sample volumes and MAS modules. This would mean 
that more spinning systems could be placed in the static magnetic field, enabling 
more samples to be run. 
There are also some limitations to this probe design.  For example, this probe 
design is not as useful for studying nuclei in samples that have short relaxation times, 
such as many quadrupolar nuclei.  Also, additional sample is needed if an increased 
SNR is desired.  The modules would be self-contained, which could limit the 
experiments to fixed angle, double resonance, and room temperature. The constant 
moving of the probe may make it more prone to mechanical breakdown, and the 
multiple spinning modules/circuits will increase maintenance problems.  Finally, 
having multiple spinning modules will require significantly more compressed air.  All 
of these limitations are relatively minor compared to the gains in 
throughput/sensitivity that would be achieved with this probe. 
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3.2.2 Magnetic field strength along the magnet bore 
 The ideal superconducting magnet for the multiple-sample probe would have 
a magnetic field strength that remained approximately constant for as long as possible 
along the axis of the solenoid.  A diagram of the field strength for an Oxford (Oxford, 
UK) 9.4 Tesla, 89 mm bore magnet is shown in Figure 3.2.  The effective field, 
defined as the point at which the field remains >80%, is ~18 cm from the center of the 
solenoid.  If all samples were confined to an 18 cm range, then only the two outer 
samples would feel a magnetic field of <95%, and then only while one of the outer 
samples was being analyzed. 
 
3.2.3 Objectives 
 The goal of Chapter 3 is to demonstrate that current probe technology can be 
used to develop a two-module SSNMR probe.  The following sections will exhibit the 
construction, spectrometer integration, proof of concept, and pharmaceutical 





 The hexamethyl benzene (HMB) used to demonstrate proof of concept was a 





Figure 3.2. Schematic of the magnetic field strength gradient experienced by 
modules positioned 5 cm apart (center to center) in a 9.4 T Oxford superconducting 
magnet. 
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 operation.  Aspirin and ibuprofen were purchased from Sigma (St. Louis, MO) and 
used as-received without further processing.  
   
3.3.2 Solid-state NMR spectroscopy 
 All spectra were acquired using a Chemagnetics (Fort Collins, CO) CMX-II 
SSNMR spectrometer operating at 75.6 MHz for 13C.  Samples were packed in a 7.5 
mm O.D. zirconia rotor with a Kel-F endcaps and drive tip.  Samples were spun at the 
magic angle at a rate of ~3.0 kHz.  Variable-amplitude cross polarization (VACP)26,27 
was used to acquire all spectra.  Proton decoupling powers of 40-80 kHz were used to 
acquire all spectra.  Acquisition parameters for hexamethylbenzene (HMB) were:  
512 data points, 30 kHz spectral width, and 17 ms acquisition time.  All spectra were 
zero-filled to 4096 points prior to Fourier transform.  No apodization was used. SNR 
measurements of HMB spectra were made by using a macro feature of the Spinsight 
software (Chemagnetics; Fort Collins, CO).  Noise was sampled over a 30 ppm 
chemical shift range.  Signal intensity was determined from the methyl peak of HMB.  




 The results section of Chapter 3 is divided into two parts.  In the first part the 
design and testing of a two-module prototype probe are described.  The second 
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describes the design and testing of a single-module probe that can be scaled up to 
seven modules. 
 A two-sample probe based upon a lumped element (Hester-Waugh)28 tuning 
circuit was developed to test the feasibility of multiple-sample probe technology.  A 
picture of the probe is shown in Figure 3.3.  The probe was designed and built in our 
laboratory with a rotational axis of symmetry which facilitated construction.  There 
were four main components to the probe: MAS modules (Figure 3.3 b and d), air 
lines, tuning circuits, and RF transmission lines.  Standard Varian (Palo Alto, CA) 7.5 
mm spinning modules were used.  The modules were approximately 1.5” in diameter 
and have the capability to spin 7.5 mm zirconia rotors to speeds of 7 kHz.  Flexible 
plastic tubing, 1/8” i.d., supplied compressed air to Delrin plastic supports.  The 
Delrin supports held the spinning module in place and delivered the drive and bearing 
gas for the spinning systems.   
 The tuning circuit was comprised of several elements based on the Hester-
Waugh28 design.  The coil was made from four turns of 16-gauge (0.0508” diameter) 
solid copper wire.  American Technical Ceramics (Huntington Station, NY) fixed 
capacitors, and variable capacitors from Polyflon (Norwalk, CT) were used to match 
and tune the circuit. A quarter wavelength isolation element was made by using 1/2” 
o.d, copper pipe and 3/16” diameter solid copper wire to complete the tuning circuit.  
Tuning wands made of mixed plastic and brass parts were used to adjust the variable 
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Figure 3.3. Picture of multiple-sample probe with lumped element (Hester-Waugh) 
tuning circuits:  (a) top tuning circuit,  (b) top MAS module, (c) RF isolation plane, 
(d) bottom MAS module, (e) bottom tuning circuit, (f) tuning wands.
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 capacitors from outside the magnet.  RF power was supplied to the tuning circuit via 
1/8” o.d., semi-rigid copper coaxial cable.
 Figure 3.4 shows a photograph of the two-module probe in the bore of the 
superconducting magnet dewar.  A PVC probe guide was used to avoid having the 
probe body rub against the magnet bore while moving.  An Emerson Electric Co. (St.  
Louis, MO) model DXM-138 stepper motor, controlled via model MO35138 
controller, was attached via pulley to a worm screw.  The worm screw could adjust 
the assembly (shown in Figure 4b) approximately 20 cm.  Operation of the stepper 
motor under the magnet had no noticeable effect on the spectra. 
The samples in the MAS modules were located approximately 12 cm apart in 
the probe.  When the top module was located in the homogeneous region of the 
magnet, it took roughly 1 s to move the bottom module into the homogeneous region 
of the magnet.  For an unidentified reason, possibly related to the controller software, 
it took approximately 2 s to lower the two-module probe.  A computer running a 
Microsoft Excel macro was used to control movement height and speed.  Although it 
was possible to interface the movement control to the spectrometer hardware, the 
difficulty in synchronizing the two programs prompted us to delay direct 
spectrometer interfacing. 
 The spectra of HMB acquired in both the top and bottom spinning modules 
are shown in Figure 3.5.  The SNR for the top module was ~320, which was 
comparable to the SNR observed using our conventional probes.  The SNR of the 




Figure 3.4.  Photograph of probe in magnet.  The probe is moved using a stepper 












Figure 3.5. HMB spectra acquired from top and bottom module.  Each spectrum was 
12 acquisitions and each acquisition was alternated between the modules: (a) 
schematic of module position in magnet and pulse timing, (b) spectrum acquired in 





The 1H 90° pulse widths for both modules were ~4.0 µs.  The spectra in Figure 3.5 
were acquired by alternating each acquisition between the top and bottom module, 
showing that it was possible to return each module in the probe to the homogeneous 
region of the magnet. 
Figure 3.6 shows a spectrum of HMB acquired with motion using a single 
module.  The purpose of this experiment was to synchronize data acquisition with 
probe/sample movement and to demonstrate robustness of the NMR acquisition.  The 
schematic in Figure 3.6a shows the timing sequence of the probe movement in the 
bore of the magnet.  Figure 3.6b is the NMR spectrum of HMB acquired while 
moving the probe as if spectra from two modules were being collected.  The 
following cycle took 5 s, where the order refers to which sample is in the 
homogeneous region of the magnet:  top module (1 s), move to bottom (1 s), bottom 
module (1 s), move to top module (2 s).  The cycle of probe position was very 
reproducible, and a spectral acquisition with a 4.8 s pulse delay was used, starting 
with the top module in the homogeneous region of the magnet.  The HMB spectrum 
obtained was comparable to those acquired without movement in Figure 3.5. 
 Aspirin and ibuprofen were used to demonstrate the pharmaceutical 
applicability of the two-module prototype.  A spectrum of aspirin was collected in 
one module while ibuprofen was collected in the other.  The sample of crystalline 
aspirin had a 1H T1 time of ~60 s at 7.05 T.  For optimal SNR per time, pulse delays 
of  ~1.25 times the T1 value are used.  The sample of aspirin was collected with a 90-s 
pulse delay, and 64 transients were acquired.  Ibuprofen has a 1H T1 time of ~2 s, and
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Figure 3.6. Spectrum of HMB acquired using the bottom module with the pulse 
sequence timing chosen to coincide with probe movement:  (a) schematic of timing of 











a 3-s pulse delay was used.  The probe pulsed the ibuprofen sample in the bottom 
module 30 times while the aspirin magnetization was allowed to equilibrate.   Then 
the stepper motor lowered the probe height until the top module was in the 
homogeneous region of the magnet.  At this point, one transient of aspirin was 
collected.  The probe was raised, and this cycle was completed 64 times.  In the end, 
64 transients of aspirin were collected along with 1920 transients of ibuprofen.  The 
13C CPMAS NMR spectra of aspirin and ibuprofen are shown in Figure 3.7.  The 
spectrum of aspirin acquired simultaneously with ibuprofen is shown in Figure 3.7b.  
The spectrum of ibuprofen is displayed in Figure 3.7c.  A spectrum of aspirin was 
acquired with 64 transients without motion to compare the spectral quality with and 
without motion.   
 Several interesting features can be observed from the spectra in Figure 3.7.  
First, the spectra of aspirin acquired with and without movement are nearly 
indistinguishable.  There may be slight differences in peak resolution, which could be 
attributed to intermittent arcing, changes in tuning, and/or the overall efficiency of 
probe operation.  Second, the field at which the aspirin was located while the 
spectrum of ibuprofen was acquired must have been very close to 7 T in order for the 
Boltzmann population difference to return to the same value as in the spectrum 
acquired without movement.  Finally, the concept of sample shuttling has been 




Figure 3.7. 13C CPMAS Spectra of aspirin and ibuprofen:  (a) aspirin acquired 
without motion, (b) aspirin acquired with motion and switching, (c) ibuprofen 
acquired with motion and switching. 
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 3.5 Conclusions 
 
 In this chapter, a two-module prototype probe was constructed using current 
probe technologies.  Spectra were collected on each module that had comparable 
SNR of those manufactured by Chemagnetics.  A stepper motor was attached and the 
motion of the probe was synchronized with data acquisition.  Lastly, the 13C CPMAS 
spectra of two pharmaceutical samples were acquired simultaneously.  To fully 
incorporate this probe, it is necessary to further investigate many areas, specifically 
RF isolation between modules and magnetic field gradient effects on relaxation.  
First, the proximity of each module in relation to the other might allow “cross talk” 
between modules.  The RF pulse on one module could potentially affect the signal in 
the other module.   Proper RF isolation will eliminate this possibility.  There were not 
issues with RF isolation on the two-module protype; however, the modules in the 
two-module prototype were ~12 cm apart.  The incorporation of additional modules 
would cause the distance between modules to be reduced to a few centimeters.     
Second, spin-lattice relaxation times are a function of magnetic field strength.  When 
a sample is relaxing outside the homogeneous region, the magnetic field gradient 
causes it to experience a slightly slower magnetic field.  The amount of time a sample 
spends at lower field strengths could affect its T1 time.  Before the probe is used for 
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 There is a significant interest in being able to quantitate the solid forms 
present in a formulated product, as these forms can significantly contribute to the 
overall chemical and physical stability, dissolution rate, bioavailability, and overall 
therapeutic efficacy of the drug product.1-4   In particular, detecting and quantitating 
mixtures of crystalline and amorphous forms of an API is a challenging problem.1,2   
Traditional analytical methods such as DSC and PXRD have difficulty in detecting 
and monitoring amorphous drug content when it is below 5%. 
 Solid-state NMR spectroscopy has great potential to quantitate crystalline and 
amorphous content in pharmaceutical formulations.  The objective of this research is 
to determine the limits of detection and quantitation crystalline and amorphous forms 
of API in formulations using 19F SSNMR.5,6  19F SSNMR provides several advantages 
over the more traditionally observed 13C nucleus such as improved sensitivity and no 
background from excipients.  However, a major concern with 19F SSNMR for 
quantitation purposes is the ability to discriminate between the crystalline and 
amorphous components.  In order for us to determine the ability of 19F SSNMR to 
quantitate API forms, it was determined that it was necessary to generate pure 
standards of fluorine-containing API.  Having pure standards of each form can greatly 
aid in quantitation, because NMR properties such as relaxation times and line widths 
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can be measured for the pure material. In addition, pure standards allow for the 
technique to be validated for the system under study.   
 In this chapter the process of selecting an appropriate compound for study will 
be described.  We identified the following characteristics that a standard should have: 
physical and chemical stability; reproducible generation of crystalline/amorphous 
forms using standard techniques such as recrystallization, desolvation, cryogrinding, 
milling, lyophilization, or spray drying; compatibility of forms such that one form 
will not induce changes in another form; and 19F SSNMR chemical shift separation 
between amorphous and crystalline forms.   
 
4.1.2 Generating stable amorphous compounds 
 Although macromolecular excipients, large peptides and proteins are usually 
amorphous, small molecule organic molecules, such as many of the current API on 
the market, are usually crystalline.  There are several common methods that are used 
to make these small-molecule compounds amorphous.  Some of these include: 
supercooling a melt, milling, vapor condensation, and precipitation.  These techniques 
are briefly described in the following paragraphs.   
 Melting a solid forms a liquid in which the molecules are randomly distributed 
with a high degree of molecular motion.  If this liquid can be cooled below its melting 
temperature (Tm) without solidification, the disorder of the liquid can be kinetically 
frozen, and is referred to as supercooled melt. 
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 Milling crystals can destroy the long-range order of the crystalline material.  
Cryomilling or cryogrinding consists of grinding a sample in a bath of liquid nitrogen.  
An advantage of cryogrinding rather than milling is the reduced likelihood of thermal 
degradation.   
 Spray drying and lyophilization are examples of precipitation from solution, 
and can be used to generate the amorphous form.  In the case of lyophilization, the 
drug solution is frozen and the solvent slowly sublimes.  As the solvent is removed, a 
high degree of disorder of the drug can be retained.  Lyophilization requires that a 
solvent exhibits a triple point and does not transition through the liquid phase prior to 
reaching the gas phase.  A liquid phase could allow the material to crystallize.  Spray 
drying consists of spraying drug solution through a heated nozzle and exposing the 
droplets to heated gas.  The solvent rapidly evaporates, and/or the material condenses 
quickly from the solution.  In many cases, the compound will retain the molecular 
disorder it possessed in the solution.  
 
4.2 Selecting a Model Amorphous Compound as a Quantitation Standard 
  
 An acceptable fluorine-containing model compound for these studies has to 
contain fluorine and be pharmaceutically relevant.  The intent of the project was to 
demonstrate the ability of 19F SSNMR spectroscopy to quantitate low levels of 
amorphous material in drug substance and drug product, so only compounds that are 
currently marketed or were previously marketed were considered. 
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 The amorphous form of the model compound should have two important 
characteristics.  First, the form should be physically stable.  A common rule of thumb 
to ensure physical stability is to be 50 °C below the glass transition, so an ideal Tg is 
greater than 50 °C above ambient temperature.7   When possible, the experiments 
were performed at ambient temperature.  If the Tg is too low, the amorphous form 
could crystallize during the experiment.  Second, the crystalline and amorphous forms 
of interest should have significantly different chemical shifts in the 19F SSNMR 
spectrum.  Chemical shift resolution of several ppm is necessary because amorphous 
materials typically have very broad peaks.  If adequate resolution cannot be achieved, 
then the amorphous and crystalline peaks must be deconvoluted. Many solid forms of 
the same drug have different SSNMR properties.  Amorphous forms of drugs 
typically have NMR line widths that are much broader (5-10 times) than their 
crystalline counterparts.  The breadth of the lines is due to the increase in distribution 
of molecular environments.  It is common for different solid forms to have different 
chemical shifts and NMR relaxation times.   
 A search was performed to locate pharmaceutical substances to consider as 
potential model compounds for quantitation using 19F SSNMR spectroscopy.  
Presented in Table 4.1 is a list of potential candidates.  The compounds in the list are 
used in many different therapeutic areas, and the vast majority of these compounds 
contained a single mono-fluoro (-F) or trifluoromethyl (-CF3) group.  Each compound 
was examined to determine the suitability for quantitation of   
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Table 4.1. Physicochemical and cost data for some of the potential model compounds 
for 19F NMR quantitation.  The data help determine which amorphous generation 
process is best suited for each compound. Sample mass is determined based on the 






amorphous content by 19F SSNMR.  Table 4.1 contains a list of common fluorine 
drug compounds, sample mass availability based on cost, the melting temperature 
(Tm) (the Tm could change based on solid form or processing), and the estimated glass 
transition (Tg) temperature.  Several examples were chosen to highlight the 
difficulties in selecting an ideal model compound.  It should be noted that many of 
these compounds were potentially chosen for development because of their relative 
physical and chemical stability and may not be representative of many of the 





 Bendroflumethiazide, ciprofloxacin, 5-fluorouracil, levofloxacin, and 
triamcinolone were purchased from Sigma (St. Louis, MO).  Dexamethasone was
purchased from Alfa Aesar (Ward Hill, MA).
4.3.2 Sample preparation 
  Multiple sample preparation methods were used to create amorphous 





 Cryogrinding was performed with a SPEX CertiPrep 6750 Freezer/Mill 
(SPEX CertiPrep, Inc., Metuchen, NJ).  Approximately 500 mg of as-received 
material was loaded into the cryovial for each process. Samples were pre-cooled for 
15 minutes, followed by 30 cycles.  Each cycle consisted of two minutes of impaction 
and two minutes of cooling time.  The impaction rate was 10 impacts/s.  After 
grinding, the cryovial was allowed to return to ambient temperature while umder 
vacuum prior to removal of the powdered sample in order to prevent the formation of 
condensate on the powder. 
 
4.3.2.2 Spray drying 
 Bendroflumethiazide and 5-fluorouracil were spray dried with a Buchi Mini 
190 (New Castle, DE).  The spray dryer was set up with an injection rate of 2-3 
mL/min, an airflow rate of 600 Nl/h, and an aspirator rate of 100%.  The solution for 
bendroflumethiazide consisted of 2-3% (wt/wt) of drug and 75% (v/v) ethanol:water.  
The inlet temperature was 75-80 °C.  Nitrogen gas was used to eliminate oxygen in 
the spray-drying chamber.  Two grams of 5-fluorouracil were dissolved in 500 ml of 
water.  The inlet temperature of the spray dryer was set to 165 °C. 
Levofloxacin and triamcinolone were spray dried with a custom-built spray 
dryer  (Bend Research, Inc., Bend, Oregon).  Approximately 200 mg of drug was 
dissolved in 10 g of warmed methanol, producing approximately a 2 wt% solution.  
The solution was injected into the spray dryer at a rate of 1.3 mL/min with an inlet 
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temperature of 70 °C.  The material was collected on a piece of 110-mm Whatman 
filter paper, and an anti-static gun was used to discharge any electrostatic charge.  The 
spray-dried material was exposed to a vacuum for one hour at ambient temperature to 
remove any residual methanol.   
 
4.3.3 Sample analysis 
 Multiple complementary techniques were used to characterize the materials 
produced by the various preparation methods.  Each analytical technique provides 
complementary information.  Each of the techniques is described below. 
 
4.3.3.1 Differential scanning calorimetry (DSC) 
 Differential scanning calorimetry (DSC) was performed on a TA Instruments 
(New Castle, DE) Q100 with a refrigerated cooling system. The DSC was calibrated 
with Indium.  Aluminum pans were filled with 5-15 mg of sample and hermetically 
sealed.  An empty hermetically-sealed aluminum pan was used as a reference.  
Samples were equilibrated at -50 °C and then ramped at a rate of 10 °C/min to 240-
300 °C.  Data analysis was performed on Universal Analysis 2000 software version 
4.3, provided by TA instruments.   
 
4.3.3.2 Solid-state NMR spectroscopy 
 19F SSNMR spectra on all solid forms of ciprofloxacin, levofloxacin, 
dexamethasone, and the solid forms of triamcinolone as shown in Figure 4.8 were 
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performed on a Bruker (Bruker, Billerica, MA) Avance 500 three-channel 
spectrometer outfitted with an 1H/19F/X triple-resonance probe and operating at 469.8 
MHz for 19F and 499.3 MHz for 1H.  Samples were packed in 4-mm zirconia rotors , 
sealed with Vespel drive trips, and spun at a rate of 15 kHz.8,9   A 2.7-µs 19F 90° 
pulse-width was used in direct polarization of the 19F nucleus with two-pulse phase 
modulated (TPPM) proton decoupling.  The spectral width was 100 kHz (212.9 ppm), 
3072 points were collected in all cases, and acquisition times were between 10 and 16 
ms. All samples acquired on the Bruker Avance 500 were referenced to a 1:1 solution 
of trifluoroacetic acid (TFA) and water at -76.54 ppm. 19F and 13C SSNMR 
spectra of bendroflumethiazide, dexamethasone, and triamcinolone (Figures 4.6, 4.11, 
and 4.12) were collected on a Tecmag (Houston, TX) Apollo three-channel 
spectrometer operating at 284.1 MHz for 19F, 301.9 MHz for 1H, and 75.9 for 13C.  A 
Chemagnetics (Varian, Inc., Fort Collins, CO) double-resonance 1H/19F probe was 
used to collect the data.  The samples were packed in 3.2-mm o.d. zirconia rotors with 
torlon endcaps and a Vespel drive tip.  Samples were spun at a rate of 10-20 kHz.  1H 
to 19F cross polarization (CP)10,11 was employed along with two-pulse phase 
modulated (TPPM) proton decoupling.  A 1H 90° pulse of 2.9  µs and a contact time 
of 2 ms were used.  A spectral sweep width of 100 kHz was used.  All spectra were 
referenced to Teflon at -121.1 ppm.  The temperature of triamcinolone samples was 
adjusted using a variable-temperature accessory that delivered liquid-nitrogen cooled 
air directly to the spin module housing.  The temperature was calibrated with 
methanol. 
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4.3.3.3 Polarized-light microscopy 
 Light microscopy was performed on an Olympus BX51 (McCrone, 




4.4.1 Introduction to sample selection 
 There is not one sample preparation method that consistently and reproducibly 
generates a stable amorphous material for all compounds.  The solubility (aqueous 
and organic), melting temperature, and sample mass are important to consider when 
selecting a process to generate an amorphous solid.  Ideally, several hundred 
milligrams of amorphous material should be relatively easy to generate. Table 4.1 
contains a list of compounds, their aqueous solubility, melting temperature, and 
available sample mass (based on cost). 
 Spray drying and cryogrinding both require several hundred milligrams of 
bulk crystalline material.  If necessary, lyophilization and melt quenching can be 
performed with significantly less.  Spex Certiprep manufactures a low sample mass 
cryovial, but low-sample mass (<100 mg) grinding was largely unsuccessful.  The 
second caveat is aqueous solubility; the solubility of a chemical is extremely 
important for spray drying and lyophilization to be applicable.  For samples with poor 
aqueous solubility, quench cooling a melt and cryogrinding are better options.  When 
using the Buchi spray dryer, larger samples masses were necessary because the 
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collected spray-dried product yield was approximately 25%.  The Buchi spray dryer 
was not designed to routinely spray dry from organic solvents.  Because of these two 
considerations, very few compounds could be spray dried with the Buchi Mini 190.  
The custom-built spray dryer from Bend Research could spray-dry from organic 
solvents safely and easily, and produced yields of approximately 75-80%.   
 
4.4.2 Initial compound selection 
 Several candidates were excluded based on available sample mass (Table 4.1), 
which was determined by the cost of the drug.  High (H) sample mass corresponded 
to a compound that was available for a cost of less than $50/gram.  A medium (M) tag 
was applied when the price was less than $200/gram, and a chemical was tagged low 
(L) when the drug exceeded  $200/gram.  All drugs with a low sample mass were 
eliminated: flecainide, flumethasone acetate, flunisolide, and the fluvastatin sodium 
salt. 
 Other candidates were excluded because it was estimated that the glass 
transition would be too low for adequate physical stability.  Byrn et al. derived a 
relationship between Tg and Tm for a list of amorphous pharmaceuticals.12   They 
found that the Tg/Tm ratio was typically between 0.7 and 0.85.12   A model compound 
for this study should have a glass transition 50 °C above room temperature (75 °C).13   
According to this estimation method, a Tg above 75 °C would correspond to a Tm 
range of 136-224 °C.  Flufenamic acid, flurbiprofen, and flutamide were attractive 
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candidates for melt quenching and cryogrinding, but the estimated glass transitions 
were too low.   
 The final criterion for excluding several of the compounds was that an 
amorphous form of the compound could not be generated.  The model compound 
search was structured to focus on previously or currently marketed fluorinated drugs.  
As noted before, many of these drug substances were likely selected for the 
thermodynamic stability of the crystalline form and low susceptibility to physical 
transformations.  5-fluorouracil was cryoground and spray dried.  In the 19F SSNMR 
spectra (not shown) there were no discernible changes in line width, line shape, or 
chemical shift between the processed material and the bulk materials.  It was not 
uncommon for the processes to generate only crystalline forms and not amorphous 
material.  Melt-quenching the compounds was not a viable method for the substances 
in this study because many organic compounds thermally degrade at or below their 
melting point.   
 Hence, the list of potential model compounds was reduced to five: 
bendroflumethiazide, ciprofloxacin, levofloxacin, dexamethasone, and triamcinolone.   
An amorphous form was generated for each of these substances, and the drug that 
best met the criteria of a good model compound was selected.  In Figure 4.1, the 
structures of the five compounds are shown.   In the next section an evaluation of 
each compound is described which highlights the suitability of that substance as





Figure 4.1. Potential model compounds and their structures.  
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4.4.3 Partial amorphous generation 
 The 19F SSNMR spectra of the bulk as-received material and cryoground 
ciprofloxacin are shown in Figure 4.2.  The isotropic crystalline NMR peak of the as-
received material shown in Figure 4.2a had a chemical shift of -119.5 ppm and a line 
width of ~500 Hz.  After cryogrinding for 60 minutes, a broad peak was observed at 
the base of the crystalline peak.  The broad peak at the base was interpreted as the 
presence of the amorphous form of ciprofloxacin.  The 19F SSNMR spectrum of the 
cryoground ciprofloxacin was deconvoluted with two peaks: one peak each for the 
crystalline and amorphous forms.   
 The crystalline form had a chemical shift of -119.5 ppm and a line width of 
~500 Hz.  The other peak, due to the presence of amorphous ciprofloxacin, had a 
chemical shift of -119.6 ppm and a line width of ~2700 Hz.  The 
amorphous peak was 5-6 times broader than the crystalline peak.  The presence of the 
crystalline peak in Figure 4.2b indicated that cryogrinding ciprofloxacin for 60 
minutes was not sufficient to fully generate the amorphous form.  The grinding 
process could potentially be lengthened to generate a pure amorphous form, but even 
if a stable amorphous form were generated for ciprofloxacin, the lack of resolution 
between the crystalline and amorphous peaks makes it an unattractive model 
compound.  Different polymorphic forms can have different chemical shifts.14   If a 
stable amorphous form could be produced for ciprofloxacin, it may be possible to use 
a different crystalline polymorph standard in the physical mixtures.  Ciprofloxacin 
was not spray dried because it is insoluble in methanol, acetone, and water. 
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Figure 4.2.  19F SSNMR spectra of a) ciprofloxacin as-received from Fluka and b) 





4.4.4 Lack of chemical shift resolution  
 The lack of significant chemical shift resolution between the crystalline and 
amorphous forms eliminated several compounds, even though pure amorphous forms 
could be generated.  For example, amorphous bendroflumethiazide was prepared by 
spray drying from an ethanol and water solution previously demonstrated by Corrigan 
et al.14   The generation of amorphous material was confirmed by 13C and 19F SSNMR 
spectra, as shown in Figure 4.3.  Figure 4.3a shows the 13C CPMAS spectrum of as-
received bendroflumethiazide.   
 When compared to the spectrum of the spray-dried material in Figure 4.3b, the 
lines became significantly broader after spray drying.  The aromatic peaks (120-140 
ppm) broadened until they were no longer distinguishable.  The 19F SSNMR spectrum 
of the as-received material is shown in Figure 4.3c.  There were two peaks located at -
55.8 and -56.8 ppm with line widths of 380 Hz and 350 Hz, respectively.  The 19F 
SSNMR spectrum of the spray-dried material had two peaks with chemical shifts of -
54.8 ppm and -56.8 ppm and line widths of 560 Hz and 1015 Hz. The broader line 
width in the spray-dried sample suggests the presence of the amorphous form.  
However, bendroflumethiazide has a single trifluoromethyl group and a single peak 
was anticipated in the 19F SSNMR spectrum of the amorphous form.   
 It is unclear why there were two peaks in the 19F SSNMR spectrum.  The solid 
crystalline form of bendroflumethiazide has two asymmetric sites per unit cell, 
meaning that there are two unique sites for each molecule. The two sites have 




Figure 4.3. 13C CPMAS spectra of a) bulk bendroflumethiazide and b) 
bendroflumethiazide spray dried from ethanol.  19F SSNMR spectra of c) bulk 
bendroflumethiazide and d) spray dried bendroflumethiazide.   
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The asymmetry explains the presence of two peaks in the crystalline 19F SSNMR 
spectrum.  However, this asymmetry should not be present in a true amorphous 
compound.   Multiple peaks in the 19F SSNMR spectrum suggest that the material was 
crystallizing in the rotor or that there is an unexplained peak in the spectrum. The 
complications due to multiple peaks in the spectrum of the spray-dried 
bendroflumethiazide and the lack of significant chemical shift resolution with the 
peaks of the crystalline material were reasons to eliminate bendroflumethiazide as a 
model candidate. 
 The amorphous form of dexamethasone was produced by cryogrinding.  The 
19F SSNMR spectra of as-received dexamethasone and cryoground amorphous 
dexamethasone are shown in Figure 4.4.  In Figure 4.4a, the 19F spectrum of the as-
received material had a single peak with a chemical shift of -165.8 ppm and a line 
width of 260 Hz.  As seen in Figure 4.4b, the spectrum of the cryoground amorphous 
form also had a single peak.  The peak exhibited a chemical shift of -164.8 ppm and a 
line width of ~2200 Hz.  The peak of the amorphous form was noticeably 
asymmetric.  NMR peaks are typically symmetric, so the asymmetry of this peak is 
notable.  The chemical shift difference between the amorphous and crystalline forms 
was not large enough to pursue dexamethasone as a model compound for these 
studies.  However, another polymorphic form of dexamethasone could possibly be 
crystallized that has a larger chemical shift difference with the amorphous form.  
Before pursuing this option further, two other candidates were considered. 
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4.4.5 Crystallization of the amorphous material 
 The next candidate that was examined was levofloxacin.  The 19F SSNMR 
spectrum of as-received levofloxacin is shown in Figure 4.5a.  This particular crystal 
form of levofloxacin had two asymmetric sites per unit cell.  The two unique sites in 
the crystal correspond to two unique peaks in the NMR spectrum.  The chemical 
shifts of the peaks were at -114.8 and -116.6 ppm with line widths of 370 and 380 Hz, 
respectively.  Amorphous levofloxacin was prepared by spray drying from methanol. 
Figure 4.5b shows the 19F SSNMR spectrum of the spray-dried amorphous form. 
There was a single peak located at -119.7 ppm with a line width of ~2300 Hz.  The 
line width of the amorphous form was 6-7 times broader than the peaks of the 
crystalline form.  The chemical shift resolution between the crystalline and 
amorphous forms was 3 ppm.   
 The 19F NMR peak resolution between forms was large enough to consider 
quantitation, yet closer examination of the spectrum of the amorphous form reveals 
the presence of a slight shoulder on the downfield side of the amorphous peak.  The 
shoulder corresponded to the chemical shifts of the crystalline form, indicating an 
impure amorphous form with a minor crystalline component.  A second 19F SSNMR 
spectrum was acquired less than 10 minutes after the first.  As one can see in Figure 
4.5c, the amorphous levofloxacin partially crystallized in the rotor while spinning at 










Figure 4.5. 19F SSNMR spectra of a) as-received levofloxacin, b) spray-dried 









 Quantitation could be attempted at lower temperatures, which could reduce or 
eliminate the crystallization of the amorphous material.  Spinning speeds could also 
be lowered to 8-10 kHz to lessen spin-induced sample heating.  However, a 
compound with a high propensity to crystallize is not ideal as a model compound for 
quantitation.  
 
4.4.6 Model compound - triamcinolone 
 The next, and final, compound that was studied was triamcinolone.  
Triamcinolone ((11β,16α)-9-fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-
dione) is a glucocorticoid steroid that has a fluorine atom at the 9-position in the 
steroid structure.15   
 Initially, amorphous triamcinolone was generated by cryogrinding.  The 19F 
SSNMR spectra of the crystalline (as-received material) and the amorphous form are 
shown in Figure 4.6. Figure 4.6a is the 19F spectrum of the as-received crystalline 
material.  The crystalline form has two peaks corresponding to two asymmetric sites 
per unit cell.  The peaks had chemical shifts of -159.1 and -160.5 ppm.  Figure 4.6b 
shows the 19F SSNMR spectrum of cryoground amorphous triamcinolone. The 19F 
SSNMR spectrum of the amorphous form has a single peak.  The line shape of the 
amorphous peak is asymmetric, similar to that noted for amorphous dexamethasone.  
The asymmetric line shape of the amorphous form of triamcinolone was observed on 




Figure 4.6. The 19F SSNMR spectra of a) crystalline (polymorph B) standard, b) 
amorphous (cryoground) standard, and the c) physical mixture of 50% amorphous 
triamcinolone and 50% polymorph B. 
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the asymmetry is unknown but could indicate a non-Gaussian distribution of 
molecular arrangements within the amorphous form of triamcinolone. 
 The peak of the amorphous form had a chemical shift of -164.9 ppm and a 
linewidth of 3300 Hz.  The 19F SSNMR spectrum of a 50:50 physical mixture of the 
two forms is shown in Figure 4.6c.  Peaks corresponding to the original crystalline 
and amorphous forms are both visible in the spectrum; however, there were two 
additional peaks that appeared at -163.2 and -164.0 ppm.  The new peaks were 
attributed to a second polymorph of triamcinolone.  The material physically 
transformed during storage, mixing, and/or acquisition of the NMR data.  A closer 
look at the spectrum of the cryoground amorphous form shows a slight hump on the 
downfield side of the peak.  The slight shoulder indicated the cryoground material 
was not a pure amorphous form and contained a minor component of polymorph B.   
 Cryoground triamcinolone was analyzed by DSC and 19F SSNMR to 
determine its suitability as an amorphous form.  The DSC of triamcinolone is shown 
in Figure 4.7.  The glass transition was not visible in the thermogram, but there was a 
crystallization exotherm at 80-105 °C.  An endotherm was also present at 220 °C, 
which was attributed to the melting temperature of polymorph A.  The temperature of 
the crystallization exotherm was relatively close to the temperatures that the sample 
may have been exposed to during SSNMR analysis due to friction generated at high 
spin speeds.  To assess reproducibility in the generation of the amorphous material, 




Figure 4.7.  DSC thermograms of a) cryoground and b) spray-dried amorphous 
triamcinolone.
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variability in the number of transitions that appeared as well as the relative 
temperatures at which they appeared.  From the DSC analysis it was clear that the  
amorphous form was difficult to reproduce by cryogrinding. In addition, when 
cryoground triamcinolone samples were analyzed with 19F SSNMR, the material 
commonly recrystallized into polymorph A.  Triamcinolone was a promising 
candidate, but the production methods used to make the amorphous and crystalline 
standards required refinement.   
 The amorphous generation method was changed from cryogrinding to spray 
drying from methanol to make a stable amorphous form of triamcinolone.   The 
spray-dried material was uniformly white, whereas the cryoground material had a 
brown tinge to it.  An anti-static gun was used to remove residual electrostatic charge 
after spray drying, and the material was exposed to a vacuum for one hour to remove 
any residual solvent. The DSC thermogram of the amorphous material generated by 
cryogrinding is shown in Figure 4.7a.  A glass transition was not visible.   
 The thermogram had a recrystallization exotherm at 92°C and a melting 
endotherm at 225 °C, attributed to the melting of polymorph A.15   The thermogram 
of the spray-dried amorphous material is shown in Figure 4.7b. The crystallization of 
polymorph A exotherm shifted to a higher temperature (~120°C).  Two endotherms 
were also observed.  The endotherm at 218°C was the melting of polymorph A; 
whereas, the endotherm at at 241 °C was attributed to the melting of polymorph B.15   
The crystallization exotherm was approximately 25 °C higher for the spray-dried 
material than for the cryoground.  The increase in temperature of the crystallization 
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exotherm is indicative of the increased physical stability of the spray-dried 
amorphous form as compared to the cryoground amorphous form.  Spray drying 
triamcinolone generated a reproducible stable amorphous form.  When analyzed with 
19F SSNMR at spinning speeds of 15 kHz, no crystallization was detected.  
 After amorphous triamcinolone was generated, the crystalline form of 
triamcinolone had to be selected. The three known crystalline forms of triamcinolone 
(polymorph A, polymorph B, and the monohydrate) have been well characterized 
with PXRD by Suitchmezian et al.15   No reference to the amorphous form of 
triamcinolone was made in their research. Polymorph A was not crystallized for this 
research: however, it appeared in many of the lots that were purchased.  In Figure 4.8, 
the 19F SSNMR spectra of an as-received lot  from Sigma (containing polymorph A), 
polymorph B, the monohydrate, and the spray-dried amorphous form are shown.  
Figure 4.8a shows the spectrum of the as-received material.  The as-received material 
is a mixture of polymorphs A and B.  Polymorph A had chemical shifts of -163.2 and 
-164.0 ppm, and the presence of two peaks in the SSNMR spectrum for a single 
fluorine indicated that there are two asymmetric sites in the unit cell.  Polymorph B 
was crystallized from methanol due to the presence of multiple polymorphs in the as-
received material.  The 19F spectrum of the recrystallized material is displayed in 
Figure 4.8b.  The peaks of polymorph B were located at chemical shifts of -159.7 and 
-161.2 ppm with line widths of 145 and 122 Hz, respectively.  The spectrum of the 
monohydrate is shown in Figure 4.8c.  The monohydrate has a single peak in the 
spectrum at -160.9 ppm with a line width of 223 Hz.  Lastly, the 19F SSNMR 
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spectrum of spray-dried amorphous triamcinolone is displayed in Figure 4.8d.  The 
spray-dried amorphous NMR peak had a chemical shift of -164.9 ppm and a line 
width at half height of 3300 Hz. 
 A vertical line highlights the chemical shift differences between the 
amorphous form, the monohydrate, and polymorph B.  The chemical shift resolution 
is 3.7 ppm between the amorphous peak and the downfield peak of polymorph B.  
Coincidentally, the upfield peak of polymorph B and the peak from the monohydrate 
overlapped.  The chemical shift resolution between the amorphous form and the 
crystalline forms were large enough to proceed with triamcinolone as the model 
compound.  Both the monohydrate and polymorph B were used as model crystalline 
forms for quantitation in Chapter 5.  
 
4.4.7 Uniform mixing of standards 
 When preparing physical mixtures, homogeneous mixing is crucial to the 
integrity of the experiment.  Homogeneous mixing could be affected by differences in 
electrostatic charge of the mixture components.  After spray drying, the amorphous 
material was charged and quite mobile.  To reduce the presence of static effects, an 
anti-static gun was used on spray-dried samples prior to mixing.  Homogeneous 
mixing could also be affected by the particle sizes of the components.   
 Polarized-light microscopy was performed on both a cryoground sample and 
polymorph B recrystallized from methanol.  The images are displayed in Figure 4.9.  
Polymorph B has long needle-shaped colorful crystals.  In the image of polymorph B 
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Figure 4.8. 19F SSNMR spectra of the four forms of triamcinolone: a) polymorphs A 
and B (as-received from Sigma), b) polymorph B, c) the monohydrate, and d) the 
amorphous form.  The vertical line highlights the spectral resolution between the 
amorphous form and the crystalline forms.  Asterisks denote spinning sideband
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 (Figure 4.9b), there is a bar that indicates a 1000-micron distance.  Some of the crystals 
were on that order in length.  In the image of the amorphous form, the particles were 
small and gray with no distinctive features.  The bar in the image of the amorphous form 
depicts a 100-micron distance.  In this case, the particles of the amorphous form were 1-2 
orders of magnitude smaller.  The vast size differences between amorphous and 
crystalline forms could result in inhomogeneous mixing.  The spray-dried amorphous 
form was not observed under the microscope but initial particle size analyses of the two 
amorphous generation methods suggested that spray drying produced particles that were 
more uniform in size.   
 Manually grinding and sieving the crystals of polymorph B could effectively 
reduce the crystalline particle size.  Polymorph B was manually ground for a few minutes 
with a mortar and pestle.  The sample was not sieved and analysis was performed with 19F 
SSNMR.  The spectra of polymorph B before and after manually grinding are shown in 
Figure 4.11.  The peaks of the material before grinding were sharp and distinct with line 
widths of 125 and 100 Hz.  After grinding, the lines were broader (240 and 210 Hz but 
the chemical shifts of the two peaks did not change.  Peak resolution was reduced in the 
ground sample due to broader lines.  The decreased intensity of the downfield peak can 
be explained by one of three possibilities.  First, the site was subjected to more internal 
disorder, leading to a broader distribution of molecular fluctuation at that particular site.  
The line would be broader, therein decreasing its intensity as compared to 




Figure 4.10.  Polarized-light microscopy (20X) images of triamcinolone a) polymorph B 




Figure 4.11. 19F SSNMR of polymorph B of triamcinolone a) recrystallized from 
methanol and b) after manually grinding for one minute. 
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grinding.  Finally, grinding could induce a transformation to the monohydrate.  As noted 
before, the peak of the monohydrate overlapped with the upfield peak of polymorph B.  
Conversion to the monohydrate would enhance the intensity of the upfield peak of 
polymorph B.  The conclusion is that triamcinolone is a fragile crystal that will need to be 
physically mixed with no grinding.  
  
4.4.8 Temperature effects on chemical shifts of triamcinolone 
 Lowering the temperature of the probe and sample in the magnet was necessary to 
maintain physical stability of the cryoground amorphous form.  No significant 
temperature dependent changes in chemical shift or line width were observed for the 
amorphous form  (-164.6 ppm).  However, a series of spectra of polymorph B were 
collected at different temperatures, and the chemical shifts of both peaks moved upfield 
while lowering the temperature.  Initially, polymorph B of triamcinolone was collected 
with no VT gas while spinning at 20 kHz.  The thermocouple read 23 °C without 
spinning and 35 °C while spinning.  Spinning-induced temperature changes have been 
observed previously by Isbester et al.17   The thermocouple was a few inches above the 
sample, so there is a difference in sample temperature versus thermocouple reading.  The 
thermocouple temperature was slowly lowered to -70 °C. The 19F SSNMR spectra of 
polymorph B at different temperatures are shown in Figure 4.12.  The chemical shifts of 
polymorph B range from -159.1 and -160.5 ppm at 35 °C to -160.2 and -161.7 ppm at -70 
°C.  The chemical shifts are plotted against the thermocouple temperature reading in 
Figure 4.13.
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 The spectra acquired at 35 and 36 °C were collected with no control of sample 
temperature.  The chemical shift changes of the two peaks exhibit similar slopes when 
changing temperature.  Spinning at 20 kHz produced a thermocouple reading 
approximately 12-13 °C above ambient temperature inside the magnet bore.  The 
chemical shift changes of the two peaks exhibit similar slopes when changing 
temperature.   
 As noted before, sample spinning induces sample heating, and changes in spin 
speed produced changes in sample temperature.  At low spinning speeds (4 kHz) the 
chemical shifts were -159.4 and -161.1 ppm, and at high spinning speeds (20 kHz) the 
chemical shift was -159.1 and -160.5 ppm.  According to the equation from the plot, the 
sample temperature changed approximately 23 °C for the downfield peak and 52 °C for 
the upfield peak.  If each peak were affected similarly, the calculated change should be 
the same for both peaks, so more points would need to be defined to fully characterize the 
relationship.   
 The changes in chemical shifts are not readily explainable.  Some compounds 
exhibit a chemical shift change with changes in crystal density.18  If it is true that the peak
of amorphous triamcinolone does not change, and the chemical shifts of polymorph B do 
change, then the temperature could be manipulated to provide a larger chemical shift 
difference for quantitation.  For these studies, the temperature was kept constant (through 
constant spinning), so it was presumed that the chemical shifts did not change between 
samples.  Additionally, polymorph B could be developed as a quicker and safer 




Figure 4.12. 19F SSNMR spectra of a) amorphous triamcinolone at -70 °C and 
polymorph B at b) 35 °C, c) -70 °C, d) -50 °C, e) -10 °C, and f) 36 °C.  The lines help 




Figure 4.13.  Chemical shift of the two 19F SSNMR chemical shifts of polymorph B of
 triamcinolone plotted at different temperatures (35 °C to -70 °C).
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 4.5 Conclusions 
 
 Many fluorine-containing compounds were analyzed for consideration as 
candidates for low-level amorphous quantitation using 19F SSNMR.  The reasons that 
most compounds were eliminated as potential candidate were due to high cost, low 
glass transition temperatures, the inability to generate a fully-amorphous solid, lack of 
chemical shift resolution between forms, and amorphous crystallization.  No single 
technique was able to produce amorphous material for all compounds.  In the case of 
small, organic, fluorine-containing molecules, cryogrinding and spray drying (from 
organic solvents) were the best options to generate amorphous compounds.  When 
possible, spray drying from methanol and acetone was the most effective and 
reproducible method that produced the most stable amorphous form.    
 The steroid triamcinolone was selected as the model compound for 19F 
SSNMR quantitation studies.  Polymorph B and the monohydrate were used as the 
model crystal forms, and both the cryoground and spray-dried amorphous forms were 
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5.1.1 Presence of amorphous materials in formulation 
 Amorphous drug substances can be produced at low levels during the 
processing and manufacturing of pharmaceuticals and can have a large influence on 
the chemical and physical stability of a drug.  For example, the high-energy 
amorphous state has the potential for undesired physical transformations, such as 
polymorphic conversions, that can lead to changes in physicochemical properties of a 
drug.  These changes can affect the drug’s therapeutic efficacy.  Additionally, the 
increased dynamics associated with the amorphous state could lead to increased 
chemical reactivity of the drug.  From a regulatory standpoint, quantitating low levels 
of amorphous drug is important to ensure safety and efficacy of a formulated drug 
product.  In the past, much of the research on amorphous solids has been focused on 
understanding the relationship between molecular mobility and drug stability.  
Recently, research efforts have included attempts to quantitate the amorphous state or 
percent crystallinity.1-4   In many of these studies, the primary objective is 
quantitation of low levels of amorphous content in a physical mixture of crystalline 
and amorphous forms.  Some of the techniques described in the next section can 
quantitate amorphous drug levels to less than one percent; however, few techniques 
are capable of studying low levels of amorphous drug in a formulated product.  In this 
chapter we describe the capability of 19F solid-state NMR (SSNMR) spectroscopy to 
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study low levels (<1%) of an amorphous drug while also monitoring chemical and 
physical changes of that form.  
 
5.1.2 Analytical methods for quantitation of amorphous solids 
Many techniques are available for the quantitation of amorphous 
pharmaceuticals.1   These techniques include powder X-ray diffraction (PXRD), 
differential scanning calorimetry (DSC), isothermal micro-calorimetry (IMC), 
solution calorimetry (SC), dynamic vapor sorption (DVS), thermally stimulated 
current spectrometry, density measurements, dynamic mechanical analysis (DMA), 
inverse gas chromatography (IGC), dissolution, infrared spectroscopy, FT-Raman 
spectroscopy, and 13C SSNMR spectroscopy.  The capabilities and limitations of 
some of the techniques will be discussed briefly. 
PXRD is one of the most widely used techniques for solid-state 
characterization and quantitation.  PXRD patterns of crystalline samples have sharp 
peaks.  Amorphous materials have very broad, featureless peaks, often referred to as 
halos.  Because PXRD is sensitive to long-range order in a crystal lattice, it indirectly 
measures the amorphous content of a sample by determining the fraction of intensity 
in the halo.  Quantitation limits for amorphous pharmaceuticals of approximately 
10% are typically reported for PXRD.1,5    
Multiple researchers have used DSC to quantitate amorphous material.5-8   In 
conventional DSC, the sample temperature is raised to cause recrystallization. The 
area under the crystallization exotherm is proportional to the amorphous content 
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present in the sample.5   Conventional DSC has detection limits of approximately 
10%, comparable to that of PXRD.  Another approach to quantitate amorphous 
material with DSC is to measure the change in the heat capacity (Cp) at the glass 
transition.  The magnitude of the ΔCp is proportional to the amorphous drug present.  
To measure the  ΔCp, modulated-temperature DSC  (MTDSC) or hyper-DSC must be 
used.9-11   The use of these techniques creates large gains in sensitivity over the use of 
conventional DSC: the limits of detection can be lowered from 10% to 1% or below.  
Unfortunately, the increased sensitivity comes at a cost: the use of MTDSC and 
hyper-DSC requires calibration curves made from pure standards.  Similar to PXRD, 
DSC does not directly measure the amorphous state.  The area of the recrystallization 
exotherm or heat capacity of the material is measured and attributed to the relative 
percentage of amorphous material.  Other calorimetric techniques, such as IMC and 
SC, measure the amount of amorphous material in samples based on the same 
properties as DSC.  The heat from the recrystallization is proportional to the 
amorphous material present in the sample.   
Dynamic vapor sorption (DVS) has also been used to quantitate amorphous 
material in a crystalline sample.  Typically, amorphous material is much more 
hygroscopic than crystalline material; therefore, the amount of water taken up by the 
sample is proportional to the amount of amorphous material present.  In order to 
quantitate the amorphous content, the amount of water taken up by both the pure 
crystalline and amorphous forms must be known.  DVS can exhibit a very low level 
of detection, but it can typically be applied only to drug substances and not 
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formulations.  FT-IR and Raman spectroscopy have been used to identify amorphous 
material.  Often the amorphous peaks will have different absorption frequencies from 
those of the crystalline.  If not, quantitation can be difficult.   
 Many of the techniques described here do not directly measure the crystalline 
to amorphous ratio, but assume that the measured parameter is related to the amount 
of one of the species present.  For example, in water vapor sorption, it is assumed that 
the increase in water content is due solely to the amorphous material present, and that 
the crystalline material does not absorb water.  If this assumption fails, then the 
technique can give an incorrect measurement of that particular parameter.  Using an 
indirect parameter to measure the amorphous state can lead to inconsistent results 
when the same system is quantitated with a variety of techniques.  For example, 
Lehto et al. used seven different techniques (PXRD, DSC, StepScan DSC, IMC, 
solution calorimetry, Raman Spectrometry and gravimetric moisture sorption) to 
quantitate amorphous lactose.8 The study concludes that the percentage of measured 
amorphous impurity may vary depending on the technique used for quantitation; 
therefore, the researchers suggest several different methods should be employed to 
achieve a more accurate value.  
Each technique has limitations in its ability to quantitate crystalline and 
amorphous forms based upon the technique itself.  For example, many techniques 
require a calibration curve, and many are highly insensitive. Some techniques require 
the use of pure amorphous and crystalline forms as standards and creating a standard 
curve of various relative percentages.  A common disadvantage of all of the described 
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techniques is that they fail when attempting to quantitate amorphous impurity in a 
drug product.  The background signal from an excipient prohibits the use of common 
solid characterization techniques (e.g. PXRD and DSC), when studying a solid drug 
formulation.  SSNMR spectroscopy is an alternative technique that can be used to 
monitor the API within a formulation.      
 
5.1.3 13C SSNMR spectroscopy 
Unlike many of the techniques detailed in the previous section, the signal 
from amorphous material is directly observed in a SSNMR spectrum.  13C SSNMR 
has been routinely used to study low levels of crystalline API in a drug product.12   
Byrn et al. have shown that formulations of crystalline prednisolone can be readily 
observed at loading levels below 5%.  Three formulations from different vendors 
were examined, and researchers reported finding a different polymorph in one of the 
formulations by 13C SSNMR.12   This demonstrates that SSNMR can discriminate 
between different crystalline solid forms at load levels of drug loading.  There are 
many challenges for observing amorphous content using 13C SSNMR.  Typically a 
SSNMR peak of the amorphous form is an order of magnitude broader than a 
crystalline peak.  The breadth of the peak reduces the overall intensity of the signal.  
For example, if an NMR peak of the amorphous form was 10 times broader than the 
crystalline peak, a sample with 10% amorphous content would correspond to a peak 
with ~1% of the crystalline peak intensity.  The breadth of the NMR peak makes it 
much more likely that separation with the crystalline peak is limited.  Polymorphic 
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impurities are usually easier to detect because of the sharpness of the lines and 
changes in chemical shift.  
13C SSNMR has been used in several studies to quantitate the amorphous 
state.2,6,8,13   Gustafsson et al. used partial least squares analysis to determine the 
percentage of amorphous lactose in the physical mixture.  Pure crystalline and 
amorphous standards were used and a calibration curve was made.  The detection 
limits were approximately 0.5% for amorphous lactose.  Although low levels of 
detection were reached, the data acquisition parameters used were non-quantitative.  
This can create a problem when the relaxation times for the material being studied are 
different than those of the standards.  Lefort et al. studied trehalose using DSC and 
SSNMR.  To determine the percentage of amorphous trehalose, a standard linear 
regression procedure was used.  The procedure quantitated amorphous trehalose to 
levels of approximately 20%.   
 Offerdahl et al. used 13C SSNMR to quantitate amorphous material 
present in crystalline physical mixtures of neotame.13   The lowest percentage 
physical mixture prepared was 20%.  A plot of the SSNMR calculated wt.% vs. the 
weighed wt.% resulted in a non-zero y-intercept.  The intercept occurred because the 
bulk crystalline material had a significant level of amorphous material present.  The 
amorphous material was not easily seen in the spectra of the physical mixtures or of 
the “pure” crystalline material because the crystalline peaks are much more intense 
than the amorphous peaks, making it difficult to observe the amorphous peak at the 
base of the crystalline peak.  The time frame of these experiments was reasonable due 
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to the number of scans and short relaxation rates of the amorphous and crystalline 
forms.  If the sample were diluted, the length of the experiments would have risen to 
unreasonable levels in order to achieve acceptable signal to noise ratio (SNR).  Thus, 
the presence of excipients effectively limits the ability to perform quantitation 
experiments.   
 The downside of SSNMR for quantitation of amorphous material is that it is 
relatively insensitive compared to other analytical techniques.  The primary reason is 
the low-energy transitions, which means that the population difference is very small 
between transition states.14 Another reason is the low (1.1%) natural abundance of 
13C.  In addition, the broadness of the amorphous peaks lessens the peak sensitivity 
even further.  Low sensitivity leads to unrealistic analysis times required to observe 
low levels of amorphous drug.  Low-level loading in a drug product would greatly 
increase these analysis times.   
 
5.1.4 19F SSNMR spectroscopy 
There are several advantages to using 19F SSNMR spectroscopy over 13C 
SSNMR spectroscopy to detect small amounts of amorphous API in the presence of 
crystalline API, especially within a formulated product. The 19F nucleus is 100% 
naturally abundant, compared to the 1.1% natural abundance of the 13C nucleus.  The 
higher abundance is important because that means a 19F spectrum with a higher SNR 
can be obtained in a fraction of the time necessary to collect a 13C spectrum with a 
similar SNR.  The number of fluorine atoms is always much lower than the number of 
 140 
carbon atoms in a molecule.  This means that the 19F NMR spectrum will be much 
less complicated than the corresponding 13C NMR spectrum because it has fewer 
peaks.  The fewer number of peaks allows for easier spectral interpretation, but it 
provides us with fewer opportunities to find chemical shift resolution between the 
solid forms.  The greatest potential advantage of using 19F SSNMR to look at solid 
forms is the lack of signal from the excipients.  No commonly used excipients contain 
fluorine, so they will not be detected in the spectrum, which means that the only 
signals will come from the API.  19F SSNMR will observe just the API.   
There are some disadvantages for using 19F SSNMR to quantitate crystalline 
and amorphous fractions in pharmaceutical materials.  First, samples must be spun at 
high magic-angle spinning (MAS) rates of 15-25 kHz to eliminate the broadening 
effects of strong 19F/19F homonuclear couplings and reduce spinning sidebands.  The 
air-generated friction due to extremely fast spinning induces sample heating.  Sample 
heating will vary based on rotor size, spinning speed, and type of module used.  This 
group has reported that spinning with a 3.2-mm Chemagnetics spinning module at 
rates as high as 20 kHz caused temperature changes of 40 °C.15 Sample heating could 
have several unintended consequences that can be problematic if the temperature is 
not adequately controlled and monitored, such as water loss, and/or changes in the 
thermal history of an amorphous solid.  Second, 19F SSNMR line widths are typically 
much broader than in 13C spectra.  The peak broadness can cause additional resolution 
issues between the crystalline and amorphous peaks.  Lastly, 19F and 1H have close 
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resonant frequencies; therefore, decoupling 1H spins from 19F requires a special probe 
configuration.  
 
5.1.5 Prevalence of fluorine in pharmaceuticals 
The obvious drawback to studying amorphous systems with 19F SSNMR 
spectroscopy is its limitation to compounds containing one or more fluorine atoms.  
No fluorine-containing drugs had been developed prior to 1957.  Fluorine is 
commonly substituted for hydrogen because of its similarity in size but large 
difference in electronegativity.  There should be little or no steric effect; however, the 
electronic environment, pKa, dipole moment, and ultimately the chemical stability 
and reactivity of nearby functional groups will be affected.   
 Recently, studies have shown that fluorine has the ability to enhance 
metabolic stability by lessening the susceptibility of nearby moieties to the enzymatic 
oxidation of cytochrome P450.16   Substitution of fluorine can also influence 
lipophilicity and affect partitioning of the drug across membranes.16   Hydrophobic 
interactions can also influence binding with enzymes or receptor sites.  The 
substitution or addition of fluorine to a drug compound has produced many drug 
compounds in the past 50 years.  Currently, estimates suggest that 5-15% of all drugs 
launched worldwide over the past half century contain one or more fluorine 
substitutions.17   It is estimated that 20% of all drugs marketed today contain 
fluorine.18   This number could be even higher for the past decade when 
agrochemicals are considered, which could be an additional application of 19F 
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SSNMR.  Some key pharmaceuticals that include fluorine are Prozac, Ciprobay, and 
Lipitor.  The growing presence of fluorine in pharmaceuticals makes 19F SSNMR an 
appropriate and invaluable tool for investigating amorphous impurities as well as for 
standard solution and solid-state characterization. 
 
5.1.6 NMR quantitation 
 NMR spectroscopy has a unique advantage over many other analytical 
techniques for the analysis of pharmaceutical formulations.  An NMR spectrum can 
be inherently quantitative because the signal observed in a spectrum is directly 
proportional to the number of nuclei present in the sample.  In pharmaceutical 
applications, the 13C nucleus is most frequently studied.   
 The first step in quantitation is to measure the spin-lattice relaxation times of 
the species of interest.  When using cross polarization (CP), it is necessary to measure 
the spin-lattice relaxation rate in the rotating frame (T1ρ).  The dynamics from cross 
polarization make quantitation more difficult, so in the following study, direct 
polarization is used to avoid some of these complexities and to take advantage of 19F 
relaxation rate differences. 
After determining which forms are present, and which forms correspond to 
specific NMR peaks, the next step is to determine the relaxation rates of the various 
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Where I is the observed intensity of the NMR peak, and Io is the magnetization 
available once an external magnetic field is applied.  When I = Io, the sample is fully 
relaxed.  Tau (τ), often referred to as the pulse delay, is the delay between radio-
frequency pulses in signal averaging.  In the studies reported here, the 19F T1 
relaxation time is measured and 19F spectra are collected.  Processing history, water 
content, lot, or the presence of oxygen can influence the T1 of a sample.  To obtain 
reliable quantitative data, the relaxation time must be monitored closely.  
Traditionally, to be quantitative, a pulse delay that is five times the longest relaxing 
component in a mixture or formulation is used.  Under these conditions, 99.3% of the 
possible nuclear magnetization is observed.  This is usually considered to be 
quantitative for NMR spectroscopy.  Any spectrum collected with a pulse delay 
shorter than this is often considered non-quantitative.  However, if the relaxation rate 
and pulse delay are taken into consideration, a quantitative value can be obtained at τ 
values less than five times the T1 value. 
 In many cases, when using traditional quantitative conditions, resolution 
between NMR peaks is not adequate to detect low levels of amorphous material.  
When that is the case, other NMR parameters can be manipulated to enhance the 
signal from the amorphous component at the expense of the crystalline component.  If 
the components in a mixture have significantly different relaxation times, the 
difference-NMR technique can be used to enhance the amorphous signal.19    
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 The difference-NMR technique is a spectral subtraction of two or more 
spectra acquired with different pulse delays to selectively eliminate a component 
from the spectrum.  Before discussing the theory of the difference-NMR technique, it 
is useful to examine the relaxation profiles that will be described in the following 
equations.  Shown in Figure 5.1 are relaxation profiles for a short (T1=1.2 s) and a 
long (T1=105 s) relaxing component, which may correspond to an amorphous and a 
crystalline T1 value, respectively.  At five times T1, or 6 s, the amorphous component 
is fully relaxed.  At longer values of 8 s and 16 s, the amorphous component remains 
fully relaxed, and the signal intensity from the amorphous component in both spectra 
will be equivalent.  However, the crystalline component has an intensity of 0.073 at 8 
s, and an intensity of 0.14 at 16 s.  In order to eliminate the crystalline component, the 
8-s spectrum is doubled to obtain nearly the same crystalline intensity as the 16-s 
spectrum.  There will be twice as much amorphous component in the doubled 8-s 
spectrum as in the 16-s spectrum, so subtraction of the 16-s spectrum from the 
doubled 8-s spectrum will result in an amorphous spectrum with little crystalline 
component.   
 At shorter τ values, such as 2 s and 4s, the amount of crystalline component 
suppressed increases, but the amorphous component is considered non-quantitative, 
since the signal of amorphous material at 2 s is approximately 84% of the signal at 4 
s.  The following text will mathematically define the basis of the difference-NMR 
technique, explaining its basic theory and advantage to expressing short-relaxing 
components in the presence of long-relaxing components.   
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Figure 5.1. The equilibrium magnetization recovery can be plotted against the time 
allowed to recover (tau).  Curve a) represents the relaxation recovery of the spin-
lattice relaxation of the amorphous form of triamcinolone (1.2 s) and curve b) 
represents the recovery of crystalline triamcinolone (105 s).  The inset displays the 
tau region of interest (2-16 s) for the final attempt of the difference-NMR technique.   
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 Assuming exponential relaxation of the NMR signal, Equation 5.1 defines the 
intensity of the NMR signal with respect to pulse delay and the spin-lattice relaxation 
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The intensities of two components can be compared by the long division of their 
respective Taylor series.  IS and IL are the intensities for the short and long relaxing 
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The greatest selectivity will be achieved when the pulse delay, τ, is much shorter than 
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The maximum selectivity achievable becomes the ratio of the relaxation rates of the 
two components.  The linearity of the ratio becomes a limiting factor in improving 
selectivity between two components.  To change the linear dependence of the initial 
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term, some spectral addition is necessary.  A spectrum with a pulse delay of 2*τ is 
subtracted from a doubled spectrum acquired with a pulse delay of τ.  The resulting 
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 for the spectral subtraction, as in Equation 5.6, the linear term is 
no longer present; and when τ is much smaller than T1S and T1L, Equation 5.6 reduces 
to Equation 5.7. 
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Equation 5.7 indicates the selectivity benefits of the difference-NMR technique in 
that the quadratic dependence of Equation 7 allows for greater selectivity of the short-
relaxing component.  The advantage of the technique is displayed graphically in 





Figure 5.2.  Plots of intensity versus T1 time for a theoretical set of curves to illustrate 
the increasing efficiency in suppression of long-relaxing components.  The intensities 
of NMR signals from spectra collected with short pulse delays of a) 2 s, b) 1 s, and c) 
0.5 s are compared with the efficiency of the d) two-component difference-NMR 




selectivity of a single spectra acquired with short pulse delays: 0.5 s, 1 s, and 2 s.  
Theoretically, the difference-NMR technique should suppress the longer relaxing 
component to less than 3% intensity when the ratio of T1 times between the short and 
long relaxing components is 23:1.  When short pulse delays are used, the same 
suppression is obtainable when the T1 ratio is 115:1. 
 To further increase the selectivity of a slow-relaxing component, spectral 
subtraction can be extended to include three or more component spectra (i.e. 
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3*1s" 3*2s+ 3s).  According to Harris et al., 97% of the short-relaxing component 
and 3% of the long relaxing component will be retained when the T1 ratio is only 
13:1.  The selectivity of the technique increases upon adding an additional component 
spectrum to the difference-NMR technique, but the noise increases as well.  
Therefore, there is a balance between selectivity, SNR, and time.   
 The two-component difference-NMR technique was used in these studies to 
selectively express the amorphous form in crystalline physical mixtures of 
triamcinolone.  Figure 5.3 shows two examples of the difference-NMR technique.  In 
the illustration, a 45% physical mixture of amorphous and crystalline triamcinolone 
was used.  The amorphous triamcinolone had a 19F T1 of 1.2 s, and the crystalline 
component had a 19F T1 of 105 s.  Two subtractions were performed; one subtraction 
was performed to obtain a quantitative value of the amorphous component (Figure 
5.3a-c), and the other was performed under conditions that achieved greater 
selectivity of the amorphous form (Figure 5.3d-f).  Two component spectra were 





Figure 5.3.  An example of the difference-NMR technique being applied to a 
physical mixture of crystalline and amorphous solid forms with two sets of NMR 
acquisition parameters.  The component spectrum acquired with an a) 8-s pulse delay, 
b) 16-s delay, and c) the quantitative (for amorphous content) subtracted [(2*(a) – b] 
spectrum.  Non-quantitative spectra acquired with d) a 2-s delay e) 4-s delay, and f) 
the subtracted [(2*d– (e)] spectrum.  Asterisks denote spinning sidebands.   
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with pulse delays of 8 s and 16 s were acquired, and for the second subtraction, 
component spectra with delays of 2 s and 4 s were collected. In both cases, the 
difference-NMR technique suppressed the long-relaxing crystalline component. The 
component.  To obtain a quantitative value for the crystalline component, an 
additional spectrum must be acquired with a pulse delay greater than five times the 
relaxation time of all components in the mixture. 
 
5.1.7 Triamcinolone as a model compound 
 The search for a fluorine-containing compound to study low-level amorphous 
quantitation using 19F SSNMR spectroscopy is detailed extensively in Chapter 4.  The 
model compound must have the characteristics of both a stable amorphous form and 
chemical shift resolution of the crystalline and amorphous forms.  For this study, the 
glucocorticoid steroid triamcinolone was selected.  Crystalline and amorphous forms 
of triamcinolone will be used to test the limits of detection of amorphous quantitation 
using 19F SSNMR spectroscopy.  The molecular structure of triamcinolone is shown 
in Figure 5.4.  
 
5.1.7 Strategy for quantitating mixtures using 19F SSNMR 
 The general strategy for quantitation was to prepare physical mixtures of the 
crystalline and amorphous forms of triamcinolone and determine the limit of 
detection and quantitation.  Although not required, the ability to differentiate the 













relaxation or chemical shift was considered.  Quantitation limits below 1% are 
considered reasonable, with detection limits of up to an order of magnitude below that 





Triamcinolone was purchased from Sigma Aldrich (St. Louis, MO) and was 
analyzed by 13C (not shown) and 19F SSNMR.  Further purification was necessary to 
generate the various crystal forms.  Pure polymorph B was obtained by crystallization 
from methanol.  Approximately 1 g of triamcinolone was dissolved in 100 mL of 
boiling methanol.  The solution was concentrated approximately two-fold by 
evaporation.  Then the solution was stirred at room temperature for several hours, 
while the material crystallized.  The crystals were vacuum filtered and dried 
overnight while exposed to a vacuum at ambient temperature.   
The monohydrate was produced by crystallization from an acetone and water 
solution.  Approximately 500 mg of as-received triamcinolone was dissolved in 200 
mL of warm acetone.  As the solution was cooling in an ice bucket, ice fell into the 
beaker.  The unknown combination of acetone and ice produced a pure monohydrate 
(according to 19F SSNMR).  Although pure hydrate was formed once, attempts to 
reproduce the pure monohydrate from an acetone and water solution were 
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unsuccessful.  In successive attempts of crystallizing the monohydrate form, 
polymorph B was also present at various levels.   
Physical mixtures were prepared three different times for quantitation with 19F 
SSNMR.  In the first attempt, polymorph B and a cryoground amorphous form were 
the prepared solid forms.  For quantitation using the conventional approach, five 
times T1, approach, physical mixtures were prepared with polymorph B (crystallized 
from methanol) and the amorphous form.  The amorphous form was prepared by 
cryogrinding the as-received triamcinolone for 60 min. Four physical mixtures of 
approximately 30%, 11%, 3%, and 1.5% amorphous were prepared through serial 
dilution.  The 30% and 3% were produced through one series, and the 11% and 1.5% 
were produced in another.  For the 30% mixture, approximately 30 mg of amorphous 
triamcinolone was added to 70 mg of crystalline triamcinolone.  The 3% mixture was 
generated by measuring approximately 10 mg of the 30% mixture and diluting with 
90 mg of crystalline triamcinolone.  All of the mixtures were vortexed in a 
scintillation vial for 5 min to ensure proper mixing.  The same method of dilution was 
applied to the second dilution series of 11% and 1.5%.  Physical mixtures were stored 
under vacuum at ambient temperature. 
 For the initial attempt using the difference-NMR technique approach, a set of 
physical mixtures was prepared with cryoground amorphous triamcinolone and 
triamcinolone monohydrate.  The monohydrate with polymorph B impurity was the 
crystal form used for the physical mixtures.  Two physical mixtures, 45% and 4.5%, 
were prepared through serial dilution.  For the 45% physical mixture, amorphous and 
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crystalline forms of triamcinolone were weighed to approximately a 1:1 mixture.  The 
4.5% mixture was produced by taking 10 mg of the 45% mixture and adding 90 mg 
crystalline material.  The samples were stored at ambient temperature in a desiccator.  
Using the difference-NMR approach, the crystalline and amorphous 
triamcinolone were prepared differently in order to generate more stable/purer 
standards. Polymorph B obtained by crystallization from methanol for the second 
attempt at the difference-NMR technique.  The amorphous form was produced via 
spray drying, and six physical mixtures were prepared through two serial dilutions.  
The mixtures containing 45%, 5%, and 0.5% amorphous material were prepared via 
one series, and the mixtures containing 10%, 1%, and 0.1% amorphous material were 
prepared through a second dilution.  Initially, pure amorphous and pure crystalline 
materials were weighed to approximately a 1:1 mixture by mass.  Roughly 10 mg of 
this first dilution was used with an additional 90 mg of pure crystalline material to 
form the 5% mixture.  Roughly 10 mg of the 5% dilution was mixed with 
approximately 90 mg of the crystalline mixture to form the 0.5% sample.  Each 
physical mixture was weighed in a scintillation vial and mixed for 10 minutes with a 
Turbula mixer (Glen Mills; Clifton, New Jersey).  The physical mixtures were stored 
under vacuum at ambient temperature.   
 
5.2.2 Cryogrinding 
Cryogrinding was performed with a SPEX CertiPrep 6750 Freezer/Mill 
(SPEX CertiPrep, Inc., Metuchen, NJ).  Approximately 500 mg of as-received 
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triamcinolone was loaded into the cryovial for each process. Samples were pre-cooled 
for 15 minutes, followed by 30 cycles.  Each cycle consisted of 2 min of impaction 
and 2 min of cooling time.  The impaction rate was 10 impacts/s.  After grinding, the 
cryovial with sample returned to ambient temperature under vacuum in order to 
prevent condensation upon removal from the vial.   
 
5.2.3 Spray drying 
Spray drying was performed with a custom-built spray dryer  (Bend Research, 
Inc., Bend, Oregon).  Approximately 200 mg of drug was dissolved in 10 g of warm 
methanol, producing approximately a 2% wt/wt solution.  The solution was injected 
into the spray dryer at a rate of 1.3 mL/min with an inlet temperature of 70 °C.  The 
material was collected on a piece of 110-mm Whatman filter paper, and a static gun 
was used to discharge any electrostatic charge.  The spray-dried material was exposed 
to a vacuum for one hr at ambient temperature to remove any methanol.   
 
5.2.4 SSNMR spectroscopy 
 Quantitation by waiting 5x the T1 value was performed on a Tecmag 
(Houston, TX) Apollo three-channel spectrometer operating at 284.1 MHz for 19F and 
301.9 MHz for 1H.  A Chemagnetics (Varian, Inc., Fort Collins, CO) double-
resonance 1H/19F probe was used to collect the data.  The samples were packed in 3.2-
mm o.d. zirconia rotors with torlon endcaps and a Vespel drive tip.  Samples were 
spun at a rate of 10-20 kHz. The samples were cooled to -70 °C using a variable-
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temperature accessory that delivered liquid-nitrogen cooled air directly to the spin 
module housing.  1H to 19F cross polarization (CP) was employed along with two-
pulse phase modulated (TPPM) proton decoupling.  A 1H 90° pulse of 2.9  µs, and  a 
contact time of 2 ms were used.  A spectral sweep width of 100 kHz was used.  The 
19F and 1H spin-lattice relaxation times (T1) were measured using a saturation 
recovery pulse sequence with at least eight increments.  The 10-s pulse delay used 
was more than five times the measured 1H T1 value for polymorph B and the 
amorphous form of triamcinolone.  All spectra were referenced to Teflon at -121.1 
ppm.  
19F SSNMR spectra on all solid forms of triamcinolone and the difference-
NMR studies were performed on a Bruker (Bruker, Billerica, MA) Avance 500 three-
channel spectrometer outfitted with an 1H/19F/X triple-resonance probe and operating 
at 469.8 MHz for 19F and 499.3 MHz for 1H.  Samples were packed in 4-mm zirconia 
rotors and spun at a rate of 15 kHz.  A 2.7-µs 19F 90° pulse-width was used in direct 
polarization of the 19F nucleus with TPPM proton decoupling.  The spectral width 
was 100 kHz (212.9 ppm), 3072 points were collected in all cases, and acquisition 
times were between 10 and 16 ms.   19F T1 relaxation data was collected on all 
samples.  Eleven points were acquired and fit to a monoexponential decay with a 
good fitting parameter.  All samples acquired on the Bruker Avance 500 were 
referenced to a 1:1 solution of trifluoroacetic acid (TFA) and water at -76.54 ppm.    
During the initial attempt at the difference-NMR technique, Vespel drive tips 
were used to seal the rotors.  Two component spectra were acquired for each physical 
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mixture (45% and 4.5%) for a total of four spectra.  The component spectra were 
collected with identical acquisition parameters with the exception of pulse delay and 
number of scans.  For the 45% physical mixture, a spectrum was acquired with a 14-s 
pulse delay and 128 scans and another component spectrum with a 28-s pulse delay 
and 64 scans.  The same conditions were used for the component spectra acquired for 
the 4.5% physical mixture.  No post-acquisition modifications were made to the FID. 
In the second attempt at the difference-NMR technique, the rotors were 
purged for one min with medical-grade oxygen gas and sealed with Vespel end caps.  
The Vespel end caps have two Teflon O-rings (Revolution NMR, Fort Collins, CO) 
and provide a gas-tight seal.  For each of the six physical mixture, eight data sets were 
acquired in this order: crystalline 19F T1 (11 increments, 1 scan) measurement, 
amorphous 19F T1 (11 increments, 12 scans) measurement, four component spectra 
(pulse delays of 2 s, 4 s, 8 s, and 16 s), a spectrum that is five times the crystalline 19F 
T1 time (600-s pulse delay and 4 scans), and an additional amorphous 19F T1 
measurement.  The four component spectra are used in the two difference-NMR 
subtraction [2*(2s)-4s] and [2*(8s)-16s].  The spectrum acquired with five times the 
crystalline 19F T1 time is used to determine the amount of crystalline material present 
by SSNMR, and the three relaxation measurements were made to ensure relaxation 
stability throughout the experiments.  Twenty dummy scans were used to equilibrate 
the magnetization in the sample prior to data collection of the four component spectra 
to minimize differences in the starting magnetic equilibrium.  The corresponding 
component spectra of the six physical mixtures (45%, 10%, 5%, 1%, 0.5%, and 0.1%) 
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were acquired with identical parameters other than the number of scans (1024, 1024, 
1024, 4096, 2048, and 8192, respectively).  It was determined that processing the 
NMR data using Spinsight was the preferred method for deconvolution of the various 
peaks.  Spinsight is the software that comes with the Chemagnetics (now Varian) 
spectrometers.  The FIDs were processed with 100 Hz Gaussian line broadening, 
1024 data points, and baseline correction was applied after the component spectra 
were subtracted.   
 
5.2.5 Data conversion XWin-NMR to Spinsight 
  SSNMR data collected on the Bruker Avance 500 with XWin-NMR software 
were transferred to a Sun workstation, and the data were converted into Spinsight 
format with in-house software.  The digital free induction decays (FIDs) from Bruker 
were processed within Spinsight by a macro written to handle the additional steps 
required to process the data.  [Note:  Bruker can convert the FIDs into an analog 
form.  In the present case, there were hundreds of data files, which means that writing 
a conversion program was preferred].  To treat the digitally filtered Bruker data, the 
DC offset must be corrected first, followed by any desired zero filling.  Next, there is 
an artifact at the beginning of the Bruker FID that arises as a consequence of the 
digital filtering.  Those points must be circularly shifted to the end of the FID (i.e., the 
first X points in the FID become the last X points of the baseline-corrected and zero-





5.3.1 Solid forms of triamcinolone 
The solid-state 19F NMR spectra of the three crystalline forms and one 
amorphous form of triamcinolone are shown in Figure 5.5.  In all spectra, the smaller 
peaks, denoted with asterisks, are spinning sidebands.  Spinning sidebands are 
artifacts of spinning the samples and occur at frequencies proportional to the spinning 
speed.    
 A 19F SSNMR spectrum of the as-received triamcinolone lots is shown in 
Figure 5.5a.  Several lots were received and analyzed, and the bulk as-received 
material usually consisted of mixtures of polymorphs A and B.  The two downfield 
peaks (-159.7 and -161.2 ppm) were assigned to polymorph B, and the two upfield 
peaks were assigned to polymorph A (-163.2 and -164.0 ppm).  Both polymorphic 
forms A and B produced two NMR peaks for a single fluorine atom in the molecule. 
In these cases, the unit cell consists of two crystallographically inequivalent 
molecules.  Each unique molecule has a different molecular environment and 
therefore a unique chemical shift.  This is supported in the 13C SSNMR spectrum (not 





Figure 5.5. 19F SSNMR spectra of the different forms of triamcinolone: a) as-
received triamcinolone from Sigma-Aldrich containing polymorphs A and B, b) the 
monohydrate form, c) polymorph B, and d) amorphous triamcinolone.  The asterisks 
denote spinning sidebands. The red line indicates the chemical shift resolution 
between polymorph B (figure 5.5c) and the amorphous form (figure 5.5d).
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 Polymorph A was present in the majority of lots received from Sigma Aldrich.  
Polymorph A is a metastable polymorph of triamcinolone that can be produced by 
dehydrating the monohydrate or crystallization from the amorphous form.  The peaks
of polymorph A significantly overlap with the chemical shift region of the amorphous 
form, making it an unsuitable crystalline form for this study.  Despite not being an 
appropriate crystalline form, polymorph A was helpful in monitoring the physical 
stability of the model forms in the physical mixtures studied in these experiments.  
 The 19F SSNMR spectrum of the monohydrate form is shown in Figure 5.5b.  
The monohydrate was produced by crystallization from an acetone and water 
solution.  The weight loss from the thermogravimetric analysis (TGA) (not shown) 
thermogram was consistent with a stoichiometric loss of a single water molecule per 
molecule of triamcinolone.  The 19F SSNMR spectrum of the monohydrate had a 
single peak at -160.9 ppm with a line width of 223 Hz.  Upon exposure to a vacuum 
overnight, the monohydrate partially converted to polymorph A.  The 19F T1 time of 
monohydrate triamcinolone was 110 s.  Because the chemical difference between the 
monohydrate and amorphous forms were substantially different, the monohydrate 
form was used as the model crystalline form for the initial attempt at quantitation 
using the difference-NMR technique.   
The 19F SSNMR spectrum of pure polymorph B is shown in Figure 5.5c.  
Polymorph B was recrystallized from methanol for these studies, and it readily 
crystallizes from a number of organic solvents.  There are two peaks in the spectrum, 
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at -159.7 and -161.2 ppm, with line widths of 145 and 122 Hz, respectively.  The 19F 
T1 time was 105 s, and the measured 1H T1 time was approximately 1 s.   
In these studies, amorphous triamcinolone was generated by cryogrinding and 
spray drying.  Both processing techniques generated an amorphous form with similar 
19F SSNMR spectra and comparable relaxation times between 2-5 s.  The spectrum of 
the amorphous form of triamcinolone is shown in Figure 5.5d.  The peak had a 
chemical shift of -164.9 ppm and a line width of 3300 Hz, which was 22x and 27x 
broader than the line widths of the two NMR peaks of polymorph B.  The dashed line 
helps illustrate the chemical shift resolution between polymorph B (figure 5.5c) and 
the amorphous form (figure 5.5d).  For these quantitation studies, increased chemical 
shift resolution improves the ability to quantitate the solid forms.  The 19F NMR peak 
shape of the amorphous form was visibly asymmetric.  Typically NMR line shapes 
are symmetric, so this observation is notable. The cause of the asymmetry is 
unknown, but it did not depend on spectrometer or field strength, because it was 
exhibited at both 300 MHz and 500 MHz on two different solid-state NMR 
spectrometers.  The asymmetry was also present for amorphous samples produced 
from cryogrinding and spray drying processes.     
Amorphous triamcinolone generated by cryogrinding was used to prepare the 
physical mixtures for the first and second quantitation attempts.  For the third and 




5.3.2 Quantitation attempt one 
 The initial attempt at quantitation was performed using 1H/19F cross 
polarization with a pulse delay longer than 5✕ the 1H T1 times of the crystalline and 
amorphous forms.  Two series dilutions produced four physical mixtures with varying 
percentages of amorphous triamcinolone (30%, 10%, 3%, and 1%).  The 19F SSNMR 
spectra of the four physical mixtures and the crystalline polymorph B standard are 
shown in Figure 5.6.  Each spectrum is zoomed in on the chemical shift region of the 
amorphous form to show the presence of low-level amorphous material.  A dashed 
line is positioned at the chemical shift of the peak to aid the eye for observing the 
low-level presence of amorphous triamcinolone.  The amorphous form was readily 
visible in the full NMR spectrum of the 30% physical mixture as shown in Figure 
5.6a.  The amorphous form was not readily visible in the full spectrum for the other 
physical mixtures, Figure 5.6b-d.  When the spectra are expanded, the spectrum of the 
10% physical mixture appears to have a small but distinguishable signal from 
amorphous triamcinolone.  The amorphous form was not observed in the spectra of 
the 3% and 1% physical mixtures.  The 19F SSNMR spectrum of polymorph B is 
shown in Figure 5.6e.  The intensity of the crystalline peaks decreases the resolution 
with the amorphous peaks at the base.  Acceptable resolution was not achievable for 
triamcinolone using this approach.   
 Two unidentified peaks were present in all four physical mixtures and the 




Figure 5.6.  Traditional quantitation attempt of the physical mixtures of polymorph B 
and amorphous triamcinolone.  19F SSNMR spectra of the four physical mixtures: a) 
30%, b) 10%, c) 3%, d) 1% and e) pure polymorph B.  Each of the spectra are 
expanded to zoom in on the region of the amorphous impurity.  The vertical line is 
located









polymorph B.  They are only observed in the spectra of polymorph B and were 
consistent in intensity from various lots of polymorph B crystallized from methanol.  
There are several potential explanations for these two peaks.  One explanation for 
these peaks is that they could be due to 13C-19F spin-spin couplings.  This explanation, 
while possible, is inconsistent with the fact that the peaks have the same chemical 
shift (in ppm) on both 300 and 500 MHz spectrometers.  The peaks could also be 
signal from a polymorphic or chemical impurity generated during crystallization from 
methanol.  Although the source of the peaks is unidentified, they are irrelevant to the 
quantitation studies.  Detection of low-level amorphous impurity was not possible 
with the traditional quantitation approach, and another approach is necessary, which 
suppresses the signal of the crystalline form. 
 
5.3.3 Quantitation attempt two 
 Amorphous levels below 10% could not be detected with the traditional 
quantitative approach; therefore, the difference-NMR technique was used to increase 
the detection of low-level amorphous impurity.  The difference-NMR technique 
separates forms based on differences in spin-lattice relaxation times.  In the case of 
triamcinolone, the 1H T1 times for the amorphous and crystalline forms are both on 
the order of a few seconds.  However, the 19F T1 times differ by nearly two orders of 
magnitude between the crystalline and amorphous forms.  The 19F T1 time of the 
cryoground amorphous form used in this experiment was determined to be 2.8 s, yet 
the 19F T1 time of the mononhydrate was measured to be 110 s, nearly 40 times 
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longer.  The difference means that this system is very amenable to use the difference-
NMR technique.   
 The amorphous form was physically mixed with the crystalline monohydrate 
to demonstrate the difference-NMR technique.  Two physical mixtures, containing 
45% and 4.5% amorphous, were prepared through serial dilution.  Two SSNMR 
component spectra were acquired for each blend using identical NMR parameters 
except pulse delay and number of scans.  To maintain quantitative conditions for the 
amorphous form, both component spectra were collected with pulse delays greater 
than 5✕ the 19F T1 time.  One of the component spectra was acquired with a 14-s 
pulse delay and 128 scans, and the other was collected with a 28-s delay and 64 scans.  
The individual component spectra and the subtraction for the two physical mixtures 
are shown in Figure 5.7.  Figure 5.7a-c shows the component spectra and subtracted 
spectrum of the 45% physical mixture.  In each of the three spectra, three solid forms 
of triamcinolone are visible: polymorph B (-159.7 ppm), the monohydrate (-160.9 
ppm), and the amorphous form (-164.9 ppm).  The monohydrate still had a large 
impurity of polymorph B after crystallization.  As would be expected, the amorphous 
intensity in the spectrum acquired with a 14-s pulse delay (Figure 5.7a) is greater than 
the amorphous intensity in the 28-s component spectrum (5.7b).  This is because the 
NMR signal from the crystalline form is suppressed more at shorter pulse delays, and 
the number of scans acquired is larger for the 14-s component spectrum.   
 The component 19F SSNMR spectra of the 4.5% physical mixture and the 




Figure 5.7. 19F SSNMR spectra of the component and subtraction spectra for each 
physical mixture in the first attempt using the difference-NMR technique.  The 
spectra of the 45% physical mixture were acquired with a a) 28-s pulse delay and a b) 
14-s delay, and the c) the subtracted spectrum. [2*(28s)–14s].  The same conditions 
apply for the 4.5% physical mixture: a) component spectrum with a 28-s delay, b) 14-
s delay and c) the subtracted spectrum, [2*(28s) –14s].
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SSNMR spectra, four forms are now visible.  In addition to the NMR peaks 
corresponding to the three forms anticipated to be present, two small sharp peaks of 
corresponding to polymorph A have appeared.  This indicates that the physical forms 
present in the sample changed some time during preparation, storage, and/or data 
acquisition. Both recrystallization of cryoground triamcinolone and dehydration of 
the monohydrate form have been shown to generate polymorph A. For this reason, 
both the monohydrate and the cryoground amorphous form were determined to be 
physically unstable for quantitation. 
 Despite the form conversion, both the subtractions for each physical mixture 
show a higher ratio of the amorphous form in comparison to the individual 
component spectra.  Afterwards, the 19F T1 time of the amorphous form was 
monitored over several hours to determine if the relaxation time had changed, and it 
was found that it increased from the initially measured value of 2.8 s to nearly 20 s.  
Through a series of experiments detailed in Chapter 6, it was determined that the 
nitrogen gas used to spin the samples purged oxygen from the rotor.  Oxygen is a 
paramagnetic relaxation agent, and as it is removed, the relaxation time of amorphous 
triamcinolone increased by more than an order of magnitude.  Changes in partial 
pressure of oxygen had no visible affect on the 19F T1 times of the crystalline forms of 
triamcinolone or the line widths and chemical shifts of both forms.  During the 
acquisition of the component spectra, the 19F T1 time increased for the amorphous 
form.  If the 19F T1 time increased to more than 5.6 s, the 28-s component spectra 
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would have considerably less NMR signal from the amorphous form; therefore, the 
subtracted spectrum would have more amorphous signal than anticipated.    
 This attempt at quantitation using the difference-NMR technique raised 
several concerns.  First, the spin-lattice relaxation times of each component in the 
mixture must be measured because the values remaining constant is paramount to the 
accuracy of the difference-NMR technique.  Second, the 19F T1 times of the 
crystalline and amorphous forms need to be monitored throughout the course of the 
experiments.  Lastly, the crystalline and amorphous solid forms should be closely 
monitored for form conversion, which could also skew quantitation results. The 
monohydrate form can potentially dehydrate during the experiment and convert to 
polymorph A.  A more physically stable amorphous form needs to be prepared to 
ensure physical stability throughout the experiments.  The final quantitation attempt is 
designed to account for these shortcomings.   
 
5.3.4 Quantitation attempt three 
 In the previous quantitation attempt, the 19F T1 times increased during some of 
the acquisition of the component spectra, and the solid forms exhibited physical 
instabilities.  The concerns that arose in the previous attempt were addressed with 
several changes.  First, the solid forms of triamcinolone were prepared in a more 
reproducible manner.  Spray drying was used to generate amorphous triamcinolone 
rather than cryogrinding.  Chapter 4 provides a more detailed discussion on the 
physical stability of the differences between spray-dried and cryoground amorphous 
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triamcinolone.  Polymorph B crystallized from methanol was used as the model 
crystalline form.  Reproducibly crystallizing the monohydrate form was difficult, and 
it was physical instable, which were both reasons to return to using polymorph B as 
the crystalline standard.  Second, the physical mixtures were purged with oxygen gas, 
and gas-sealed with an MAS drive tip containing two O-rings, which would prevent 
the sample from being purged by nitrogen gas while spinning.  Third, the 19F T1 times 
of the crystalline and amorphous forms were closely monitored (when possible) 
during the course of the experiments to ensure relaxation time stability and accuracy.  
Fourth, dummy pulses were added to minimize differences in the magnetic 
equilibrium of the individual component spectra.  Lastly, an additional spectrum was 
acquired to provide a quantitative value for the crystalline form.  
 Prior to quantitation, the 19F T1 times of the amorphous and crystalline 
standards were measured.  Pure spray-dried amorphous triamcinolone was purged 
with oxygen gas and sealed.  After purging and sealing a sample of amorphous 
triamcinolone, the measured 19F T1 time was 1.6 s.  After spinning for 48 hrs in a 
sample spinner, the 19F T1 time was 1.5 s.  The relaxation time had not increased, and 
the drive tips provided a reliable seal.  The 1.6-s 19F T1 time was less than the 2.8-s 
19F T1 time measured during the previous quantitation attempt.  The drop in relaxation 
time was attributed to increased partial pressure of oxygen gas in the rotor.  The 19F 
T1 time of pure polymorph B was also monitored after purging with oxygen gas.  The 
T1 time of polymorph B was 105 s, and did not change after spinning for 48 hrs.  The 
relaxation time of the amorphous form had dropped, yet the crystalline form was 
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unchanged.  This was likely due to the crystal lattice preventing penetration of the 
oxygen molecules.  Because the increased partial pressure of oxygen only affected the 
amorphous form of triamcinolone, the T1 ratio of our forms was increased.  Increasing 
the T1 ratio improves selectivity of the difference-NMR technique.   
 During the quantitation experiments, four relaxation measurement 
experiments were performed for each physical mixture.  Due to the large differences 
in relaxation times, the 19F T1 times of the crystalline and amorphous forms were 
measured separately.  A T1 measurement was performed for the amorphous and 
crystalline forms both before and after the component spectra were acquired.  The 
measurements ensured that the T1 times had not increased during the experiment due 
to sample annealing or healing and/or loss of partial pressure of oxygen gas.  The 19F 
T1 time of polymorph B was 105 s (+/- 5 s) in the six physical mixtures.  The 19F T1 
time of the amorphous form was 1.2 s for the 45% and 10% physical mixtures before 
and after collection of the component spectra.  The NMR signal of the amorphous 
form was too low to measure in the other physical mixtures.  The 19F T1 time dropped 
from 1.6 s for the pure amorphous standard to 1.2 s for the 45% and 10% physical 
mixtures.  The reduction in T1 could be attributed to additional disorder of the 
amorphous state in the physical mixtures or an increased partial pressure of oxygen 
gas relative to the standard.  
 Along with the three relaxation experiments, five 19F SSNMR spectra of each 
physical mixture were acquired.  Of the five spectra acquired, four spectra were 
acquired as component spectra for the difference-NMR subtractions with pulse delays 
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of 2 s, 4 s, 8 s, and 16 s.  All other experimental NMR parameters remained the same, 
including the number of scans.  These four component spectra were spectrally 
subtracted in three different ways.  A spectral subtraction, [2*(2s)-4s], was performed 
that yielded the best crystalline suppression.  The subtraction is considered qualitative 
(QL), because the component spectra (2 s and 4 s) were collected with pulse delays 
shorter than five times the 19F T1 time (1.2 s) of the amorphous form,.  The other two 
subtractions combined component spectra with pulse delays of 8 s and 16 s.  The 
pulse delays of these component spectra were greater than five times the 19F T1 time 
of the amorphous form, and are considered quantitative.  The two component spectra 
were combined in two different ways.  First, a straightforward application of the 
difference-NMR technique [2*(8s)-16s] provided a spectrum with a quantitative 
value for the amorphous drug.  This subtraction is referred to as the first quantitative 
subtraction (QT1).  The third subtraction, [1.927*(8s)-16s], accounted for the 
exponential nature of the crystalline 19F T1 curve between 8 and 16 s.  The subtraction 
was still quantitative for the amorphous and is referred to as the second quantitative 
subtraction (QT2).   
 The three subtractions using the difference-NMR technique did not return a 
quantitative value for the crystalline form.  The fifth spectrum was acquired to obtain 
NMR peak areas for the crystalline material in each mixture.  The spectrum was 
acquired with a 600-s pulse delay that allowed for full relaxation of both solid forms, 
specifically the crystalline form.  This is referred to as the quantitative crystalline 
(QTC) spectrum.   
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Table 5.1. Descriptions of the four spectra (three subtractions and the QTC) used to 
measure the amorphous content in the six physical mixtures. 
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The QTC and component spectra were transferred to Spinsight for subtraction 
and deconvolution.  Isotropic peak areas of the amorphous peak in the difference-
NMR subtraction spectra (QL, QT1, and QT2), and crystalline peaks in the QTC 
spectrum were measured.  The areas of the spinning sidebands were not 
deconvoluted, yet the signal loss from the sidebands was taken into account. The 
following procedure outlines the deconvolution scheme applied to the NMR data of 
the six physical mixtures.   
Initially, the 19F SSNMR spectra of pure amorphous and crystalline spectra 
were deconvoluted to determine the values of the principle parameters that define a 
peak in a SSNMR spectrum: chemical shift (ppm), line width (Hz), and line shape 
(Gaussian/Lorentzian ratio, %GL).  The defined parameters limited the ability of the 
user to adjust parameters for a better fit, especially when peaks were difficult to 
deconvolute due to relatively low intensities.  In Figure 5.8, an example of the 
deconvolution scheme for one of the physical mixtures is shown.  There are five 
traces in this figure: two peaks for the crystalline form (c1 and c2), two peaks for the 
amorphous form (a1 and a2), and a trace of the deconvoluted sum. The trace of the 
deconvoluted sum is difficult to distinguish from the acquired spectrum.  Because of 
the asymmetry of the amorphous NMR peak, two peaks were required for 
deconvolution.   
The parameters used to define the four peaks in the deconvolution scheme are 
presented in the table in Figure 5.8.  The peaks of the crystalline form had chemical 




Figure 5.8. Shown is an example of the deconvolution scheme applied to a 19F 
SSNMR spectrum.  The scheme was applied to each spectrum of the six physical 
mixtures
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The line shapes were determined to be 49 and 42% Gaussian. The two peaks used to 
deconvolute the amorphous form were at chemical shifts of -163.1 and -165.8 ppm 
with corresponding line widths of 3315 and 2462 Hz.  Both amorphous peaks were fit 
with a 100% Gaussian line shape, and the ratio between the two peaks was 1.35:1.  
The ratio of amorphous peaks was maintained within the limitations of the Spinsight 
software to maintain the integrity of the deconvolution.  The chemical shifts and line 
widths were controlled within 0.05 ppm and 5 Hz, respectively.  The assumption was 
made that these deconvolution parameters did not change.  It is possible that line 
widths might be affected by the dilution of the amorphous material in the crystalline 
material.  Barich et al. have studied the effects of dilution of ibuprofen in excipients 
that cause anisotropic bulk magnetic susceptibility (ABMS).20   ABMS produces line 
broadening due to changes in the local electronic environment.  19F SSNMR line 
widths of the different forms of triamcinolone have not been fully investigated; 
therefore, the line widths are assumed to be constant, with respect to the bulk forms, 
throughout all physical mixtures.  
 The deconvolution procedure provided peak areas for the three subtraction 
spectra, and the QTC spectrum for each of the six physical mixtures.  Because of the 
acquisition and subtraction conditions, quantitation was not straightforward.  For 
example, a deconvoluted amorphous area of the QL subtraction spectrum was 
obtained, yet the component spectra of QL were acquired using non-quantitative 
conditions.  The amorphous area measured is less than the representative amount of 
amorphous drug in the mixture.  Table 5.2 can be used to account for the percent of  
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Table 5.2. The percent of crystalline (%C) and amorphous (%A) material was 
calculated for the individual component spectra and the spectral subtraction based on 
the relaxation profiles for the amorphous and crystalline forms.  The correction factor 






the total amorphous and crystalline area in each sample.  For the case of the three 
subtractions listed, the amorphous form should be 100%.  The crystalline form is 
suppressed, and will have a much lower percentage.   
 Using the relaxation profiles for the two forms in Figure 5.1, the relative 
intensity of each form was determined for each component spectrum.  For the QT1 
subtraction, the amorphous form was completely relaxed during the acquisition of 
each of the component spectra yielding 100% amorphous intensity.  Because the 
crystalline 19F T1 time was much longer than the pulse delays used for the component 
spectra, the two component spectra contained 7.3 and 14% of the total crystalline 
signal.  When the difference-NMR technique was applied for the QT1 subtraction, 
there was a calculated residual crystalline signal (0.54%) remaining, and 100% of the 
total amorphous signal.  The QT2 subtraction spectrum was performed to adjust for 
the residual crystalline signal.  A coefficient of 1.927 was used for the QT2 
subtraction to mathematically eliminate the residual crystalline signal. During the 
subtraction, the resulting %A was less than 100%. The deconvoluted areas of the  
amorphous peaks were multiplied by a correction factor of 1.08 to account for the 
loss in amorphous signal.   
 The QL component spectra were acquired with conditions that did not allow 
full relaxation of either solid form.  According to the relaxation profile, the relative 
percentages for the amorphous form were less than 100 for both the 2-s and 4-s 
component spectra.  Even though the amorphous form was not fully relaxed, 
quantitation was performed.  Based on the measured 1.2-s 19F T1 time, the amorphous 
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signal observed in each component spectrum was calculated.  The 2-s component 
spectrum had 81.1% of the total amorphous signal remaining, and the 4-s component 
spectrum had 96.4% of the signal.  After performing the QL difference-NMR 
subtraction, only 65.8% of the total amorphous signal remained.  The deconvoluted 
areas were multiplied by a correction factor of 1.52 to account for the loss in signal. 
 Last, the sideband areas needed to be calculated to finalize the quantitative 
amorphous signal.  If the crystalline and amorphous peaks lose the same percentage 
of signal to their sidebands, the sideband areas can be ignored.  The sideband areas 
were deconvoluted for the pure amorphous and crystalline forms.  The spinning 
sidebands of the amorphous peak represented 7.7% of the total amorphous signal, 
whereas, the sidebands of the crystalline peaks represented 14.3% of the crystalline 
signal.  Because of the difference, the area values need to be adjusted.  After the 
corrections for magnetization for the subtractions, another coefficient (1.08) was 
multiplied to the amorphous area in each of the three subtractions to account for the 
amorphous signal lost to the spinning sidebands.  Thus far, the deconvolutions and 
mathematical adjustments have provided a quantitative value for the amorphous form 
but not the crystalline.   
 The difference-NMR subtractions were performed to obtain a quantitative 
value for the amorphous form.  The QTC spectrum for each physical mixture was 
acquired to determine the quantitative value for the crystalline form.  Similar to the 
amorphous form, the deconvoluted area was multiplied by an adjustment factor (1.17) 
to account for the signal lost to the spinning sideband intensity.  Before a quantitative 
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value can be obtained for the physical mixtures, one final correction was made.  As 
mentioned previously, the QTC spectrum allowed time for full relaxation of all 
forms, specifically the crystalline form.  The intensity of a spectrum is directly 
proportional to the number of scans acquired, and the amorphous and crystalline peak 
areas were collected with different scan counts.  The deconvoluted peak areas of the 
QTC spectrum were multiplied by the ratio of scans used in acquiring the component 
spectra and the QTC spectrum.  For example, if 1024 scans were used to acquire the 
component spectra, and four scans were used to acquire the QTC spectrum, then the 
area of the crystalline peaks in the QTC spectrum would be multiplied by 256 to 
account for the difference in relative signal.   
 Table 5.3 lists the quantitation data for the six physical mixtures of the 
amorphous and crystalline forms of triamcinolone.  The (measured) wt% by SSNMR 
spectroscopy and (known) wt% by mass values in Table 5.3 agree well for each 
physical mixture.  Quantitative values were calculated for all six physical mixtures 
using each of the three subtraction techniques.  At the 0.1% the amorphous signal 
present in the QT1 and QT2 subtraction spectra was so low that only the QL 
subtraction data were presented.  The three subtractions agree well with each other.  
 The error for each physical mixture could arise from a variety of places.  The 
physical mixtures were prepared with amorphous and crystalline standards.  The 
standards could be less than 100% pure.  The particle size of each form could 
contribute to less than homogenous mixing.  When collecting the data, the component 
spectra were collected in series.  If probe tuning fluctuates or the probe arcs, each  
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Table 5.3.  Quantitation of the six physical mixtures using three subtractions of the 






component spectrum would be affected differently.  Prior to acquisition, 20 dummy 
pulses were applied to each component spectrum in an attempt to achieve a common 
magnetic equilibrium for the individual component spectra.  The dummy scans were 
pulsed at the pulse delay time values, so each component spectrum used a dummy 
pulse with a different delay.  The delay could contribute to changes in the observed 
crystalline signal.  The 19F T1 times for both forms are relied upon heavily in 
acquisition and mathematical adjustments made to the deconvoluted peak areas.  If 
the relaxation rates were not measured precisely or changed during the experiments, 
the effects could contribute to error in the quantitation values.  Error could also occur 
during deconvolution.  The deconvolution scheme was heavily restrictive, and in 
some cases left significant residual signal.  Error occurs at some level in all of the 
steps of quantitation.  Each spectrum was only acquired once.  A change in one of the 
four scans of the QTC spectrum could result in distorted crystalline peak areas.  
Despite the potential error, the wt% by SSNMR and wt% by mass agree well. 
 Figure 5.9 shows the plot of amorphous wt% by SSNMR versus the 
amorphous wt% by mass for the QL subtraction data.  The trend line has a R2 value 
near one, a slope less than 1, and a small negative y-intercept.  The slope indicates 
that in most cases the wt% by SSNMR is underestimating the amorphous content or 
overestimating the crystalline content.  The value of the intercept (0.067) is on the 
order of the lowest value intended to quantitate.  The quantitation numbers are easier 
to appreciate when presented with the 19F SSNMR subtraction spectra.  Unlike many 




Figure 5.9. Plot of wt% by SSNMR spectroscopy versus wt% by mass of physical 











observe the amorphous signal at low levels.  Figure 5.10 displays the 19F SSNMR 
spectra of the QT1 and QL subtractions for the six physical mixtures.  The QT1 
subtraction series is on the left, and the QL subtraction series is on the right.  In each 
spectrum, polymorph B and the amorphous form of triamcinolone should be present.  
For the QT1 series, amorphous signal is visible down to the 1% (Figure 5.10d) level 
and quantitated to the 0.5% level.   
 In the QL series, amorphous signal is visible to the 0.5% (Figure 5.10e) level 
and quantitated to the 0.1% level.  In the corresponding spectra for each mixture, the 
QL spectrum has a lower SNR.  This is expected because shorter pulse delays were 
used to acquire the component spectra.  The QL subtractions of the 1% and 0.5% 
physical mixtures exhibit phasing anomalies.  Each subtraction was performed 
several times with different phasing conditions of the component spectra.  In all of the 
spectra, a 19F signal from the Teflon O-rings is visible near -121 ppm, and its 
spinning sideband (-154 ppm) is visible in a few of the subtraction spectra.  The peaks 
from Teflon do not interfere with quantitation.  No peaks are present from polymorph 
A, indicating that the mixtures were physically stable throughout all experiments.   
 The difference-NMR technique is powerful in suppressing the long-relaxing 
crystalline component while still being quantitative.  Adjusting NMR parameters is a 
valuable tool for solid-state form quantitation.  In Figure 5.11, the 19F SSNMR 
spectra for the 5% and 0.5% mixtures illustrate how changing the pulse delay and 
using the difference-NMR technique can suppress the crystalline signal.  Each 




Figure 5.10.  19F SSNMR spectra for the QT1 and QL subtractions of the six 
physical mixtures.  The spectral series on the left consists of the QT1 subtraction 
spectra,  and the series on the right consists of the QL subtraction spectrum for each 
physical mixture: a) 45%, b) 10%, c) 5%, d) 1%, e) 0.5%, and f) 0.1%.  
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spectrum of the 5% sample acquired with 4 scans and a 600-s pulse delay.  
Polymorph B is visible, while the amorphous signal is not.  If the presence of 
amorphous material were not suspected, the SSNMR operator would typically pulse 
the sample at approximately the T1 time.  Under these conditions, amorphous signal 
would not be observed.  Figure 5.11b and c are the spectra acquired with 16-s and 2-s 
pulse delays.  Simply shortening the pulse delay suppresses the crystalline signal 
enough to see the amorphous signal.  Figure 5.11d and e are the QT1 and QL 
difference-NMR spectra for the 5% mixture.  The amorphous signal becomes even 
more prevalent.  Figure 5.11c and d appear to have similar amorphous content, yet the 
spectrum in Figure 5.11d is traditionally thought to be quantitative.  The spectrum in 
Figure 5.11c was acquired with a 2-s pulse delay (less than five times the T1).  In the 
0.5% series, Figure 5.11f-j, no amorphous signal is visible until the QL subtraction 
spectrum (Figure 5.11j).  The QT2 spectrum is not displayed; however, it exhibits 
small gains in crystalline suppression.     
 There is no indication which difference-NMR subtraction (QT1, QT2, or QL) 
is the best at quantitating the amorphous form of triamcinolone.  All three subtraction 
processes have similar absolute error.  Due to the time-intensive nature of acquiring 
the data, the samples were only analyzed once.  For future studies, a pulse sequence 
should be written that collects two scans at one pulse delay and one scan at twice the 
pulse delay 180° out of phase.  The pulse sequence can acquire the difference-NMR 




Figure 5.11.  Increased expressions of amorphous triamcinolone in the 5% and 0.5% 
physical mixtures acquired with different parameters. a-e are spectra of the 5% 
mixture and f-j are spectra of the 0.5% mixture.  a) 600-s pulse delay, b) 16-s pulse 
delay, c) 2-s pulse delay, d) difference-NMR subtraction [2*(8s)-16s], and e) 
[(2*(2s)-4s].  The 0.5% physical mixture collected with a f) 600-s pulse delay, g) 16-s 
pulse delay, h) 2-s pulse delay, and the difference-NMR subtractions i) [(2*8s)-(16s)] 
and j) [(2*(2s)-4s].  Asterisks denote spinning sidebands.   
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 The pulse sequence would minimize the affects of fluctuations of spectrometer 
operating conditions, eliminate differences in the initial magnetic equilibrium of the 




 Quantitating amorphous materials is extremely difficult and requires the 
application of many different techniques depending on the drug substance.  When 
applicable, 19F SSNMR spectroscopy is a powerful addition to the list of techniques.   
 From the presented work, 19F SSNMR can distinguish and monitor four 
different forms (two crystalline, one amorphous and one hydrate) of triamcinolone.  
The ability to simultaneously monitor multiple forms is extremely valuable in 
understanding the physical nature of a drug substance and product.  Mixtures of the 
crystalline and amorphous forms of the drug can be observed without much difficulty. 
As the percentage of amorphous content drops, the SSNMR operator can alter 
parameters to selectively express different components in the sample.  Here, the 
difference-NMR technique was applied and allowed detection of amorphous levels to 
0.5%.  Potentially, the limits of detection and quantitation could be further decreased 
with shorter pulse delays, more scans, and a third component in the difference-NMR 
subtraction.   With careful monitoring of the sample and NMR relaxation, reliable 
quantitative spectra can be obtained for crystalline and amorphous materials.  
 Although the studies performed here only looked at drug substance, in theory, 
 190 
the technique can be applied to a formulation without much additional effort.  The 
addition of excipients should not affect the 19F SSNMR spectrum.  Of all the 
techniques currently used to investigate the amorphous state, 19F SSNMR is unique 
because detection in a formulation should only differ from a physical mixture in the 
amount of time required to acquire a spectrum.  19F SSNMR proves to be a very 
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 In Chapter 5, physical mixtures of crystalline and amorphous forms of 
triamcinolone were quantitated with 19F solid-state NMR spectroscopy (SSNMR).  
The physical mixtures of triamcinolone were quantitated by spectral subtraction of 
two component spectra using the difference-NMR technique.  The ability to obtain 
accurate quantitation data depends in part upon knowing the NMR relaxation times of 
the components being studied.  As mentioned in Chapter 2, there are two relaxation 
values that need to be accounted for when using cross polarization between two 
nuclei.1   In the case of triamcinolone, the NMR experiments were performed with a 
single-pulse pulse sequence that directly excited the 19F nucleus.  Direct polarization 
simplified the quantitation method because it was unnecessary to account for the two 
cross-polarization dependent relaxation times.  The only relaxation time values to 
consider were the 19F spin-lattice relaxation times (T1) of the crystalline and 
amorphous components.  
 The difference-NMR technique is based on the assumption that NMR 
relaxation times are known for each component in the sample.  The component 
spectra of the difference-NMR technique for each physical mixture of triamcinolone 
were collected over the course of several hours to several days depending on the 
percentage of amorphous content.  It was necessary to ensure that the 19F T1 times of 
the crystalline and amorphous forms remained constant throughout the time course of 
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the experiments.  To demonstrate the 19F T1 times remained constant, the T1 times 
were measured on the pure amorphous standard every two hours over a period of 18 
hrs.  The relaxation time started at ~3 s and increased to ~19 s.  Upon sample removal 
from the NMR probe and reinsertion, the relaxation time returned to ~3 s.   
 In magic-angle spinning experiments, the spin-lattice relaxation time of a 
sample rarely changes in the spectrometer.  If an increase in relaxation time occurred, 
the increase is typically non-reversible.  Experiments were performed on several 
batches of differently prepared (cryoground and spray-dried) amorphous 
triamcinolone and with very similar relaxation time results.  The 19F T1 times 
increased 3-6 times their original value over a period of 10-20 hours spinning in the 
magnet.  In all cases, the relaxation returned to its original value upon removal from 
the spectrometer and reinsertion.  Before the mixtures of triamcinolone could be 
quantitated, the mechanism for relaxation change must be examined and then 
controlled. 
 
6.1.2 Relaxation time changes 
 NMR relaxation times for crystalline organic solids are often considered to be 
constant, yet they can change based on processing conditions, thermal history, sample 
healing, and the presence of NMR relaxation agents.  The following is a review of 
how relaxation times can change based upon processing and environmental 
conditions.   
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 Lubach et al. studied the effects of processing (grinding, lyophilizing, spray 
drying, and compaction) on the 1H T1 times of crystalline lactose.2   The 1H T1 time 
was measured, and a 13C SSNMR spectrum was collected for each sample.  
Compaction of lactose resulted in a three-fold reduction in the 1H T1 time (243 s to 79 
s) from the bulk material.  Similarly, cryogrinding lactose for 2 min reduced the 1H T1 
time an order of magnitude (243 s to 23 s).  In both cases, there were no form changes 
readily apparent in the NMR spectra.  The researchers suggested that the reduction in 
T1 times were due to the increase in several factors that create sites of high mobility: 
reduction in particle size, introduction of crystal defect sites, and the generation of 
amorphous material.  The 1H T1 time for a lactose sample cryoground for 60 min was 
measured over 30 days, and the relaxation time increased from 0.77 s after initially 
being ground to ~6 s after 30 days with little spectral evidence of recrystallization.  
The increase in relaxation time was attributed to sample healing.   
 More recently, unpublished results from our laboratory have shown that the 
relaxation time for gabapentin changes drastically when the material is processed.  
The 1H T1 time of the bulk material was 134 s.  After being cryoground for 10 
minutes the 1H T1 time decreased to 7.3 s with no spectral evidence of a solid-state 
form change.  Preliminary research has been performed to study the 1H T1 times of 
aspirin after being cryoground for various lengths of time.  When cryoground for 10 
minutes, the 1H T1 time dropped from 57 s to 14 s.  In the absence of excipients, 
aspirin is known to remain crystalline.   Without  amorphous material present in 
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samples of cryoground aspirin, the decrease in relaxation time was attributed to 
reduction in particle size and/or an increase in crystal defects.    
 Although the spin-lattice relaxation times change, the mechanism for how 
they change can help understand the physical nature of the sample as well as the 
presence of any additional species (e.g. water).  Rigid crystalline solids with no 
relaxation sinks (e.g. methyl groups) lack the molecular mobility to necessary to 
transfer energy to the surface and have long spin-lattice relaxation times.  When 
highly mobile regions, such as methyl groups, are present, the magnetization can be 
transferred via 1H spin diffusion.  These regions of increased molecular mobility act 
as sinks for more efficient relaxation of the entire sample.  Cryogrinding lactose 
reduces particle size while generating crystal defects and amorphous material, all of 
which can increase the efficiency of spin diffusion.  Amorphous material has 
increased molecular mobility as compared to the crystalline form, and typically has 
shorter relaxation times. 
 The drastic changes in the 19F T1 times of amorphous triamcinolone were a 
significant cause for concern, as they could have a dramatic impact upon the 
reliability of the quantitation methods used in Chapter 5.  The following sections will 
present experiments which were designed to eliminate potential changes in relaxation 
time during quantitation experiments and demonstrate that changes in the partial 
pressure of oxygen can affect the relaxation rate of several representative 






 Triamcinolone was obtained from Sigma Aldrich (St. Louis, MO) and 
cryoground and spray dried by the following procedures.  Triamcinolone was also 
crystallized from methanol.  Dexamethasone was purchased from Alfa Aesar (Ward 
Hill, MA) and analyzed without any further processing.  Dextran was provided from 
the laboratory inventory of Dr. Ales Medek (Pfizer Inc., Groton, CT).  Acetyl 
salicylic acid (aspirin) was obtained from Sigma Aldrich (St. Louis, MO).  Aspirin 
was used as received and cryoground for 20 mintes.   
 
6.2.2 Sample preparation and handling 
 Cryogrinding was performed using a Spex Certiprep 6750 Cryo mill.  Thirty 
milling cycles were performed for triamcinolone and 10 cycles for aspirin with each 
cycle consisting of two minutes of grinding and two minutes cooling.   Prior to the 
initiation of grinding, the samples were pre-cooled for 15 minutes.  After the 
cryogrinding, the samples were exposed to a vacuum for 45 minutes to allow a return 
to ambient temperature before the cryovial was opened.  If the cryovial was opened 
too soon after grinding, the sample could still be cold and be at risk of condensation. 
 Spray drying of triamcinolone was performed on a custom-built spray dryer 
(Bend Research, Bend, OR).  Approximately 200 mg of material was dissolved in 
approximately 12 mL (10g) of warm methanol for an approximate concentration of 
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2% (wt/w).  A 1.3-mL/min injection rate was used with an inlet temperature of 70 °C 
The spray-dried material was collected on a 110 mm diameter Whatman filter paper.  
Harvested product yields were between 70-80%.  All solid-state analysis was 
performed by solid-state NMR spectroscopy. 
 Unless otherwise noted, triamcinolone, dexamethasone, and dextran were 
“deoxygenated” by spinning packed samples in the NMR probe at 15 kHz.  The drive 
tips were opened and exposed to ambient oxygen conditions.  When “oxygenated,” 
the samples were packed in zirconia rotors and directly exposed to medical-grade 
compressed oxygen gas for one minute.   
 Aspirin was oxygenated by exposing the packed NMR rotor to compressed 
oxygen gas for one minute, then sealing the rotor with a Kel-F drive tip with two O-
rings for a gas-tight seal.  To deoxygenate, the sample-containing rotor (without 
endcap) was sealed in the anti-chamber of a glove box and cycled three times in the 
following manner: vacuum exposure for 10 minutes then nitrogen gas purge for one 
minute.  The rotors were capped inside the glove box under positive nitrogen 
pressure.   
  
6.2.3 Solid-state NMR spectroscopy 
 SSNMR data of triamcinolone, dexamethasone and dextran were collected on 
a Bruker Avance 500 NMR triple-resonance spectrometer (Billerica, MA) operating 
at 469.8 MHz for 19F and 499.3 MHz for 1H.  Spectra were acquired using a Bruker 4-
mm 1H/19F/X triple-resonance MAS probe.  Samples were packed in zirconia rotors 
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and sealed with Vespel drive tips or a Vespel drive tip with two O-rings (Revolution 
NMR, Fort Collins, CO).  Samples were spun at rates of 10-15 kHz.  When low-
temperature studies were performed, a Bruker BCU-Xtreme (Billerica, MA) chilling 
unit was used.  Nitrogen gas was used for sample spinning, frame cooling, and low-
temperature chilling.  All samples acquired on the Bruker Avance 500 were 
referenced to a 1:1 water and trifluoroacetic acid (TFA) solution at -76.54 ppm.  
SSNMR data of triamcinolone were collected with 1H/19F cross-polarization and 
direct 19F excitation.  19F and 1H relaxation data were collected primarily with 
saturation recovery, but inversion recovery was utilized at times for comparison.  
Relaxation data were collected with 8-11 increments and fit to a mono-exponential 
decay.  For triamcinolone, dexamethasone, and dextran, the relaxation profiles were 
designed such that a relaxation measurement was made and then followed by the 
acquisition of the spectrum.  The spectrum was collected with a combination of a 
long pulse delay and specific number of scans such that 2 hrs passed between 
relaxation measurements (e.g. 60 scans and a 120 s pulse delay).  
 The 13C SSNMR spectra and 1H T1 relaxation times of aspirin were collected 
on a Chemagnetics CMX 300 spectrometer (Fort Collins, CO) operating at 298.7 
MHz for 1H and 75.1 MHz for 13C.  Samples were packed in custom-made 7-mm 
zirconia rotors and sealed with a Kel-F purchased from Revolution NMR (Fort 
Collins, CO).  The rotors were open on one end, which was capped with a Kel-F drive 
tip with two o-rings also from Revolution NMR.  The rotors were spun at 4 kHz and 
data was collected on a double-resonance 1H/X probe outfitted with a module 
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purchased from Revolution NMR.  1H relaxation measurements were made with a 
saturation recovery pulse sequence with Spinal 64 decoupling.  Twenty increments 
(0.1 s to 350 s) were collected for each relaxation measurement..  Each increment was 
collected with a 3.4-µs 90° 1H pulse, 512 acquisition points, and 12 acquisitions.  The 




6.3.1 Observation of changing NMR relaxation times  
 Prior to quantitation of the triamcinolone physical mixtures, the following 
experiments were performed on amorphous triamcinolone to understand the 
mechanism behind drastic changes in the 19F T1 times upon exposure to oxygen.   
 To test the constancy of the measured relaxation times, a sample of spray-
dried amorphous triamcinolone was spun overnight and the 19F T1 time was measured 
every two hours.  The relaxation measurements are plotted in Figure 6.1 and 
correspond to the initial relaxation profile.  At the beginning of the profile, the 19F T1 
time was 3.6 s.  After 18 hrs spinning in the magnet at 15 kHz, the relaxation time 
increased to 19.5 s, more than 5 times its initially measured value.  After 
approximately four hours, the 19F T1 time appeared to plateau.  Based upon this initial 
observation, the most likely explanation is that the amorphous triamcinolone could 
have annealed in the NMR rotor due to the heat and pressure produced from spinning 
at 15 kHz, thereby resulting in a longer relaxation time.     
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Figure 6.1.  The 19F T1 time of amorphous triamcinolone was monitored over 18 hrs 
(initial relaxation profile).  The 19F T1 times were measured again (second relaxation 






 After acquiring the initial relaxation profile, the sample remained packed and 
was stored in a desiccator in a laboratory freezer.  Several days later, the 19F T1 time 
of the same cryoground amorphous triamcinolone sample was measured a second 
time to determine if the relaxation time had changed.  The 19F T1 time had decreased 
to 3.6 s.  In Figure 6.1, a second relaxation profile followed a similar rise in relaxation 
time over the next 10 hrs.  Typically, NMR relaxation times for a sample only 
increase with a change in solid form, hydration, or some material processing (e.g. 
grinding or compression).  The initial relaxation time point, the rate of increase in 
relaxation times, and the maxima reached (~16 s) were remarkably similar for both 
relaxation profiles.  Shown in Figure 6.2 are the 19F SSNMR spectra collected after 
the 3.6 s and 18 s relaxation measurements.  There were no significant changes in 
chemical shift, line width, or peak shape.  The 1H T1 time was monitored as well and 
increased from 1.1 s to 1.8 s, an increase of ~65%.  Although both T1 times increased, 
the relative increase of T1 times for 1H and 19F nuclei are drastically different.  In the 
initial relaxation profile there was a slight oscillation after the relaxation time had 
plateaued.    
 There are several potential causes of the reversible changes in 1H and 19F 
relaxation times.  Some of these include changes in water content, pressure induced 
from spinning, temperature (between time points and/or during NMR data 
acquisition), residual solvent (methanol) from spray drying, and paramagnetic 
oxygen.  Before determining which of these potential causes resulted in the changing 
relaxation times, the possible mechanisms are discussed below.    
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Figure 6.2.  Expansion on the single peak in the 19F SSNMR spectra of amorphous 






 It is possible that water content and residual methanol could affect relaxation 
times by influencing the mobility of the molecules in the amorphous state.  When a 
sample spins at high speeds (~15 kHz), surface water could be expelled from the 
surface of the sample, effectively drying the sample, yet the water could still be 
present in the rotor.  Hypothetically, when the sample stops spinning, water could 
return to the surface of triamcinolone.  The presence of water would provide greater 
mobility, which generally corresponds to shorter T1 times.  This hypothesis 
corresponds to the trends in the data.   
 The pressure induced from sample spinning could cause changes in relaxation.  
Barich et al. observed changes in SSNMR line widths of ibuprofen after the NMR 
samples were packed under different pressures.3   Compaction could potentially 
reduce the void space between two molecules.  The magnetic susceptibility of air 
could be lower than that of triamcinolone. The additional magnetic susceptibility due 
to the increase in density caused ibuprofen lines to broaden.  The increased pressure 
from spinning could compact the sample and increase the spin-lattice relaxation time.  
After the sample spinning stopped, the material could possibly decompress and 
relaxation time would decrease. 
 The sample temperature could also play a role in the changing relaxation 
times, as temperature is directly correlated with molecular mobility.  The sample 
temperature increases due to spinning over the course of the relaxation profile.  In 
order for the spin-lattice relaxation time to increase as temperature increase, the 
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extreme narrowing conditions must hold.  Also known as the fast-motional regime, 
extreme narrowing conditions apply when the correlation time is faster than the 
nuclear precession rate.  As the sample warms due to spinning, the relaxation time 
will rise.  Typically solid-state samples are in the slow motional regime, where T1 
time decreases with increasing temperature. 
 Lastly, oxygen gas has been widely used as a paramagnetic relaxation agent in 
solution NMR spectroscopy.  Prosser et al. have used oxygen to probe membrane 
immersion depths with solution 19F NMR spectroscopy.4-6   Oxygen partitions into 
membranes with increasing concentration at greater depths.  The immersion of a 
fluorinated detergents was determined by changes in relaxation times for individual 
fluorine groups.  The relaxation time of the deepest penetrating groups were the 
shortest due to an increased exposure to oxygen.  Other researchers studied the same 
effect on 1H spin-lattice relaxation times of aromatic polymers in the solid state.7-11   
Observations were made that adsorption of paramagnetic oxygen on aromatic 
polymers significantly decreased 1H T1 times.7,10 Capitani et al. studied 1H spin-lattice 
relaxation changes of polymers in solids without magic-angle spinning.7-11 In one 
study, the amount of oxygen adsorbed was different between polymorphs and 
reportedly higher in amorphous fractions of syndiotactic polystyrene.9   In the case of 
poly(phenylene oxide) or poly(1-oxy-2-phenyltrimethylene), 1H T1 times differed up 
to four orders of magnitude between oxygenated and deoxygenated samples.9   
 Oxygen is uncharged and demonstrates no preference for specific nuclei.4  In 
the solid state, oxygen has displayed preferential adsorption to aromatic rings.7,10 
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Oxygen has also been observed to differentially adsorb to amorphous and crystalline 
domains of polymers.7 Paramagnetic oxygen has been studied using solution 19F 
NMR spectroscopy and static 1H solid-state NMR spectroscopy.  However, research 
has not been reported on the effects of oxygen on spin-lattice relaxation times in 
magic-angle spinning experiments.  Additionally, the effect has not been observed or 
studied for small-molecule solid-state pharmaceuticals.  In the case of triamcinolone, 
oxygen gas could enter the rotor while packing under ambient conditions, and 
nitrogen gas could purge the sample during spinning elevating the relaxation time.  
The proceeding studies were designed to examine each potential cause.  
 
6.3.2 Testing the cause of relaxation change 
 Spray-dried amorphous triamcinolone was used to probe the origin of the 
change in relaxation.  First, the 19F T1 time was measured every two hours over a 15-
hour time period while spinning at 15 kHz, and a similar relaxation profile was 
produced a third time.  As illustrated in Figure 6.3, the 19F T1 time was initially 3.6 s.  
The relaxation time increased drastically over the following eight hours.  After eight 
hours, the relaxation continued to increase but at a much slower rate.  At 15 hours, the 
19F T1 time was approximately 20 s, and appeared to still be increasing.  After the 
relaxation increase was observed, the following tests were performed to determine 
which factor caused the 19F T1 value to decrease below 5 s.   
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Figure 6.3. Plot of 19F T1 relaxation time versus time after being exposed to changes 
in several variables to determine the cause of the relaxation drop.  The table describes 
the physical conditions that the sample was exposed to during collection.
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 In Figure 6.3, a table and graph show how specific environmental variables 
were tested that could have been attributed to the reduction in relaxation.  The factors 
adjusted include sample temperature during acquisition, sample temperature during 
storage (between time point measurements), location of the sample in between 
relaxation measurements, and spinning between acquisitions.  The effects of oxygen 
gas on relaxation time were not probed during these experiments.  After the relaxation 
was profiled, the sample temperature was lowered to 260 K.  Upon cooling, the 
relaxation time dropped from 19.5 s to 16.6 s.  If the NMR conditions are in the fast-
motional regime, spin-lattice relaxation time will drop when lowering the 
temperature. However, it is more likely that amorphous triamcinolone is in the slow-
motional regime where the opposite trend would be observed (decreased temperature 
results in increase relaxation time).  Over the next five hours, the 19F T1 time was  
maintained a constant value between 16.6 and 16.8 s.  Lowering the sample 
temperature did not elicit a drop in relaxation time of the magnitude that had been 
observed.   
 From 20.5 to 22.5 hrs the probe temperature was slowly raised in 10 K 
increments to 290 K.  There appears to be a downward trend in Figure 6.3 during 
these time points.  As probe temperature is raised, the 19F T1 time drops slightly.  This 
trend is consistent with a sample being in the slow-motional regime.    
 From 23 to 38 hrs, the probe temperature was kept constant during acquisition 
(290 K).  If the increase in relaxation was related to sample spinning, storing the 
sample in the auto-sampler between relaxation measurements should have led to a 
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change in relaxation times by returning to the initial value.  During relaxation 
measurements, the sample was spun at 15 kHz.  The relaxation time dropped slightly 
to approximately 15.5 s, spiking once to 17.9 s.  After 38 hrs, no significant drop in 
19F T1 time had occurred despite having spent 12.5 consecutive hours not spinning in 
the auto-sampler.  The sample temperature had been lowered and raised, and the 
sample was static between relaxation measurements with no dramatic change in 
relaxation time.   
 Next, the rotor was removed from the spectrometer and stored in a desiccator 
in a laboratory freezer (~265 K) for 2 hrs.  At 40 hrs from the start of the relaxation 
profile, the rotor was reinserted in the probe (290 K), spun to 15 kHz, and the 19F T1 
time was measured.  The 19F T1 time dropped to 4.5 s.  The two hours the sample was 
static was a much shorter time then had been previously monitored.  The freezer 
temperature was in the range of temperatures that had not induced a significant 
relaxation time change.  The 19F T1 time was measured (41.5 hrs) after spinning 1.5 
hours to display the increase in relaxation rate (13.6 s)., which was consistent with 
previous observations.   
 Sample temperature during acquisition and between measurements caused 
little or no change to the relaxation time.  Although water content and residual 
methanol had not been directly tested, the hypothesis of their contribution relied on an 
environment created by spinning at high speeds.  When the rotor was static between 
time points from 23 to 38 hrs, little or no change in 19F T1 time was observed.   The 
relaxation times were not significantly affected by not spinning the sample between 
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measurements.  The reverse kinetics of the relaxation phenomenon were not well 
understood, but the 19F T1 time had dropped from 15.7 to 4.5 s in 1.5 hrs.  The set of 
experiments directly or indirectly illustrated that the relaxation changes observed 
were not due to spinning, temperature, water content, or residual methanol.  However 
the process method, and the presence of oxygen gas was not eliminated.   
 Amorphous triamcinolone was prepared again, but this time by cryogrinding 
to remove any factors due to sample generation.  The relaxation time was measured 
with both inversion recovery and saturation recovery pulse sequences to reaffirm that 
it was not a systematic error of the pulse sequence.  The 19F T1 time rose from 4.5 to 
8.3 s using the saturation recovery experiment, and 4.2 to 7.2 s with the inversion 
recovery experiment.  The relaxation profile had a similar shape to that of the spray-
dried amorphous triamcinolone.  However, the maximum 19F T1 time of 8.3 s was 
considerably lower than the 19.5-s 19F T1 time of the spray-dried amorphous 
triamcinolone.  The amorphous generation process was not the cause of the effect; 
however; different samples produced different maxima.  All of the proposed 
hypotheses had been disproved with the exception of the effects of oxygen.   
 To determine if oxygen played a role in reducing the relaxation, amorphous 
triamcinolone sample was studied in four oxygen environments: high oxygen gas 
environment (rotor purged with oxygen gas), medium oxygen gas environment (the 
rotor was opened to ambient conditions), low oxygen environment (purged with 
nitrogen gas), and a very low environment (spun at 15 kHz for two hrs).  After each 
change in oxygen concentration, the relaxation time was measured, and reported as 
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follows: 1.4 s, 3.9 s, 5.1 s, and 9.8 s.  When exposed to oxygen, the relaxation 
dropped to the lowest observed 19F T1 value for amorphous triamcinolone.  As the 
oxygen concentration decreased, the relaxation time increased.   
 This result suggested that the changes in relaxation time were caused by a 
reduction in paramagnetic oxygen by a nitrogen purge during data acquisition.  The 
probe was connected to several lines delivering nitrogen gas; bearing and drive gas 
for spinning, frame cooling line, variable temperature lines, and nitrogen gas was 
used to insert and eject rotors from the auto-sampler to the probe.  At all points of the 
study, the sample was exposed to nitrogen levels that were far greater than ambient 
percentages until the rotor was removed from the spectrometer.  Even when the 
sample was stored in the auto-sampler the positive pressure created from the nitrogen 
gas in the frame cooling exited through the auto-sampler.  The return to the depressed 
relaxation rate is as quick as it takes ambient gas to reenter the rotor.  The rise of the 
relaxation rate when exposed to nitrogen gas is dependent on sample packing and end 
cap seals.  A tighter drive tip seal could explain the difference in the slope and 
maxima of the relaxation profiles. The phenomenon was much more dramatic for the 
19F T1 time rather than for the 1H T1 times for amorphous triamcinolone.   
 Once changes in partial pressures of oxygen gas were identified as the likely 
cause of the changes in relaxation time, a sample of spray-dried amorphous 
triamcinolone was used to test the hypothesis.  First, a rotor containing amorphous 
triamcinolone was purged for one minute with oxygen gas and gas sealed.  Under 
exposure to oxygen, the measured 19F T1 time was 1.7 s.  The sample was spun for 48 
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hours to purge with nitrogen gas.  The measured T1 time after purging was 27.9 s.  
Lastly, to demonstrate the reversibility, the sample was purged with oxygen gas a 
second time, and the 19F T1 decreased to 1.5 s.  This result confirms that oxygen is the 
source of the changes in relaxation time.  
 The changes in relaxation time by oxygen was demonstrated on a single solid 
form of a single small-molecule compound, but there is the question of how 
generalized this phenomenon is to other solid forms, other NMR nuclei (e.g. 1H), and 
polymers.  To test this, several other compounds were studied to display the presence 
or lack of effect in different pharmaceutically related systems.  In the following 
examples the effect is displayed in multiple nuclei, multiple solid forms (crystalline 
and amorphous), with small molecules, and excipients.    
 
6.3.3 Dextran 
 Dextran is a polysaccharide consisting of glucose molecules joined in various 
lengths.  The effect was measured on dextran in a similar manner as amorphous 
triamcinolone.  The relaxation time was measured every few hours and plotted 
against time in Figure 6.4.  The sample was spun over a period of 18 hrs and the 1H 
T1 relaxation time was monitored throughout.  The relaxation rate climbed from 
approximately 3.6 s initially to approximately 4.3 s after 18 hrs.  The 1H T1 time 
increased approximately 20%.  After 18 hrs, the relaxation had not fully reached a 
maximum as the relaxation time was still climbing.  At 19 hrs the sample was ejected 
and stored in the auto-sampler to demonstrate that being out of the probe/magnet, at 
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ambient temperature, and static had little effect on relaxation time.  The relaxation 
time dropped slightly (4.2 s), yet not to the original value.  The drop in time could be 
due to a slightly higher concentration of oxygen gas in the auto-sampler.  The rotor 
was removed from the magnet and placed on the lab bench at ambient temperature 
and pressure.  The measured relaxation time had dropped to 3.8 s, near the original 
value.  The effect is reversible and noticeable at changes less than an order of 
magnitude.  Oxygen exposure to dextran changes the 1H T1 relaxation time.  Dextran 
is a high molecular weight amorphous polymer, with no 19F atoms, aromaticity or 
conjugated bond systems, yet it still displays the relaxation effects upon exposure to 
oxygen.   
 
6.3.4 Crystalline dexamethasone 
 Similar to triamcinolone and dextran, the relaxation time profile of as-
received dexamethasone was measured every two hours for 16 hours.  The 19F T1 
relaxation time profile is plotted in Figure 6.5.  The 19F T1 time was initially 56.3 s 
and plateaued at approximately 60.5 s.  The 1H T1 time was also monitored during 
this experiment, and it did not change appreciably (TO=2.30 s, TF =2.29 s) over 16 
hours.  When the sample rotor was removed from the probe, opened to ambient air, 
closed, and reinserted, neither the 19F T1 time (59.9 s), nor the 1H T1 time (2.26 s) 
dropped appreciably.  The 19F T1 time did not return to its original measurement of 
56.3 s after opening and measuring the sample T1 again (indicated by the    in 
Figure 6.5).  There are several explanations for the 19F T1 time not returning to its 
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Figure 6.4. Dextran 1H T1 relaxation time profile.   
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Figure 6.5.  a) 19F T1 relaxation time profile of as-received crystalline 
dexamethasone and b) the same sample measured again after removing from the 










originally measured value.  First, the observed change in relaxation time could have 
been due to sample healing while spinning at high speeds.  Crystal healing would be 
observed as a non-reversible relaxation change.  Secondly, it could be due to 
instrumental operation error.  The probe could have arced causing a change in the 
SNR of an increment in the relaxation measurement.  The arcing could be the reason 
for a lower time point.  In relaxation studies, the associated error is dependent on the 
number of increments acquired and the number of acquisitions per increment.  
Typically, an error of  +/-10% is associated with these measurements.  The initial 
time point is within this range, but well beyond the limits of every other measured 
time point in the experiment.  For crystalline dexamethasone, oxygen gas has no 
observable effect on the 1H and 19F T1 times.   
 
6.4 Other Applications 
  
 There are many potential applications where the ability to control the 
relaxation time could be beneficial for sample analysis.  A few of these potential 
applications are discussed below. 
 
6.4.1 Difference-NMR technique 
 The selectivity enhancement in a difference-NMR experiment is directly 
related to the ratio of the relaxation rates of the components in a sample.  In the case 
of detecting low levels of amorphous triamcinolone, purging with oxygen gas yields 
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an unquestionable advantage by reducing the 19F T1 time of the amorphous form and 
not affecting the 19F T1 of the crystalline form.  To control the change in relaxation 
time, the samples were purged with oxygen gas and capped with O-ring sealed end 
caps.  The increased partial pressure of oxygen gas reduced the 3.6 s 19F T1 relaxation 
time of amorphous triamcinolone to 1.2 s without significantly affecting the 
relaxation time of crystalline triamcinolone (105 s).  The ratio of relaxation times 
between the crystalline and amorphous forms increased from 29 times to 88 times. 
Such a powerful effect has not been demonstrated for SSNMR magic-angle spinning 
applications.  Spin-lattice relaxation time changes upon exposure to oxygen could 
allow for a multitude of research opportunities.  
 
6.4.2 Processing of aspirin 
 In addition to the benefits from the difference-NMR technique, a brief study 
of aspirin is included to illustrate a potential application.  As a pure powder, aspirin is 
known to have one stable crystalline form and remain crystalline despite conditions in 
which the material was processed.  In our laboratory, the 1H T1 time of bulk aspirin 
and cryoground samples were measured.12   After cryogryinding for 2 minutes, the T1 
time decreased to 42 s.  Upon grinding for 60 minutes, it dropped to 14 s.  The 
spectrum of each cryoground sample and the bulk sample were identical indicating no 
change in solid form. 
 In these studies, the 1H T1 times of bulk aspirin were compared to aspirin that 
had been cryoground for 20 minutes.  Both samples were cycled between an oxygen 
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gas purge, a nitrogen gas purge, and another oxygen gas purge to observe the range of 
differences between the relaxation times.  After each purge, the 1H T1 time was 
measured.  In Figure 6.5, the T1 times of bulk unprocessed aspirin were compared to 
the times for cryoground aspirin at each environment.  Unprocessed aspirin shows a 
small change in relaxation from an oxygen-purged environment to a nitrogen-purged 
environment.  Cryoground aspirin, which is the same crystalline form and has an 
identical SSNMR spectrum, had a relaxation time of 8.6 s.  When purged with 
nitrogen gas, the relaxation time increased to 55.5 s.  After the nitrogen purge, the 
relaxation time was much closer to the relaxation time (59.5 s) of the unprocessed 
aspirin.   
 In the case of processed lactose, the drastic changes in relaxation time were 
attributed to increased sites of high mobility, more specifically crystal defect sites, 
reduced particle size, and generation of amorphous material.2   As mentioned before, 
an amorphous form cannot be generated from pure aspirin.  Therefore, the reduction 
in relaxation time was likely due to an increased number of crystal defect sites and a 
reduction in particle size.  Both a decrease in particle size and generation of crystal 
defects would allow oxygen to penetrate the crystal lattice more effectively.  
Oxygenating samples could potentially help study the presence of crystal defects in 





Figure 6.6. The 1H T1 times of as-received aspirin (solid line) and cryoground aspirin 
(dashed line) after (1) purging with oxygen, (2) purging with nitrogen, and (3) 














 The partial pressure of oxygen gas has been demonstrated to have a dramatic 
effect on the 19F and 1H spin-lattice relaxation times of several representative 
pharmaceutical compounds.  The effect on relaxation should be well understood 
especially when acquiring SSNMR data while spinning with nitrogen gas.  Changes 
in the level of oxygen could affect the sensitivity of your experiment, particularly 
important while quantitating.   
 The presence of oxygen has been demonstrated to dramatically effect both 1H 
and 19F relaxation times.  Processing a material can affect the magnitude of the 
relaxation effect when oxygen is present, as was the case for aspirin.   
 Although there are potentially intriguing applications for the use of 
paramagnetic oxygen, the changes in relaxation time highlight the importance in 
understanding the physical environment of a material before and during SSNMR data 
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